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Introduction
Heart failure is a pathophysiological state in which an abnormal cardiac function is responsible 
for the failure of the heart to pump blood at a rate commensurate with the requirements of 
the metabolizing tissues.[1] The estimated prevalence of symptomatic heart failure in Europe 
varies from 0.4% to 2% of the general population, with a signiﬁcant increase of the prevalence 
with age.[2-4] Since the proportion of elderly is increasing in Europe and the mean age of 
the heart failure population is approximately 74 years, a signiﬁcant rise of the prevalence 
of heart failure can be expected in the coming decades. As 900 million people are living in 
the countries represented by the European Society of Cardiology an astonishing 10 million 
heart failure patients can be accounted for.[1,5] Furthermore, the proportion of the health 
Heart Failure
Figure 1. NYHA class to predict survival in the heart failure patient. The SOLVD investigators and the 
CONSENSUS trial have shown shown survival rates from as high as 81 percent at 4 years in asymptomatic 
patients (NYHA class I) to as low as 36 percent at 1 year in patients with NYHA class IV.
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care budget spend on costs for care of heart failure patients is also rising dramatically.[6-8] 
Despite the introduction of new treatment modalities, the number of heart failure related 
hospital admissions continue to rise especially in older patients. At this time 2% of all hospital 
admissions (medical and surgical) and 5% of all medical admissions are heart failure related.[9] 
Furthermore, a number of recently introduced treatment strategies failed to improve the 
outcome of heart failure patients and the prognosis of most patients still remains poor. 
New York Heart Association Classiﬁcation (NYHA class) criteria are most often used to 
asses the functional class and to evaluate the prognosis of the heart failure patient (Table 
1). Depending on the functional status, diﬀerent mortality rates have been described.[10-
12] The one year mortality rate varies between 5% for NYHA class I patients to more than 
64% for class IV heart failure patients.[10-12] In line with these data, the Studies of Left 
Ventricular Dysfunction (SOLVD) trial and the Cooperative North Scandinavian Enalapril 
Survival Study (CONSENSUS) trial demonstrated that survival rates may be as high as 81 
percent at 4 years in asymptomatic patients (NYHA class I) to as low as 36 percent at 1 year 
in patients with NYHA class IV (Figure 1).[11,12] In conclusion, despite optimal medical 
therapy, patients with advanced heart failure symptoms do have a poor prognosis justifying 
aggressive screening and treatment strategies.
Etiology and symptoms of congestive heart failure
The most common cause of chronic heart failure is coronary artery disease (CAD). Multicenter 
heart failure trials have reported that up to 70% of the patients had CAD as the underlying 
etiology of heart failure.[13,14] In CAD patients the sequelae of acute myocardial infarction, 
with loss of functioning myocytes, development of myocardial ﬁbrosis, and subsequent left 
ventricular remodelling, eventually leads to left ventricular dilatation and symptoms of left 
ventricular dysfunction. Other causes of systolic and diastolic dysfunction are longstanding 
hypertension, idiopathic dilated cardiomyopathy, hypertrophic obstructive cardiomyopathy, 
restrictive cardiomyopathy and valvular disease.
The two major classes of symptoms in heart failure are due to excess of ﬂuid accumulation and 
a reduction in maximal cardiac output during exercise. Fluid accumulation leads to edema, 
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dyspnea, hepatic congestion and ascites. The reduction in cardiac output during exercise 
results in fatigue and weakness. Presenting symptoms can develop acutele (days to weeks) or 
more insidiously (months). Shortness of breath at rest and/or during exercise and orthopnea 
are more pronounced in the acute phase of heart failure, while fatigue and peripheral edema 
characterise the chronic stadium of heart failure.
Clinical evaluation of the heart failure patient
Patients with left ventricular dysfunction or heart failure may present themselves to the 
physician in diﬀerent ways. First, with a syndrome of decreased exercise tolerance. Complaints 
of a reduction in their exercise tolerance due to dyspnea and/or fatigue can be the reason for 
seeking medical attention. The physician should determine whether the principal cause is 
left ventricular dysfunction or another abnormality (e.g., pulmonary disease), which is often 
diﬃcult. Secondly, patients present themselves with a syndrome of ﬂuid retention. Complaints 
of leg or abdominal swelling can be the primary symptom. Thirdly a patient can present 
himself with no symptoms or symptoms of another cardiac or noncardiac disorder, for example 
atrial fribrillation.[1,15] The evaluation of the cause of left ventricular dysfunction starts with 
a thorough history and careful physical examination. History of hypertension, diabetes, 
hypercholesterolemia, coronary/valvular/peripheral vascular disease, rheumatic fever, chest 
irradiation and exposure to cardiotoxic agents  should be inquired since all are known risk 
factors for the development of structural heart disease leading to heart failure. Family history 
should be acquired as recent studies suggest that as many as 20% of cases of idiopathic 
dilated cardiomyopathy may be of familial origin and require family screening.[1,15]
Physical examination of the heart may suggest the presence of cardiac enlargement, murmers, 
or a third heart sound. History and physical examination can provide important information 
about the underlying etiology, but identiﬁcation of the structural abnormality leading to 
heart failure generally requires invasive or noninvasive imaging of the cardiac chambers 
or great vessels. The echocardiogram (2D) coupled with Doppler ﬂow studies may help to 
identify primary cardiac disorders and to distinguish between pericardial, myocardial or 
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valvular abnormalities. The diﬀerence between primarily systolic or diastolic dysfunction can 
be determined by the measurement of the left ventricular ejection fraction. A patient with an 
ejection fraction less than 40% is considered to have a systolic dysfunction.[1,15] Furthermore, 
echocardiography can be used for the quantitative assesment of other cardiac parameters (e.g., 
dimensions, geometry, thickness, and regional wall motion of the right and left ventricle) to 
evaluate the cardiac function. Radionuclide ventriculography, magnetic resonance imaging and 
computed tomography can provide further information on the global and regional function 
of the heart.[1,3,15] Coronary angiography is usefull to determine the presence of coronary 
artery disease which is believed to be the underlying cause in approximately two thirds of 
patients with heart failure due to left ventricular systolic dysfunction.[6] After establishing 
the possible etiology of cardiac dysfunction a standardized treatment algorithm should be 
applied to optimize the outcome of medical therapy.
Sudden death and heart failure
In heart failure patients death is frequently sudden and even though other causes, like 
myocardial infarction, stroke or electromechnical dissociation may contribute to the high 
sudden death rate, most often, death is caused by malignant ventricular arrhythmias. Although, 
in absolute numbers, more patients with advanced stages of disease will die suddenly, the 
proportion of sudden death is even higher in the group of patients with moderate symptoms 
(New York Heart Association class I and II heart failure symptoms, 64% of all death) 
compared to the group with advanced symptoms (NYHA class III and IV, 59% and 33% of 
all death respectively.[16] 
Therapeutical options 
- Pharmacological therapy
Diuretics. Diuretics remain the ﬁrst choice treatment modality for heart failure 
symptoms. When ﬂuid overload is present they relieve symptoms. Diuretics interfere with 
the sodium retention by inhibiting the reabsorption of sodium or chloride at speciﬁc sites 
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in the renal tubulus. In controlled short-term trials diuretic therapy resulted in a reduction 
in jugular venous pressure, pulmonary congestion, peripheral edema, and body weight, all 
of which were observed within days of initiating of therapy.[17] Furthermore, diuretics have 
been shown to improve cardiac function, symptoms, and exercise tolerance (intermediate 
term follow-up studies) in patients with heart failure.[18] However diuretics should always 
be used in combination with other drugs in heart failure patients, since they may control 
symptoms and ﬂuid retention but are unable to maintain the clinical stability of patients with 
heart failure for long periods of time.[19] Appropiate use of diuretics remain however the key 
element in the success of other drugs used for the treatment of heart failure.[19]
Beta-blockers. There is strong evidence that beta-blockers improve survival in heart 
failure patients. Large randomized trials have shown a signiﬁcant reduction in morbidity and 
mortality in patients treated with beta-blocker.[17,20] The Cardiac Insuﬃciency Bisoprolol 
Study (CIBIS-II) trial has been stopped early 
and also conﬁrmed a beneﬁcial eﬀect of 
beta-blockers on mortality.[21] Betablokkers 
act by inhibiting the adverse eﬀects of the 
sympathetic nervous system in patients with 
heart failure. The COPERNICUS (Carvedilol 
Prospective Randomised Cumulative Survival) 
trial, a prospective trial with Carvedilol, 
enrolled clinically stable patients with severe 
heart failure symptoms, demonstrated a 
reduction in mortality in patients with 
advanced disease.[21]
ACE inhibitors. Angiotensin 
converting-enzyme inhibitors interfere with 
the renin-angiotensin system by inhibiting 
the enzyme responsible for the conversion of 
Figure 2. The sites of action of ACE inhibition 
and Angiotensin-II-receptor blockers (AT) in the 
renin-angiotensin system (RAS) pathophysiology. 
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angiotensin I to angiotensin II (Figure 2). Overwhelming evidence exists that ACE inhibitors 
delay the appearance of heart failure symptoms or their worsening, and improve symptoms 
in patients with mild or moderate disease. ACE inhibitor therapy reduces the number of 
hospital admissions for heart failure and results in a reduction of the risk of a myocardial 
infarction.[22] ACE inhibitors are eﬀective in patients with diﬀerent stages of disease 
(mild, moderate, severe) and in patients with or without coronary artery disease. So ACE 
inhibitors should be prescribed to all patients with heart failure due to left ventricular systolic 
dysfunction. 
Aldosterone receptor antagonists are eﬀective in reducing morbidity and mortality 
in patients with heart failure on top of optimal pharmaceutical therapy.[23] Spironolactone 
is a competitive antagonist of aldosterone receptors in the heart, kidney and other organs, 
and interferes with the negative eﬀects of aldosterone in heart failure patients (Figure 3). 
Figure 3.  Mechanism of action of spironolactone (competitive antagonist at aldosterone receptors in heart, kidney 
and other organs).          
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In the Randomized Aldactone Evaluation Study (RALES) trial a signiﬁcant 30% reduction 
of mortality and 35% reduction of hospitalizations for heart failure was reported in the 
group of patients treated with aldactone.[23] So, in patients with heart failure due to systolic 
dysfunction, next to ACE inhibitors, diuretics, beta-blockers, spironolactone would appear 
to be the therapy of choice.
Other drugs. Digoxin improves the contractility of the cardiac muscle and is part of 
the pharmacological treatment for heart failure patients. The Digitalis Investigation Group 
(DIG) trial showed a large reduction in recurrent heart failure hospital admissions, but the 
eﬀect on al cause hospital admissions was limited (6% reduction of the total number of all 
cause hospital admissions).[13] At this time, Angiotensin-II-receptor blockers should not be 
considered equivalent or superior to ACE inhibitors in the treatment of heart failure (Figure 
2). The Vasodilator Heart Failure Trial (Val-Heft) trial showed no beneﬁt of valsartan on 
combined mortality and morbidity when the patients were on both ACE inhibitor and beta-
blocker at baseline.[24] They play mainly a valuable role in the treatment of heart failure as a 
replacement therapy if ACE inhibitors are not tolerated (cough as a side eﬀect in 5-10%).
In conclusion, the pharmacological treatment of heart failure patient is a combination of the 
above mentioned drugs. The optimal treatment regimen should be evaluated and monitored 
on a regular basis in every individual patient.
- Implantable Cardioverter Deﬁbrillator (ICD) therapy
As sudden death in heart failure patients is in the majority of cases caused by a malignant 
ventricular arrhythmia implantation of a deﬁbrillator (ICD) may have a positive eﬀect 
on mortality. Eﬃcacy of ICD therapy is well established both in secondary and primary 
prevention trials.[25,26] Implantation of an ICD improves survival in patients with ischemic 
cardiomyopathy (LVEF < 40%), nonsustained ventricular tachycardia, and inducible (non-
suppressible) ventricular tachycardia as reported by 2 randomized trials (Multicenter 
Unsustained Tachycardia Trial (MUSTT) and Multicenter Automatic Deﬁbrillator Implantation 
Trial (MADIT)).[25-27]  However, MADIT II was not designed to show an eﬀect of ICD 
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treatment in HF patients. Recently though, the Sudden Cardiac Death in Heart Failure Trial 
(SCDHeFT, n=2521 pts, LVEF<35%, 70% NYHA class II, 30% class III, ischemic and non-
ischemic patients) demonstrated that ICD therapy decreased the relative risk of death by 
23% (regardless of the underlying cause) whereas Amiodarone had no eﬀect on mortality.[28] 
Concerning ICD treatment of HF patients with a non-ischemic cardiomyopathy results are 
conﬂicting as the Deﬁbrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation 
(DEFINITE) trial (458 patients, LVEF 21%) reported, despite a signiﬁcant reduction of 
arrhythmic death, a non-signiﬁcant eﬀect of ICD therapy on all-cause mortality.[29]
- Surgery for congestive heart failure
Coronary revascularization. Screening for myocardial ischemia and viability is 
important. As demonstrated by a number of studies revascularization may not only improve 
symptom status, exercise capacity but also may have an eﬀect on mortality. Since the last 20 
years studies have shown that revascularization of patients with left-ventricular dysfunction 
can result in an improvement of 25% or more of the long-term survival.[30] Symptoms and 
prognosis might improve after surgery, however the operative risk is increasing with age and 
worsening left ventricle function. A low left ventricular ejection fraction (<25%) is associated 
with increased operative mortality.[31] When more than 40 percent of the left ventricle is 
scarred or metabollically inactive, surgical mortality is high and recovery of left ventricular 
function from revascularization is much less.[31] The assesment of myocardial viability has 
shown to be essential to determine the potential beneﬁt of revascularization.[32,33]
Mitral valve surgery. Functional mitral regurgitation is a signiﬁcant complication and 
almost always present in patients with severe dilated cardiomyopathy, regardless of etiology. 
Mitral regurgitation is associated with progressive ventricular dilatation, an escalation of 
congestive heart failure symptomatology, and signiﬁcant reductions of long-term survival.[34] 
Historically, the surgical approach to mitral regurgitation was mitral valve replacement, 
but mitral valve reconstruction has shown excellent clinical outcome in cardiomyopathy 
patients.[35] In selected patients, mitral valve repair, in which the subvalvular apparatus 
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(including the chordal and papillary muscles) is left intact, leads to a reduced ventricular size, 
improvements in left ventricular ejection fraction and symptoms of heart failure.[35,36]
Surgical Remodeling of the Left ventricle. With the process of heart failure the progression 
of the thinning and dilatation of the left ventricle continues. Dor has presented a technique 
to improve heart failure symptoms by surgical exclusion of dyskinetic or akinetic ventricular 
aneurysms.[37] However at this time, methods that preserve myocardial integrity (e.g. mitral 
reconstruction) in patients with end-stage heart failure should be evaluated ﬁrst.
-Cardiac transplantation
For patients with medically refractory severe end-stage heart failure and no other surgical 
options, treatment of choice is cardiac transplantation. If carefully screened the one year 
survival is 80-90% and 5 years survival 70%.[38] However the shortage of donororgans limit 
the clinical use of heart transplantation. For example in the Netherlands only 40 to 45 heart 
transplantations are performed each year. Mechanical left ventricular assist devices are now 
available to support patients who are on the heart tranplant waiting list and may serve as a 
deﬁnitive therapy for end-stage heart failure in the near future.[39] despite the fact that some 
patients may live for some time with a left ventricular assist device, until now no artiﬁcial 
heart is available.[39]
Prognosis
Despite the signiﬁcant medical improvements achieved during the last decades, still 
more than half of the patients with congestive heart failure will die within 3 years of 
diagnosis.[5,8,40] Since only a small percentage of the patients is eligible for heart failure 
surgery or transplantation, new therapeutical developments have been explored in the last 
decade. Cardiac resynchronization therapy was introduced during the last few years as an 
alternative treatment option for patients with end-stage congestive heart failure.
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Cardiac resynchronization therapy
Introduction 
The current treatment modalities for patients with heart failure are heart transplantation, 
surgical revascularization or medical therapy as described earlier.[5-7] Since the number 
of donor hearts is limited and revascularization is associated with a high morbidity and 
mortality, medical treatment remains the only option in most patients. However, medical 
treatment remains sub optimal in terms of clinical beneﬁt and long-term prognosis.[5,7] 
Thus, alternative therapeutic approaches for heart failure patients have been explored. 
Cardiac resynchronization therapy (CRT), developed during the last decade, is based on 
the ﬁnding that a signiﬁcant number of heart failure patients (approximately 30%) have 
pronounced ventricular asynchrony which contributes to left ventricular dysfunction.[41] 
Simple electrical resynchronization by biventricular pacing may result in a more coordinated 
ventricular contraction since both ventricles are stimulated nearly simultaneously.[42,43] 
Ventricular resynchronization by multisite biventricular pacing, was introduced by Bakker in 
Utrecht. The ﬁrst observational studies by Cazeau et al. and Bakker et al already demonstrated 
eﬃcacy.[41,44] These authors implanted atrio-bi-ventricular pacemakers in patients with severe 
heart failure and an intraventricular conduction delay (reﬂecting ventricular asynchrony), as 
reﬂected by a QRS duration >120 ms. Since the introduction of cardiac resynchronization 
therapy (CRT) a large number of acute hemodynamic studies have tested the eﬀects of atrio-
bi-ventricular pacing [41,45,46] and/or atrio-LV pacing.[47,48] It was demonstrated that CRT 
results in a signiﬁcant increase in cardiac output, systolic arterial pressure and pulse pressure, 
and in LV dP/dT (contractility index), furthermore it was demonstrated that cardiac ﬁlling 
pressures decreased.[44-48] After evaluation of these acute studies, clinical eﬀectiveness of 
resynchronization therapy was evaluated in a large number of uncontrolled and controlled 
studies.[41-55]
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Technical aspects of cardiac resynchronization therapy
Since right ventricular pacing is very common, the main technical diﬃculty of cardiac 
resynchronization therapy is related to left ventricular (LV) pacing. In the early years an 
epicardial route was used wich required a thoracotomy or thoracoscopy under general 
anaesthesia.[41,44]. The most commonly used method however was proposed by Daubert 
et al [56] who used a transveneous insertion technique to place a pacing lead through the 
coronary sinus over the LV free wall. A coronary sinus venogram is obtained during balloon 
oclusion, and the LV pacing lead is inserted through the coronary sinus with help of a 
dedicated guiding catheter. The LV lead is positioned as far as possible in the venous system, 
preferably in the (postero-) lateral vein.[56] The other leads are positioned in the high right 
atrium and in the septal region of the right ventricle.[57] 
Mechanisms of beneﬁt by cardiac resynchronization therapy
Three diﬀerent mechanisms have been identiﬁed underlying the beneﬁt of CRT: Firstly, A-V 
sequential pacing allows for optimization of the AV-delay resulting in an atrial and ventricular 
activation sequence with an optimal LV ﬁlling time to improve systolic performance. 
Aurricchio et al [55] programmed an optimal AV-delay in 27 patients using hemodynamic 
parameters (increase in dP/dtmax). Five patient-speciﬁc AV-delays were preset for each 
patient depending on the percentages of the patient`s intrinsic PR-interval. The authors 
concluded that patients with a wide surface QRS complex had maximum acute beneﬁt when 
a patient-speciﬁc AV-delay was programmed.
Secondly, CRT shortens the interventricular conduction delay, resulting in a reduction of the 
RV-LV dyssynchrony as demonstrated by St John Sutton et al.[53] And thirdly, as demonstrated, 
resynchronization therapy reverses LV asynchrony (intraventricular conduction delay) which 
is mainly caused by mechanical dispersion of the motion between the septum and the lateral 
wall. Yu and coworkers [58] have shown a decrease in LV dyssynchrony (assessed by tissue 
Doppler imaging) after CRT. A-V optimization and the restoration of inter- and intra-
ventricular synchrony all contribute to the beneﬁcial eﬀects observed after CRT (improvement 
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of systolic function, reduction of mitral regurgitation, reverse remodeling). Importantly, the 
relative contribution of these 3 mechanisms to the success of CRT is currently unknown.
Selection criteria CRT
Cardiac resynchronization therapy has been introduced as a novel treatment option for 
patients with congestive heart failure and conduction delay.[49-55] The initial results with 
this technique are promising and improvement in clinical symptoms, exercise capacity, quality 
of life and systolic function, have been demonstrated in large controlled clinical trials.[49-
55] In addition, a signiﬁcant reduction in hospitalization rate has been demonstrated with 
resynchronization therapy and a meta-analysis of follow-up studies has shown an improved 
survival following resynchronization.[59] The inclusion criteria used in the randomized, 
controlled clinical trials are heart failure patients with NYHA class III or IV functional status, 
a left ventricular (LV) ejection fraction <35% and QRS duration >120 ms with left bundle 
branch block morphology.[49-55]  Last years additional inclusion criteria are evaluated to 
further optimize clinical response and to reduce of the percentage of clinical non-responders 
to CRT treatment for heart failure patients. The use of echocardiography (especially the tissue 
doppler imaging) is being evaluated for the selection of potential responders to CRT.[60-62] 
Clinical results CRT trials
The MIRACLE, MUSTIC, PATH-CHF, INSYNC, MIRACLE ICD, COMPANION 
and CARE-HF trials have been published and demonstrate signiﬁcant improvements in 
NYHA class, quality of life score, exercise tolerance, and left ventricular function.[49-55] 
The MIRACLE trial evaluated 453 moderate-to-severe heart failure symptomatic patients 
treated by biventricular pacing during 6 months of follow-up. Patients were divided in a CRT 
(n=228) and a control group (CRT OFF). After 6 months follow-up the CRT patients not 
only experienced an improvement in functional class, 6-minute walking distance and quality 
of life score, but also a reduction in morbidity and mortality, when compared to the control 
group. Fewer patients in the CRT group required hospitalization or intravenous medications 
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for the treatment of heart failure, when compared to the control group.[49,53] The recently 
published Cardiac Resynchronization Therapy Heart Failure (CARE-HF) trial included and 
followed 813 patients who received standard pharmacologic therapy for heart failure.[55] The 
patients were randomly assigned to receive medical therapy alone or with CRT. A signiﬁcant 
diﬀerence in mortality rate was seen between the two groups, in favour of the CRT treated 
patients (20% vs 30%, p<0.002).[55]  
Measurement of response, end-points of CRT trials
Table 2 summarizes the clinical end-points used in the major CRT clinical trials.[49-55] LV 
reverse remodeling was indicated in the MIRACLE trial by a signiﬁcant reduction of the 
LV end diastolic diameter and the LV end systolic diameter.[49] In our CRT treated patient 
population (n=40) the hospitalization rate for congestive heart failure was signiﬁcantly 
reduced after implantation of the CRT device (0.5±1.5 days/year vs. 3.9±5.3 days/year, p<0.05) 
and survival rate was 87.5% at 2 year follow-up.[63] In the Comparison of Medical Therapy, 
Pacing, and Deﬁbrillation in Heart Failure (COMPANION) trial a total of 1520 patients who 
had advanced heart failure (New York Heart Association class III or IV) due to ischemic 
or nonischemic cardiomyopathies and a QRS interval of at least 120 msec were randomly 
assigned in a 1:2:2 ratio to receive optimal pharmacologic therapy alone or in combination 
with cardiac-resynchronization therapy with either a pacemaker or a pacemaker–deﬁbrillator. 
The primary composite end point was the time to death from or hospitalization for any cause. 
This trial showed that the risk of death from or hospitalization for heart failure was reduced 
by 34 percent in the pacemaker group and by 40 percent in the pacemaker-deﬁbrillator group 
when compared to the pharmacologic-treated patient group.[54]
Clinical non-responders to cardiac resynchronization therapy
Despite the encouraging results and beneﬁcial response to CRT comparable to medically 
treated heart failure patients [6,49], individual responses vary signiﬁcantly.[59] Clinical studies 
with diﬀerent numbers of patients demonstrated that 20-30% of patients did not beneﬁt from 
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CRT.[49-51] Reuter and coworkers showed that 18% of their CRT patients did not respond 
clinically.[63] When data from the MIRACLE Trial are analyzed carefully, the number of 
non-responders (according to patient’s perception) ranged from 12% to 20%, depending on 
the deﬁnition of a responder. In particular, 30% of patients did not improve in NYHA class 
and 2% of patients even deteriorated in NYHA class after CRT.[49] At the Leiden University 
Medical Center 22% of the CRT patients did not improve in functional NYHA class after 
6 months of CRT therapy.[64,65] So, despite the traditional inclusion criteria, still it is 
estimated that 20-30% of patients may not respond to CRT. These observations have shifted 
the attention to the identiﬁcation of patients, who are likely to respond to CRT, before 
implantation of the pacemaker, in order to reduce the number of non-responders. After 
evaluation of 61 CRT patients for QRS duration, we found that QRS duration at baseline was 
not predictive for response to CRT and could therefore not be used for adequate selection of 
clinical responders.[66] Additional inclusion criteria are needed to further optimize clinical 
response and to reduce of the percentage of clinical non-responders to CRT treatment for 
heart failure patients. Last years diﬀerent groups have studied the use of echocardiography 
for evaluation of CRT therapy and for the selection of potential responders to CRT.[60-62] 
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Aim and outline of the thesis
The aim of this thesis was to evaluate the eﬀectiveness of cardiac resynchronization therapy 
(CRT). Characterization of the clinical responders and non-responders from the CRT registry 
at the Leiden University Medical Center was performed to evaluate if diﬀerent parameters 
could predict clinical outcome of CRT and potentially lead to an increase of the percentage 
of clinical responders to CRT.
In chapter 2, the percentage of patients with an implantable cardioverter deﬁbrillator who 
could potentially beneﬁt from a CRT device were evaluated. In chapter 3 the ﬁrst 40 CRT 
implantations at the Leiden University Medical Center were evaluated for clinical response 
and long term follow-up. Chapter 4 to 6 evaluates the diﬀerence in clinical outcome between 
sinus rhythm and atrial ﬁbrillation patients, between diﬀerent underlying etiology (ischemic 
versus idiopathic cardiomyopathy) and for plasmamarkers of congestive heart failure (atrial- 
and brain natriuretic peptide). In chapter 7 all diﬀerent clinical parameters were evaluated 
at long term follow-up in a large group of CRT treated patients (n=125). The QRS duration is 
evaluated to predict clinical outcome before CRT device implantation in chapter 8. In chapter 
9, 10 and 11 tissue doppler imaging (an echocardiographic method) is used to evaluate and 
predict left ventricular dyssynchrony before and after CRT. Finally a review of the diﬀerent 
echocardiographic methods to evaluate and predict clinical respons with CRT is described 
in chapter 12.
The last chapter concerns the summary and conclusions of the thesis.  
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Table 1. New York Heart Association Classiﬁcation of Heart Failure
Class I. No limitation: ordinary physical exercise does not cause 
undue fatigue, dyspnoea or palpitations.
Class II.  Slight limitation of physical activity: comfortable at rest but ordinary activity 
results in fatigue, dyspnoea or palpitations.
Class III.  Marked limitation of physical activity: comfortable at rest 
but less than ordinary activity results in symptoms.
Class IV.  Unable to carry out any physical activity without discomfort: symptoms of 
heart failure are present even at rest with increased discomfort with any 
physical activity.
Table 2. End-points of large clinical CRT trials.
   
1. NYHA class
2. Quality of Life Score
3. 6-minute hall walk test
4. LVEF/LV reverse remodeling
5. Hospitalization rate
6. Mortality rate
NYHA: New York Heart Association Class; LVEF: Left Ventricular Ejection Fraction.  
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ICD-therapy prevents sudden death in patients at high risk, but incidence of death due to 
heart failure remains unaltered. Recent data suggest that biventricular (BV) pacing is useful 
in patients with heart failure. It is unclear, how many patients with an ICD indication may 
have an indication for BV pacing. Therefore all patients who received an ICD were analyzed 
for eligibility of BV pacing using the following criteria: NYHA class III or IV, QRS duration 
>120 ms, depressed LVEF. 390 consecutive patients received an ICD from June 1996 till 
March 2001. Underlying disease was ischemic heart disease in 66%. In the 390 patients the 
mean LVEF was 36±17%, 20% were in NYHA class  III-IV and 16% were in NYHA class II 
with an LVEF <30%.  Of these 140 patients, 79 had a QRS duration >120 ms. Thus, 79 (20%) 
patients were eligible for BV pacing in addition to ICD-therapy. Patients who received a BV 
pacemaker in addition to ICD-therapy had a superior survival, improved in NYHA class 
and showed a signiﬁcantly lower hospitalization rate as compared to patients who received 
an ICD only. Screening for eligibility of BV pacing may be considered in patients with CHF 
scheduled for ICD implantation. 
Implantable cardioverter deﬁbrillator (ICD) therapy aims for the prevention of sudden 
cardiac death in high-risk patients. The AVID Trial has shown that the risk of sudden death in 
patients with severely depressed left ventricular function can be reduced by an ICD, although 
mortality remains high 1. A large number of deaths can be attributed to end-stage heart failure 
2. In these patients, biventricular (BV) pacing may be considered in adjunct to ICD-therapy. 
It is currently unclear, how many patients with a standard ICD indication also have a possible 
indication for BV pacing. Therefore, the aim of the present study was to analyze the potential 
need for BV pacing in patients with standard indications for ICD treatment.  
Abstract
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All patients who underwent ICD implantation in our hospital during a 5-year period (from 
June 1996 till March 2001) were analyzed for eligibility of BV pacing. Selection criteria were: 
severe heart failure symptoms (NYHA class III or IV), QRS duration of >120 ms (LBBB) and 
depressed left ventricular ejection fraction (<35%) 3-13. 
Several studies have suggested that patients with mild-moderate heart failure (NYHA class 
II), LBBB and QRS duration >120 ms and a left ventricular ejection fraction <30% may 
also beneﬁt from BV pacing  6,13,14. These patients were also identiﬁed among the patients 
undergoing ICD implantation. Follow-up was obtained during a 1-year period.
390 consecutive patients were referred for ICD implantation (June 1996 till March 2001). 
There were 318 men, mean age 59±13 years. Underlying cardiac disease is shown in Figure 
1. Indications for ICD implantation were out-of-hospital cardiac arrest (52%), ventricular 
tachyarrhythmia (46%) and preventive (2%). Sinus rhythm was present in 92% of the patients. 
The mean QRS duration was 121±35 ms (range 80-230 ms). The mean LVEF was 36±17%. The 
incidence of severe heart failure (NYHA class III or IV) was 20%; 62 patients were in NYHA 
class II with an LVEF <30%. Of these 140 (36%) patients, 79 (20%) had a QRS duration >120 
ms, being eligible for BV pacing in addition to ICD-therapy. Underlying cardiac disease is 
shown in Figure 2. Of the the 79 eligible patients, the most recent 20 received a biventricular 
Methods
Results
Figure 1 - Etiology of cardiac disease in the 390 
patients treated with an ICD.
DCMP = dilated cardiomyopathy; 
VF = ventricle ﬁbrillation
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pacemaker. During follow-up of 1 year, the hospitalization rate for congestive heart failure was 
2.86±4.05 days/year in the patients receiving an ICD only as compared to 0.48±1.5 days/year 
(P<0.05) in the patients receiving a biventricular pacemaker. One year mortality was 20% in 
the patients receiving an ICD, as compared to 10% in the patients receiving a biventricular 
pacemaker.
NYHA class did not improve in the patients receiving an ICD (from 2.6±0.6 to 2.8±0.8, 
NS), whereas the patients who received a biventricular pacemaker improved signiﬁcantly in 
NYHA class (from 3.2±0.6 to 2.1±0.6, P<0.05).
Currently, ICD implantation is an accepted 
Figure 2 - Etiology of cardiac disease in the 79 
ICD treated patients eligible for biventricular 
pacing.
DCMP = dilated cardiomyopathy
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therapy to prevent death from tachy-arrhythmias. An improvement in long-term outcome 
has been reported as compared to patients who were treated medically 7. However, in patients 
with more advanced heart failure, mortality remains high mainly due to pump failure. In 
these patients, BV pacing may be an option. Recent studies have shown direct improvement 
in pump function, whereas other studies with longer follow-up have demonstrated a sustained 
beneﬁt in terms of improvement in left ventricular ejection fraction, heart failure symptoms 
(NYHA class), peak oxygen consumption, and 6 minute walking test 1,3. In the current analysis, 
the potential need for BV pacing was estimated at 20% among the 390 ICD devices that were 
implanted at our institution in a 5-year period, similarly to data from Stellbrink et al 15. During 
the 1-year follow-up period, it became evident that patients who received a BV pacemaker 
in combination with an ICD, improved signiﬁcantly in NYHA class, had a superior survival 
with a signiﬁcant reduction in hospitalization rate. Thus, in patients with moderate-severe 
heart failure, screening for eligibility for BV pacing may be indicated.
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Biventricular pacing has been introduced to treat patients with end-stage heart failure, and 
short-term results of this technique are promising. Since data on longer follow-up are limited 
to 3 months follow-up, the sustained eﬀect of biventricular pacing is unclear and long-term 
survival is unknown. Forty patients with end-stage heart failure, NYHA class III or IV, left 
ventricular (LV) ejection fraction (EF) <35%, QRS duration >120 ms and left bundle branch 
block morphology received a biventricular pacemaker. At baseline, at 3, and 6 months after 
implantation the following parameters were evaluated: New York Heart Association (NYHA) 
class, Minnesota Quality of life score, QRS duration on surface electrocardiogram, 6-minute 
walking distance and LVEF. Long-term follow-up was obtained up to 2 years. All clinical 
parameters improved signiﬁcantly at 3 months and remained unchanged at 6 months follow-
up. LVEF increased from 24 ± 9 % to 34 ± 11%. Before implantation, patients were hospitalized 
(for congestive heart failure) on average 3.9 ± 5.3 days/year, as compared to 0.5 ± 1.5 days/
year after implantation. Long-term follow-up showed a survival of  87.5% at 2 years. Thus, 
biventricular pacing resulted in improvement of symptoms and quality of life, accompanied 
by improvement in 6-minute walking distance and LVEF. These eﬀects were observed at 
3 months post-implantation and were maintained at 6 months follow-up. Moreover, 2-year 
survival was excellent. 
Abstract
Eﬀectiveness of Resynchronization Therapy in Patients with End-Stage Heart Failure
 43 
Recently, biventricular pacing has been introduced to treat patients with end-stage heart 
failure1. The short-term results of this technique are promising; diﬀerent studies have 
demonstrated improvement of hemodynamic measurements 2-4 and systolic left ventricular 
(LV) function5. Studies with intermediate follow-up have demonstrated improvement in 
symptoms, quality of life, exercise capacity and LV function.5-9 Most studies have few patients 
and follow-up is frequently limited to 3 months. In the present study, sustained clinical beneﬁt 
and long-term prognosis were evaluated in a relatively large cohort of patients with end-stage 
heart failure treated with biventricular pacing.
 Patients
The traditional inclusion criteria for biventricular pacing were applied 1: end-stage heart 
failure, NYHA class III or IV; LV ejection fraction (EF) <35%; QRS duration >120 ms, or 
>200 ms for paced QRS (in patients with a previous pacemaker), left bundle branch block 
morphology. Consecutive patients with ischemic and nonischemic etiology were included; 
etiology of heart failure was assessed by left- and right-sided heart catheterisation and 
coronary angiography. Patients with atrial ﬁbrillation were also included.
Pacemaker implantation
The LV pacing lead was inserted transvenously via the subclavian route. A coronary sinus 
venogram was obtained during balloon oclusion, and the LV pacing lead was inserted through 
the coronary sinus with help of a dedicated 8F guiding catheter. The lead was positioned as 
far as possible in the venous system, preferably in the (postero-)lateral vein10. The other leads 
were positioned in the high right atrium and in the septal region of the right ventricle. The 
leads were connected to a dual chamber biventricular pacemaker (programmed in DDD-R 
mode, when sinus rhythm was present or in VVI-R mode when atrial ﬁbrillation was present). 
When a conventional indication for a deﬁbrillator existed, a combined device was implanted. 
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Total implant procedure duration, LV lead implantation time and ﬂuoroscopy time were 
measured. 
Clinical evaluation
Patients were evaluated at the outpatient clinic at baseline and at 3 and 6 months following 
biventricular pacing. Heart failure symptoms were classiﬁed using the NYHA Score. Quality 
of life score was assessed using the Minnesota Living with Heart Failure questionnaire.11 
This questionnaire contains 21 questions concerning the patient’s perception of the eﬀects 
of heart failure on daily life activities. Questions are scored from 0 to 5, resulting in a total 
score from 0 to 105, with the highest score reﬂecting the worst quality of life. A surface 
electrocardiogram (12-lead at 50 mm/s) was obtained at all visits and the QRS morphology 
and duration were measured. Exercise tolerance was evaluated using a 6-minute hall walk 
test at all visits.12  Resting 2-dimensional echocardiography was performed at baseline and 6 
months follow-up to assess LVEF. From the apical 2- and 4-chamber images, the LVEF was 
determined using the biplane Simpson’s rule.13 
Long term follow up
The long-term follow-up was performed by chart review, telephone contact and outpatient 
clinical visits. Follow-up data were acquired up to 2 years. Events were classiﬁed as cardiac 
death (deﬁned by the hospital chart documenting arrhythmic death, sudden cardiac death or 
death attributable to congestive heart failure or myocardial infarction), nonfatal myocardial 
infarction and congestive heart failure requiring hospitalization. Moreover, the  average 
length of hospital stay per patient (expressed in days/year) was compared before and after 
pacemaker implantation.
Statistical analysis
Continuous data were expressed as mean ± SD and compared using the Student t test for 
paired and unpaired data when appropriate. Univariate analysis for categorical variables was 
performed using the chi-square test with Yates’correction. Simultaneous comparison of >2 
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mean values was performed by using 1-way ANOVA.The (event-free) survival of patients 
was evaluated using Kaplan-Meier curves. For all tests a P-value <0.05 was considered 
signiﬁcant.
Patient population
Forty patients were included (31 men, mean age 64 ± 10 years). The mean NYHA class was 
3.3 ± 0.5. According to the inclusion criteria, all patients had severe LV dysfunction, with 
a mean LVEF of  24 ± 9% (range 11 to 35%). Nineteen (48%) patients had heart failure of 
ischemic etiology and 21 (53%) of nonischemic etiology. Mean QRS duration on surface 
electrocardiogram ranged from 120 to 240 ms.
Pacemaker implantation
Eleven patients had previously undergone 
pacemaker implantation for conventional 
indications for permanent pacing (1VVI 
and 10 dual-chamber pacemakers); in these 
patients a left ventricular lead (Easytrack 
4512-80, Guidant, MN, USA or Attain-
SD 4189, Medtronic Inc., MN, USA) 
was implanted, while the right atrial and 
ventricular leads were left unchanged. All patients received a biventricular DDD-R pacemaker 
(34 Contak TR or CD, Guidant, MN, USA and 6 InSync III or CD, Medtronic Inc., MN, 
USA), programmed in DDD-R mode when sinus rhythm was present (n=26) and for each 
patient the atrioventricular interval was adjusted to maximize the mitral inﬂow duration using 
pulsed Doppler echocardiography. In patients with atrial ﬁbrillation (n=4), the pacemaker was 
programmed in the VVI-R mode. In 16 patients, a biventricular pacemaker with deﬁbrillator 
options was implanted. Mean implantation procedure time was 121 ± 45 minutes, with a LV 
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Figure 1. Individual locations of the LV-leads.
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lead positioning time of 57 ± 33 minutes and a ﬂuoroscopic time of 36 ± 29 minutes. A succes 
rate of 100% was achieved for the ventricular lead implantation. Early dislodgement of the 
LV lead occurred in 3 (7.5%) patients within 4 days after implantation and lead repositioning 
was necessary. No other complications were observed. The lead position of the individual 
patients is shown in Figure 1.
Clinical follow-up at 3 and 6 months
NYHA score. The mean NYHA score 
improved from 3.3 ± 0.5 at baseline to 2.1 
± 0.8 at 3 months (P<0.05), and remained 
unchanged at 6 months (P<0.05 vs 
baseline, NS vs 3 months) (Figure 2). At 3 
months follow-up, 9 (23%) patients were 
in NYHA class I, 21(54%) in NYHA 
class II, 7 (18%) in NYHA class III and 
2 (5%) in NYHA class IV. At 6 months 
follow-up, 7 (18%) of the patients were 
in NYHA class I, 20 (52%) in class 
II, 10 (26%) in class III and 1 (3%) in class IV. The distribution of patients according to 
NYHA class at 6 months was not signiﬁcantly diﬀerent from the distribution at 3 months. Of 
interest, 2 patients exhibited additional improvement in NYHA class at 6 months, whereas 
7 demonstrated initial improvement at 3 months followed by worsening at 6 months. The 
individual data are presented in Figure 3. 
Quality of life, Minnesota score. Quality of life score at baseline was 42 ± 14 and decreased 
by a mean of 33% at 3 months follow-up (P<0.05) and remained unchanged at 6 months 
follow-up (Figure 4A). Of note, 21 patients improved more than 25% in quality of life score.
QRS duration. At baseline mean QRS duration was 180 ± 31 ms, and decreased 
signiﬁcantly to 148 ± 27 ms (P<0.05) at 3 months follow-up which remained unchanged at 6 
Figure 2. Mean NYHA score at baseline, 3 months and 6 
months after pacemaker implantation. A signiﬁcant decrease 
in NYHA class was observed at 3 months post-implantation 
which remained unchanged at 6 months. *: P<0.05.
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Figure 3 - Individual NYHA scores at baseline, 3 months and 6 months after pacemaker implantation. 
Figure 4A. Mean Quality of Life score at baseline, 3 months and 6 months after pacemaker implantation. A signiﬁcant 
decrease was observed at 3 months, which remained unchanged at 6 months.  
QOL: Quality of life score; *: P<0.05.
Figure 4B. Mean QRS duration at baseline, 3 months and 6 months after pacemaker implantation. A signiﬁcant reduc-
tion in QRS duration was observed at 3 months, which remained unchanged at 6 months. *: P<0.05.
Figure 4C. Mean 6-minute walking distance at baseline, 3 months and 6 months after pacemaker implantation. The 
6-minute walking distance increased signiﬁcantly at 3 months after implantation and remained unchanged at 6 months. 
6-min WT: 6-minute walk test; *: P<0.05.
Figure 4D. Mean LVEF at baseline and at 6 months after pacemaker implantation. The LVEF increased signiﬁcantly 
after 6 months pacing. LVEF: Left ventricular ejection fraction; *: P<0.05.
4A 4B
4C 4D
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months follow-up (Figure 4B). 10 (25%) patients had a >25% reduction in QRS duration at 6 
months follow-up.
Six-minute hall walk test. The mean distance walked was 262 ± 92 m at baseline, which 
had improved on average 51% (P<0.05) at 3 months follow-up and remained unchanged at 
6 months follow-up. 23 (61%) patients had improved >25% in walking distance at 6 months 
follow-up (Figure 4C). 
Left ventricular ejection fraction. LVEF was 24 ± 9 % at baseline and improved signiﬁcantly 
at 6 months follow-up (34 ± 11%, P<0.05) (Figure 4D). A relative improvement of 25% or more 
was observed in 29 (73%) patients. 
Symptoms vs change in other parameters. An improvement in NYHA class by 1 grade or 
more was observed in 31(78%) patients. The changes in the other parameters in patients with 
and without improvement in NYHA class are summarized in Table 1. All clinical parameters 
at baseline tested were not signiﬁcantly diﬀerent. However, the non-responders tended to 
have a lower LVEF, were more frequently in NYHA class IV, had a worse quality of life score 
and less performance during the 6-minute walk test.
Hospitalization before vs after pacemaker implantation. Before implantation, patients were 
hospitalized (for congestive heart failure) on average 3.9 ± 5.3 days/year, as compared to 0.5 ± 
1.5 days/year after implantation (P<0.05). The number of annual hospitalisations per patient 
decreased from 0.8 ± 1.1 before to 0.1 ± 0.3 after implantation (P<0.05).
Figure 5. Survival curve of the 40 patients.
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Long-term prognosis. The 
mean follow-up was 11.2 ± 5.4 
months (range 1.6 to 27.2 months) 
and 21 patients (53%) had a follow-
up longer than 1 year. During 
follow-up, 5 (12.5%) patients died: 
1 sudden cardiac death, 2 due to 
end-stage heart failure and 2 of 
non-cardiac origin (1 sepsis and 
1 prostate cancer). The actual 
survival curve is shown in Figure 
5. During follow-up 4 additional 
events included: 1 nonfatal 
myocardial infarction and 3 
patients requiring hospitalisation 
due to congestive heart failure. 
 
Biventricular pacing in 40 patients with end-stage heart failure resulted in an improvement in 
symptoms (NYHA class) and quality of life, accompanied by improvement in more objective 
parameters including  6-minute walking distance and LVEF. These eﬀects were observed at 
early follow-up (3 months post-implantation) and were maintained at 6 months follow-up. In 
addition, annual hospitalization-rates for heart failure decreased signiﬁcantly after pacemaker 
implantation and excellent long-term survival (up to 2 years) was observed.
Long-term survival
At present, not many data are available on the long-term survival of patients with end-stage 
heart failure following biventricular pacing. It has been questioned whether biventricular 
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pacing may result in improved long-term survival. Potentially, the therapy could result in a 
higher mortality as observed with long-term treatment of patients with heart failure using 
positive inotropic agents to enhance systolic LV function.14 These agents force the failing 
heart to further increase its energy expenditure, resulting in further failure with an adverse 
eﬀect on patient longevity. Based on the experiences with inotropic agents, concern existed 
in the use of biventricular pacing and therefore, data on the long-term survival of patients 
with biventricular pacemakers is needed. Nelson et al 15 demonstrated in an elegant study 
with 10 patients with end-stage heart failure that biventricular pacing did not result in 
enhanced cardiac oxygen consumption. The authors actually showed a reduction in oxygen 
consumption during biventricular pacing as compared to an enhanced oxygen consumption 
during dobutamine infusion. Nelson et al 15 suggested that the beneﬁcial eﬀect may mainly 
result from resynchronization instead of enhanced systolic function. In extension of the 
short-term results by Nelson et al 15, the current data show excellent long-term survival in 
a relatively large group of patients with end-stage heart failure treated with biventricular 
pacing. Moreover, the hospitalization-rates for heart failure decreased signiﬁcantly. Besides 
the issue of reduced oxygen consumption secondary to resynchronization, other issues may 
still contribute to the favorable prognosis obtained with biventricular pacing. In the current 
study and in previous studies, improvement of systolic function has been demonstrated 
5,9,16, and LV systolic function has been demonstrated an powerful predictor of long-term 
survival.17 In addition, Etienne et al 18 have shown a reduction in mitral regurgitation 
following biventricular pacing, which is important since severe mitral regurgitation carries a 
poor prognosis.19 Moreover, Stellbrink and colleagues 20 have recently demonstrated reverse 
remodeling in 25 patients treated for 6 months with biventricular pacing, which is also 
important for long-term prognosis. Thus, various issues may contribute to the favorable long-
term survival observed in the current study, and further studies (evaluating these diﬀerent 
variables using a more extensive echocardiographic protocol and preferably a control group) 
are needed to provide more insight in the mechanisms underlying this beneﬁt.
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Cardiac resynchronization therapy (CRT) is a new therapeutic option for drug-refractory 
end-stage heart failure patients. Large experience has been obtained in patients with sinus 
rhythm, whereas the use of CRT in patients with chronic atrial ﬁbrillation (AF) has not been 
studied extensively. Accordingly we evaluated the clinical response and long-term survival 
of CRT in heart failure patients with chronic AF, and the results were compared to patients 
with sinus rhythm undergoing CRT.
Sixty patients with end-stage heart failure (30 with sinus rhythm and 30 with chronic AF), 
NYHA class III-IV, LVEF<35%, QRS>120ms and a left bundle branch block  received a 
biventricular pacemaker. NYHA class, Minnesota Quality of Life score, and 6-minute 
walking distance were evaluated at baseline and after 6 months of CRT. Long-term follow-
up was obtained up to 2 years. NYHA class, Quality of life score and the 6-minute walking 
distance improved signiﬁcantly in both groups after 6 months of CRT. On an individual 
basis, the number of non-responders was higher in the group of patients with AF. Still, long-
term survival was comparable between patients with sinus rhythm and AF. Patients with AF 
demonstrated comparable beneﬁt from CRT as compared to patients with sinus rhythm.
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Many patients with severe congestive heart failure also develop chronic atrial ﬁbrillation 
(AF) and cardiac resynchroization therapy (CRT) has been shown to also improve symptoms, 
exercise capacity and systolic left ventricular function in these patients [1-8]. Two issues 
remain unresolved in patients with AF: First, various studies have shown that 20-30% of 
patients (with sinus rhythm) do not respond to CRT, despite adequate selection criteria [4]; it 
is unknown whether the number of non-responders to CRT is the comparable in patients with 
AF. Second, the long-term beneﬁt of CRT in patients with AF has not been demonstrated. 
These issues are addressed in the current study.
 Patients, Study Design
Based on traditional selection criteria of patients with drug-refractory heart failure (NYHA 
class III or IV, left ventricular ejection fraction  <35%, QRS duration >120 ms or >200 ms 
for a paced QRS, and left bundle branch block conﬁguration), 30 consecutive patients with 
sinus rhythm and 30 consecutive patients with AF underwent implantation of a CRT device. 
All AF patients had persistent (>3 months) AF. All included patients are part of a prospective 
registry on the clinical evaluation of patients receiving a CRT device.
 Pacemaker Implantation 
Despite the presence of persistent AF all patients received a 3 lead pacing system. The left 
ventricular pacing lead (Easytrack 4512-80, Guidant, MN, USA or Attain-SD 4189, Medtronic 
Inc., MN, USA) was inserted transvenously via the subclavian route. A coronary sinus 
venogram was obtained during balloon occlusion, and the left ventricular pacing lead was 
inserted through the coronary sinus with help of a dedicated 8F guiding catheter. The lead 
was advanced as far as possible in the venous system, preferably in the (postero-)lateral region. 
The other leads were positioned in the high right atrium and in the right ventricle. The leads 
were connected to a dual chamber biventricular pacemaker (26 Contak TR, Guidant, MN, 
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USA and 6 InSync III, Medtronic Inc., MN, USA). In 28 patients (15 with sinus rhythm and 
13 with AF) a conventional indication existed for a deﬁbrillator, and these patients received a 
combined device (26 Contak Renewal CD, Guidant, MN, USA and 2 InSync CD, Medtronic 
Inc., MN, USA). If sinus rhythm was present the pacemaker was programmed in the DDDR 
mode and in the patients with AF, the pacemaker was switched in the VVI-R mode. 
 
Clinical Evaluation
At baseline and after 6 months of CRT patients were clinically evaluated. Heart failure 
symptoms were classiﬁed using the NYHA Score. Quality of Life score was assessed using 
the Minnesota Living with Heart Failure questionnaire[9]. This questionnaire contains 21 
questions concerning the patient’s perception of the eﬀects of heart failure on daily life 
activities. Questions are scored from 0 to 5, resulting in a total score from 0 to 105, with 
the highest score reﬂecting the worst quality of life. QRS duration and morphology were 
measured from the surface electrocardiogram by 2 independent observers. Exercise capacity 
was evaluated by assessing the 6-minute walking distance [10]. Resting 2D echocardiography 
was performed at baseline and 6 months follow-up to assess left ventricular ejection fraction. 
From the apical 2- and 4-chamber images, the left ventricular ejection fraction was determined 
using the biplane Simpson’s rule [11]. Interrogation of the device revealed the percentage of 
ventricular pacing in the AF patients over 6 months of CRT.
 Long-term Follow-up 
Long-term follow-up was performed by chart review, telephone contact and outpatient 
clinical visits. Follow-up data were acquired up to 2 years. Events were classiﬁed as cardiac 
death (deﬁned by the hospital chart documenting arrhythmic death, sudden cardiac death or 
death attributable to congestive heart failure or myocardial infarction), nonfatal myocardial 
infarction and congestive heart failure requiring hospitalization. Moreover, the average length 
of hospital stay per patient (expressed in days/year) was compared before and after pacemaker 
implantation.
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 Statistical Analysis 
Data were expressed as mean ± SD. Comparison of data was performed using the Student t 
test for paired and unpaired data when appropriate. In case of non-normal distribution of 
data, the Mann-Whitney U test was used. Univariate analysis for categorical variables was 
performed using the chi-square test with Yates’correction. Simultaneous comparison of >2 
mean values was performed by 1-way ANOVA with Bonferoni correction. For all tests a P-
value <0.05 was considered signiﬁcant.
 Baseline Characteristics
Thirty consecutive patients with sinus rhythm and 30 consecutive patients with AF underwent 
CRT and were included in the study. The study population comprised 51 men, 9 women, and 
the mean age was 65±9 years. Underlying etiology was non-ischemic in 31 (52%) and ischemic 
in 29 (48%) patients. The mean NYHA class was 3.2±0.4, with the majority (80%) of patients 
in NYHA class III. Medication included diuretics in all patients, angiotensine converting 
enzyme inhibitors in 90%, beta-blockers in 50%, spironolactone in 39%, and amiodarone 
in 27% of patients; all patients also used anti-coagulants. Of the 30 AF patients, 17 (57%) 
required permanent ventricular pacing, due to previous atrioventricular junction ablation 
(18±6 months before CRT). There were no signiﬁcant diﬀerences in baseline characteristics 
between the patients with sinus rhythm and AF (Table 1).
 Six-months Follow-up: Clinical Evaluation 
In patients with sinus rhythm (n=30) the mean QRS duration on the ECG decreased from 
180±33 ms to 160±21 ms (P<0.05). The mean NYHA class decreased from 3.2±0.4 to 2.2±0.8 
(P<0.05) after 6 months of CRT. The 6–minute walking distance improved signiﬁcantly by 
76%, and the quality of life score decreased by 28%. Of note, 21 (70%) patients had improved 
>25% in walking distance at 6 months follow-up and 17 (57%) patients had a reduction >25% 
in quality of life score. LVEF improved signiﬁcantly after 6 months CRT (Table 1).
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In the AF patients the mean QRS duration decreased from 205±15 ms to 164±35 ms (P<0.05). 
The mean NYHA class decreased from 3.2±0.4 to 2.3±0.6 (P<0.05) after 6 months of CRT. 
In addition, the 6-minute walking distance increased signiﬁcantly by 66% (P<0.05), and the 
quality of life score decreased by 19% (P<0.05). Of note, 18 (60%) patients had improved 
>25% in walking distance at 6 months follow-up and 14 (47%) patients had a reduction >25% 
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in quality of life score. The left ventricular ejection fraction increased from 20±11% to 27±8% 
(P<0.05) after 6 months of CRT (Table 1). When AF patients with and without atrioventricular 
node ablation were compared, the clinical improvement was comparable between both groups 
(Table 2). In the patients without atrioventricular node ablation however, the percentage of 
ventricular pacing was 82% vs 100% in the ablated patients (P<0.05). 
Responders were deﬁned as those patients who improved at least 1 class in NYHA score 
after 6 months of CRT. At 6-months follow-up, 43 (72%) patients were accordingly classiﬁed 
as responders and 17 (28%) as non-responders. There was a signiﬁcant diﬀerence between 
the percentage of responders in the sinus rhythm group when compared to the AF group 
(n=24, 80% versus n=19, 64% respectively, P<0.05). In the AF group there was a diﬀerence in 
percentage of clinical responders favouring the atrioventricular node ablated patients when 
compared to the non-ablated patients (71% versus 54%, ns). 
 Follow-up Data 
Patients with sinus rhythm were 
hospitalized for congestive heart 
failure on average 3.9±4.8 days/year 
before pacemaker implantation, 
as compared to 0.5±1.5 days/year 
after implantation (P<0.05). The 
number of annual hospitalizations 
per patient decreased from 
0.8±0.9 before to 0.2±0.4 after 
implantation (P<0.05). The mean 
follow-up of SR patients was 25±9 
months (range 8 to 37 months). 
During follow-up, 3 (10%) patients died, due to end-stage heart failure (Figure 1). After 2 
years of follow-up the mean NYHA class remained signiﬁcantly reduced from 3.2±0.4 to 
        Figure 1. Mortality curves of the sinus rhythm (n=30) and atrial   
        ﬁbrillation (n=30) heart failure patients. 
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2.3±1.0 (P<0.05) and the Quality of Life score remained reduced from 43±13 to 30±19 (P<0.05). 
Patients with AF were hospitalized for congestive heart failure on average 4.1±4.8 days/year 
before CRT, as compared to 0.7±1.8 days/year after implantation (P<0.05). The number of 
annual hospitalizations per patient decreased from 0.9±1.0 before to 0.3±0.5 after implantation 
(P<0.05). The mean follow-up of the AF patients was 19±11 months (range 4 to 46 months). 
During follow-up, 7 (23%) patients died: 6 (20%) due to end-stage heart failure and 1 of non-
cardiac origin. After 2 years of follow-up the mean NYHA class remained reduced (from 
3.2±0.4 to 2.4±0.8, P<0.05) and the Quality of Life score also remained improved (from 43±17 
to 33±24, P<0.05). When survival was compared between the sinus rhythm and AF groups, the 
mortality rate was not statistically diﬀerent among both groups, although the patients with 
AF tended to have a higher mortality (10% versus 23%, p=0.07). The actual survival curves of 
the 2 patient groups are shown in Figure 1. 
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In the current study the beneﬁt of CRT in patients with AF was compared to that in patients 
with sinus rhythm. The main ﬁndings can be summarized as follows:
1.beneﬁt, as measured by clinical parameters (NYHA class, exercise capacity, quality of life 
score) was comparable between patients with sinus rhythm and AF; 2.the individual number 
of non-responders was higher in patients with AF; 3.the reduction in hospitalization rate was 
comparable between AF and sinus rhythm patients; and 4. long-term survival on CRT was 
comparable between both groups. Various studies have demonstrated the beneﬁt of CRT 
in patients with heart failure [4,5,6]. These studies showed an improvement in symptoms, 
exercise capacity and systolic LV function [4,5,6]. Besides, a reduction in hospitalization 
for decompensated heart failure was shown and a favourable mid-term survival on CRT 
as compared to optimal medical therapy [4,5,6]. Recent studies focusing on the beneﬁt of 
CRT in patients with AF, demonstrated that patients with AF may also beneﬁt from this 
therapy [5,12,13]. Initially, Etienne and colleagues [12] showed in 11 patients with AF an 
acute improvement in hemodynamics immediately following CRT. In a sub study from the 
MUSTIC Trial [13] 37 patients with AF were evaluated, showing improvement in clinical 
parameters following a 3-month period of active CRT. In particular, a 10% improvement 
in 6-minute walking distance and a 13% improvement in peak oxygen consumption were 
shown. The mortality at 9-months follow-up was 11%. In the current study, similar results 
were obtained. Both patients with sinus rhythm and AF exhibited beneﬁt from CRT, and 
both groups demonstrated signiﬁcant improvement in clinical parameters. The individual 
response to CRT in patients with AF is currently not clear. Careful analysis of data from 
the MIRACLE Trial has revealed that 20-30% of patients do not respond to CRT [4]. In 
the current study, we have shown that the number of responders was higher in the patients 
with sinus rhythm as compared to the patients with AF. Of interest, when patients with 
AF were separated into patients with previous atrioventricular node ablation and without 
ablation, it appeared that beneﬁt was larger in patients with previous ablation. Leon and 
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colleagues [14] evaluated 20 patients with AF, heart failure and permanent right ventricular 
pacing after atrioventricular node ablation after upgrading to CRT. These patients exhibited 
a 33% improvement in the quality of life score and a 44% improvement in left ventricular 
ejection fraction; values higher than the modest improvements observed in previous studies 
with AF patients undergoing CRT [12,13]. In these previous studies, substantial percentages 
of patients with AF did not undergo AV node ablation. It is conceivable, that an (partial) 
explanation for the higher beneﬁt in ablated patients may be that AV node ablation ensures 
100% ventricular stimulation, whereas even with optimized rate control in our non-ablated 
patients only 82% ventricular pacing was obtained during CRT. These observations suggest 
that AV node ablation may be beneﬁcial in patients with AF to achieve maximal beneﬁt from 
CRT. Besides the improvement in clinical parameters, hospitalization for decompensated 
heart failure was signiﬁcantly reduced after CRT, both in patients with sinus rhythm and AF. 
This observation is in line with previous studies showing an 80% reduction in hospitalization 
rates in patients with sinus rhythm [4,5,6]. The long-term survival of patients with AF 
undergoing CRT has not been evaluated previously, and the results in the current study 
indicate a comparable survival between patients with sinus rhythm and AF. However the 
number of patients evaluated is small and larger studies are needed to further evaluate long-
term survival after CRT in patients with AF. A limitation of the current study is that the SR 
patients are programmed at a lower rate of 50 bpm and the AF patients at a lower rate of 
70 bpm which may have impacted on the observed outcomes.  Secondly, patients with and 
without previous atrioventricular node ablation were included. The patients with a previous 
atrioventricular node ablation received right ventricular pacing at the time of implantation of 
the CRT device, which may have altered left ventricular synchrony. This may have inﬂuenced 
the current results, and further studies in patients with and without atrioventricular node 
ablation are needed.
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Cardiac resynchronization therapy (CRT) is a recently introduced therapeutical option for 
patients with severe heart failure and intraventricular conduction disturbances. However, it is 
estimated that 20-30% of patients may not respond. Patients with ischemic cardiomyopathy 
(IC) may respond less favorably to CRT compared to patients with idiopathic dilated 
cardiomyopathy (IDC). Accordingly, the beneﬁcial eﬀects of CRT were evaluated in 2 subsets 
of patients: IC and IDC. Seventy-four patients with end-stage heart failure, New York Heart 
Association class (NYHA) III/IV, left ventricular (LV) ejection fraction <35%, QRS>120ms 
and left bundle branch block received a biventricular pacemaker. At baseline and 6 months 
after implantation the following parameters were evaluated: NYHA class, Minnesota Quality 
of life score, QRS duration and 6-minute walking distance. With 2D echocardiography the 
LV ejection fraction and severity of mitral regurgitation were assesed before and 6 months 
after CRT. Long-term follow-up and hospitalization rate were obtained up to 2 years. Of 
the 74 patients, 46%(n=34) had IC and 54%(n=40) IDC. At 6 months follow-up all clinical 
paramaters, QRS duration, LV ejection fraction and mitral regurgitation improved signiﬁcantly 
in both groups. Long-term (2-year) follow-up showed a survival rate of 87.5% for patients with 
IDC and 88.3% for patients with IC. The percentages of responders to CRT (deﬁned an 
improvement in NYHA class ≥1 grade) were the comparable in both groups (65% vs 71%). 
Thus, the underlying etiology of heart failure (IC vs IDC) was not related to the response to 
CRT. 
Abstract
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The eﬀect of cardiac resynchronization therapy (CRT) in patients with ischemic 
cardiomyopathy (IC) was compared to that in patients with idiopathic dilated 
cardiomyopathy (IDC). If underlying etiology would have an inﬂuence on clinical outcome, 
this may then be useful to optimize the selection of patients who are likely to respond to 
CRT.
Patients, study protocol. Consecutive patients (n=74) who received a biventricular 
pacemaker for congestive heart failure were included. The traditional selection criteria for 
CRT were applied: -NYHA class III or IV; -left ventricular (LV) ejection fraction <35%; -
QRS duration >120 ms; -and left bundle branch block morphology.1-3 Clinical evaluation was 
performed before pacemaker implantation and repeated after 6 months of CRT. Clinical 
evaluation included assessment of NYHA class, quality of life score (using the Minnesota 
questionnaire) and performance of the 6-minute walk test. A resting electrocardiogram 
was acquired, and QRS duration was measured at baseline and after 6 months of CRT. 
In addition, resting 2-dimensional echocardiography was performed to assess LV 
ejection fraction and mitral regurgitation before and 6 months after CRT. In addition, 
hospitalization rate (before vs after CRT) and long-term survival (up to 36 months) were 
compared between the 2 groups.  
Assessment of etiology underlying heart failure. The etiology was considered IC in the 
presence of signiﬁcant coronary artery disease (≥50% stenosis in one of major epicardial 
coronary arteries) on coronary angiography, whereas patients with normal coronary arteries 
were classiﬁed as having IDC. All coronary angiographies were performed within 6 months 
of pacemaker implantation.
2-dimensional echocardiography. Patients were imaged in the left lateral decubitus 
position using a commercially available system (Vingmed system FiVe, General Electric 
– Vingmed, Milwaukee, WI, USA). Images were obtained using a 3.5 MHz transducer, at 
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a depth of 16 cm in the parasternal and apical views (standard long-axis, 2-chamber and 
4-chamber images). Standard 2-dimensional and color Doppler data (3 consecutive beats), 
triggered to the QRS complex, were saved in cineloop format. The LVEF was calculated 
from the conventional apical 2- and 4-chamber images, using the biplane Simpson’s rule.4 
The severity of mitral regurgitation was graded semi-quantitatively from color-ﬂow Doppler 
in the conventional parasternal long-axis and apical 4-chamber images. Mitral regurgitation 
was characterized as: mild=1+ (jet area/left atrial area<10%), moderate=2+ (jet area/left atrial 
area 10-20%), moderately severe =3+ (jet area/left atrial area 20-45%), and severe=4+ (jet 
area/left atrial area >45%).5 
Pacemaker implantation. First, a coronary sinus venogram was obtained using 
the balloon catheter. Next, the LV pacing lead (Easytrack 4512-80, Guidant, MN, USA 
or Attain-SD 4189, Medtronic Inc., MN, USA) was inserted transvenously via the 
subclavian route with the help of a 8F guiding catheter, and positioned in the (postero-
)lateral vein.6 The right atrial and 2 ventricular leads (with separate connectors) were 
positioned conventionally. The atrioventricular delay was optimized by 2-dimensional 
echocardiography so that it provided the longest ﬁlling time for completion of the end-
diastolic ﬁlling ﬂow before LV contraction.7,8 A biventricular DDD-R system was used in 
all patients (Contak TR, Guidant, MN, USA, n=30, InSync III, Medtronic, MN, USA, 
n=10). In 34 patients an indication existed for a deﬁbrillator, and these patients received a 
combined device (Contak CD/Renewal, n=32, Guidant, MN, USA, InSync CD, Medtronic, 
MN, USA, n=2).
Clinical evaluation. Clinical evaluation was performed at hospital admission before 
implantation of the biventricular pacemaker and after 6 months of CRT at the outpatient 
clinic. NYHA score was used to classify heart failure symptoms. Quality of life score was 
assessed using the Minnesota Living with Heart Failure questionnaire.9 This questionnaire 
contains 21 questions concerning the patient’s perception of the eﬀects of heart failure on 
daily life activities. Questions are scored from 0 to 5, resulting in a total score from 0 to 105, 
with the highest score reﬂecting the worst quality of life. Exercise tolerance was evaluated 
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by assessing the 6-minute walking distance and expressed in meters.10
Long-term survival, hospitalization rate. The long-term follow-up was performed 
by chart review, telephone contact and outpatient clinical visits. Follow-up data were 
acquired up to 3 years. Events were classiﬁed as cardiac death (deﬁned by the hospital chart 
documenting arrhythmic death, sudden cardiac death or death attributable to congestive 
heart failure or myocardial infarction), nonfatal myocardial infarction and congestive heart 
failure requiring hospitalization. Moreover, the average length of hospital stay per patient 
(expressed in days/year) was compared before and after pacemaker implantation. 
Statistical analysis. Data were expressed as mean ± SD. Comparison of data was 
performed using the Student t-test for paired and unpaired data when appropriate. In 
case of a non-normal distribution, the Mann-Whitney U-test was used. Proportions were 
compared using Chi-square analysis with Yates’ correction. For all tests, a P-value <0.05 was 
considered signiﬁcant.
Patient population. A total of 74 consecutive patients was included, with 40 (54%) 
having IDC and 34 (46%) IC. Of the IC patients, 31 (91%) had a prior infarction (90% 
anterior wall, 71% with a Q-wave) and the mean number of stenosed coronary arteries was 
2.3±1.0. The study population comprised 58 men, 16 women, with a mean age of 65 ± 11 years. 
According to the inclusion criteria, all patients had wide QRS complex (177 ± 29 ms, range 
120-220 ms) and left bundle branch block conﬁguration. The mean NYHA class was 3.1±0.4, 
with the majority (85%) of patients in NYHA class III. Medication included diuretics in 
all patients, ACE inhibitors in 85%, beta-blockers in 60%, spironolactone in 42%, and 
amiodarone in 30% of patients. No diﬀerences in baseline characteristics were observed 
between patients with IC and IDC (see Table 1).
Six-months follow-up: Clinical evaluation. In the 40 patients with IDC, the mean QRS 
duration on the electrocardiogram decreased from 178 ± 29 ms  to 164 ± 21 ms (P<0.05). The 
mean NYHA class decreased from 3.2 ± 0.4 to 2.3 ± 0.9 (P<0.05) after 6 months of CRT. The 
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6–minute walking distance improved signiﬁcantly from 258 ± 146 m to 362 ± 159 m (P<0.05), 
and the quality of life score decreased from 43 ± 16 to 33 ± 17 (P<0.05). LV ejection fraction 
improved from 23±13% to 32±11% (P<0.05). Twelve (30%) patients had severe (3-4+) mitral 
regurgitation at baseline. In 10 (83%) patients, mitral regurgitation improved by 1 grade or 
more after 6 months of CRT. 
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Two IC patients died (due to progressive heart failure) during the 6-months follow-
up period and data were collected in the remaining 32 patients with IC. The mean QRS 
duration decreased from 175 ± 29 to 158 ± 26 ms (P<0.05). The mean NYHA class decreased 
from 3.1 ± 0.4 to 2.2 ± 0.7 (P<0.05) after 6 months of CRT. In addition, the 6-minute walking 
distance increased signiﬁcantly from 305 ± 137 to 422 ± 133 m (P<0.05), and the quality of life 
score decreased from 39 ± 17 to 26 ± 15 (P<0.05). The LV ejection fraction increased from 
21±9% to 30±12% (P<0.05). Eleven (34%) patients had severe (3-4+) mitral regurgitation 
at baseline. In 9 (81%) patients, mitral regurgitation improved by 1 grade or more after 6 
months of CRT. Comparison of the 6-months follow-up results for the 2 groups showed no 
signiﬁcant diﬀerences (see Table 1).
Hospitalization rate, long-term survival. The IDC patients were hospitalized (for 
congestive heart failure) on average 3.8 ± 5.1 days/year before pacemaker implantation, 
as compared to 0.6 ± 1.5 days/year after implantation (P<0.05). The number of annual 
hospitalizations per patient 
decreased from 0.7 ± 1.0 before 
to 0.2 ± 0.3 after implantation 
(P<0.05). The mean follow-up 
of the 40 patients was 14.2 ± 7.8 
months (range 3.3 to 35.6 months). 
During follow-up, 5 (12.5%) IDC 
patients died: 1 sudden cardiac 
death, 3 due to end-stage heart 
failure and 1 of non-cardiac origin 
(sepsis). 
Before implantation, the 
IC patients were hospitalized 
(for congestive heart failure) on average 3.9 ± 4.8 days/year, as compared to 0.5 ± 1.9 days/year 
after implantation (P<0.05). The number of annual hospitalisations per patient decreased 
        Figure 1. Mortality curves of the sinus rhythm (n=30) and atrial   
        ﬁbrillation (n=30) heart failure patients. 
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from 0.8 ± 1.2 before to 0.1 ± 0.5 after implantation (P<0.05). The mean follow-up of the 34 
IC patients was 13.8 ± 6.8 months (range 0.8 to 36.4 months). During follow-up, 4 (11.7%) 
patients died: 3 due to end-stage heart failure and 1 of non-cardiac origin (prostate cancer). 
No signiﬁcant diﬀerence between the IDC and IC group existed for the hospitalization 
rate per year, the annual hospitalizations and survival rates. The actual survival curves are 
shown in Figure 1.
Responders versus etiology. Responders were deﬁned as those patients who improved 
at least 1 class in NYHA score after 6 months of CRT. At 6-months follow-up, 50 (68%) 
patients were accordingly classiﬁed as responders and 24 (32%) as non-responders. In the 
responders, the mean NYHA class decreased from 3.2±0.4 to 1.8±0.5 (by deﬁnition). The 
responders also showed a signiﬁcant improvement in 6-minute walking distance (from 280 
± 109 m to 427 ± 113 m, P<0.05) and a signiﬁcant reduction in quality of life score (40 ± 16 vs 
25 ± 13, P<0.05). The non-responders showed no improvement in any of these parameters 
(Table 2). In addition, all baseline values for these clinical parameters were not signiﬁcantly 
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diﬀerent among the responders and non-responders (Table 2). Importantly, the percentages 
of patients with IC and IDC were comparable between responders and non-responders 
(Figure 2). 
 
In line with previous observations 1-3, CRT resulted in a signiﬁcant improvement 
in symptoms, exercise capacity (as reﬂected in the 6-minute walking distance) and systolic 
function (as expressed in LV ejection fraction). In the current study, CRT improved the 6-
minute walking distance by 38% on average, comparable to the 23% shown by Cazeau et al.11 
The LV ejection fraction improved signiﬁcantly, which is in line with previous observations 
by Sogaard et al12 showing an improvement from 33±6% to 39±7% (P<0.01). In addition, 
most (82%) of our patients showed a reduction in severity of mitral regurgitation. These 
ﬁndings are also in line with data recently presented by Breithardt et al13, although these 
authors reported only on acute improvement following CRT. In addition, data from the 
MIRACLE Trial demonstrated a signiﬁcant improvement in mitral regurgitation after 6 
months of CRT.1 
Discussion
Figure 2. The precentages of patients with IC or IDC in the responder
 and nonresponder groups
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The improvements in the aforementioned parameters also translated into clinically 
relevant beneﬁt. A signiﬁcant reduction in the mean number of hospitalization days per 
year (on average 86%) was observed and the annual number of hospitalizations decreased 
from 0.8 ± 1.1 to 0.2 ± 0.4  (P<0.05). Also, the mid-term survival was good, with 89% of 
patients being alive at 6 months and 88% at 1 year; only 9% of patients died from ongoing 
heart failure. This result was comparable to data obtained from a recent meta-analysis, 
based on 11 reports of 4 randomized studies with 1634 patients, although the data from this 
meta-analysis are limited to only a 3-6 month follow-up period.14
Although the results in patient groups are encouraging and response to CRT 
is beneﬁcial as compared to medically treated patients 1,15, individual responses vary 
signiﬁcantly.14 Studies in limited numbers of patients demonstrated that 20-30% of patients 
did not beneﬁt from CRT.1-3 In the currrent study, we have evaluated whether underlying 
etiology inﬂuenced response to CRT. However, as can be observed from Table 1, patients 
with IC and IDC both responded to CRT, as reﬂected in an improvement in clinical 
parameters. Moreover, the magnitude of beneﬁt (eg the reduction in NYHA class, the 
increase in 6-minute walking distance) were comparable between the 2 groups. Thus, in 
conclusion, the underlying etiology of heart failure (IC or IDC) was not related to the 
response to CRT.
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Cardiac resynchronization therapy (CRT) has recently been introduced to treat patients 
with drug-refractory heart failure.[1][2] Studies have demonstrated immediate hemodynamic 
improvement after CRT, followed by improvement in symptoms, quality of life  and exercise 
capacity.[1][2] Although the majority of patients responds well to CRT, 20% does not improve 
in symptoms. The main problem is the lack of objective parameters to measure the eﬀect of 
CRT. 
Natriuretic peptides are nowadays used in studies involving patients with heart failure.[3] 
In the current study, the value of these markers to objectively assess response to CRT, was 
evaluated. 
Patients, Study Design
Based on traditional selection criteria (NYHA classIII-IV, left ventricular ejection 
fraction(LVEF)<35%, QRS duration>120 ms and left bundle branch block conﬁguration), 
30 consecutive patients (23men, mean age 65±12years) underwent biventricular pacemaker 
implantation; 13 had ischemic and 17 idiopathic dilated cardiomyopathy. Medication consisted 
of diuretics, ACE inhibitors, spironolactone, beta-blockers, and/or amiodarone, and remained 
unchanged during the entire study.
The day before implantation, echocardiography  was performed in combination with tissue 
Doppler imaging (TDI) (to assess LVdyssynchrony). Clinical evaluation included assessment 
of NYHA class, ECG (QRS duration, morphology), quality of life, and 6-minute walking 
distance. Blood samples were obtained for analysis of natriuretic peptides (ANP, BNP). The 
evaluation was repeated 7 months after CRT.
Echocardiographic Analysis
Using a commercially available system (Vingmed system FiVe, General Electric– Vingmed, 
Milwaukee, WI, USA), standard 2-dimensional and color Doppler data were saved in cineloop 
Introduction
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format. The LVEF was calculated  using the biplane Simpson’s rule. The severity of mitral 
regurgitation was graded semi-quantitatively from color-ﬂow Doppler in the conventional 
parasternal long-axis and apical 4-chamber images. Tissue Doppler parameters were measured 
from color images by oﬀ-line analysis. The digital cineloops were analyzed using commercial 
software (Echopac 6.1, General Electric–Vingmed, Milwaukee, WI, USA). The sample volume 
was placed in the basal portions of the septal and lateral walls (using the 4-chamber images), 
to derive velocity proﬁles. Timing of peak systolic velocity was measured from the onset of 
the QRS-complex to the peak systolic velocity and expressed in ms. The diﬀerence between 
the timing of the peak systolic velocities of the septum versus the lateral wall, indicating 
dyssynchrony between the septum and lateral wall, was measured. 
Natriuretic Peptides
Peripheral venous blood was collected in sampling tubes containing EDTA as the anticoagulant. 
Plasma was separated and stored at -80°C until the measurement of N-terminal ANP and 
N-terminal BNP concentrations by immunoassays (N-terminal- ANP ELISA [1-98] code 
number BI-20892 and N-terminal-BNP EIA [1-76], code number BI-20852; Biomedica, Wien, 
Austria). 
Statistical Analysis
Data were expressed as mean ± SD. Comparison of data was performed using the Student t 
test for paired and unpaired data when appropriate. Since BNP and ANP are not normally 
distributed, we applied a log-transformation. Paired student’s t-tests were applied to evaluate 
diﬀerences in the log-transformed BNP and ANP levels before and after CRT. Analysis 
of variance was applied to evaluate BNP and ANP patterns between responders and non-
responders.
Univariate analysis for categorical variables was performed using the chi-square test with 
Yates’correction. Simultaneous comparison of >2 mean values was performed by using 1-way 
ANOVA with Bonferoni correction. For all tests a P-value<0.05 was considered signiﬁcant.
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Figure 1A. Mean N-terminal ANP levels in responders and non-responders before (Base) and after 7 months (7m-FU) of 
cardiac resynchronization therapy. 
A N P : 
F i g u r e 
1B. Mean N-terminal BNP levels in responders and non-responders before (Base) and after 7 months (7m-FU) of cardiac 
resynchronization therapy.  BNP: brain natriuretic peptide. ANP: atrial natriuretic peptide.
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Baseline Data
The QRS duration was 176±22ms.The mean NYHA class was 3.1±0.3, the quality of life score 
was 39±18, and the 6-minute walking distance was 259±130m. LVEF was 21±9% (range 12-33%). 
Five patients had 4+, 5 had 3+ and 7 had 2+ mitral regurgitation. TDI demonstrated a delay 
between peak systolic velocity in the septum and the lateral wall of 72±30 ms, illustrating LV 
dyssynchrony. Plasma levels of  ANP and BNP were 10522±8091 pmol/L and 1242±955 pmol/L, 
respectively.
Follow-up Data
Based on the improvement in NYHA class at 7 months, patients were divided into responders 
(n=20) and non-responders (n=10).  Baseline characteristics were not diﬀerent between the 
2 groups(Table 1). All echocardiographic results at baseline were comparable, except for the 
LV dyssynchrony: responders exhibited a larger delay between the septum and lateral wall, 
as compared to non-responders(Table 1).  Mean plasma levels of peptides were not diﬀerent 
between the two groups(Table 1). 
Responders.  The improvement in symptoms was accompanied by an improvement in quality 
of life score (from 39±15 to 28±15, P<0.01), 6-minute walking distance (from 264±106 m to 
385±122 m, P<0.01) and LVEF (from 22±7% to 31±9%, P<0.05) Mitral regurgitation grade 3+ 
or 4+ was present in 6 patients and improved by ≥1 grade in 5. TDI showed an improvement 
of dyssynchrony: the delay in peak systolic velocities between the septum and lateral wall 
improved from 90±20 ms to 44±28 ms (P<0.01). Plasma levels of  ANP and BNP decreased 
signiﬁcantly (Figure 1A,B). Fifteen of 20 (75%) of responders showed >10% reduction in 
ANP/BNP plasma levels.
Non-responders.  Neither quality of life score, exercise capacity nor LVEF  improved; mitral 
regurgitation grade 3+ or 4+ was present in 4 patients and none improved at follow-up. TDI 
did not show improvement in LV dyssynchrony. In the non-responders, plasma levels of ANP 
and BNP did not improve(Figure 1A, B). 
Nine of 10 (90%) non-responders did not show >10% reduction in ANP/BNP plasma levels.
Results
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The majority of patients with end-stage heart failure beneﬁts from CRT, although objective 
assessment of response is diﬃcult.[1][2] Studies have used improvement in NYHA class as a 
marker of beneﬁt, which is  a rather subjective parameter; more objective parameters, such as 
quality of life score, 6-minute walking distance, and LVEF  have also been used.[2]
In search of additional parameters to address severity of heart failure, natriuretic peptides have 
been used.[3] In the current study, patients with an improvement in clinical status, showed 
a reduction in ANP/BNP plasma levels after CRT, suggesting the usefulness of natriuretic 
peptides as an objective and quantitative marker to evaluate response to CRT.
Natriuretic peptides may be even more useful as prognostic markers then as diagnostic 
markers. Omland et al have shown that elevated plasma levels of natriuretic peptides, in 
particular BNP, were predictive of mortality.[4] The potential prognostic value of natriuretic 
peptides in patients treated with CRT therapy needs further study. 
Discussion
Chapter6
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Introduction: Cardiac resynchronization therapy (CRT) has been introduced to treat patients 
with end-stage heart failure, and results of this technique are promising. The aim of our study 
was to assess the sustained beneﬁt of CRT in a large patient cohort with end-stage heart 
failure at long-term follow-up. In addition, the prognosis of responders and non-responders 
was evaluated.  
Methods and Results: 125 patients with end-stage heart failure, NYHA class III or IV, LVEF 
<35%, QRS duration >120 ms and left bundle branch block morphology received a biventricular 
device. At baseline and 6-months after implantation the following parameters were evaluated: 
NYHA class, Minnesota Quality of life score, QRS duration on surface ECG, 6-minute 
walking distance and LVEF. Follow-up was obtained up to 3-years. After 6-months patients 
were divided in clinical responders and non-responders according to improvement in NYHA 
class. All clinical parameters improved signiﬁcantly at 6-months follow-up. Hospitalization 
for heart failure was 3.8±4.9 days/year before and 0.7±1.6 days/year after CRT. Survival at 1-, 2- 
and 3-year follow-up was 93%, 88% and 85%. Responders (78%) showed a signiﬁcantly better 
survival than non-responders at 2- and 3-year follow-up (96% and 93% for responders vs 81% 
and 73% for non-responders, P<0.05).
Conclusions: The improvement in functional status and symptoms after CRT is maintained at 
long-term follow-up (up to 3-years). The clinical improvement was associated with a signiﬁcant 
reduction in hospitalization-rate which was also maintained over the years. Pre-implantation 
selection of responders may result in even better long-term survival. 
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Health care costs for patients with heart failure are rising rapidly with the exponential rise 
in patients with heart failure [1,2]. Current treatment modalities for this speciﬁc patient 
population include heart transplantation, surgical revascularization or medical therapy [1,2]. 
Since the number of donor hearts is limited and revascularization is associated with a high 
morbidity and mortality for heart failure patients, medical treatment remains the only option 
in many patients with end-stage heart failure. However, medical treatment still remains sub-
optimal in terms of clinical beneﬁt and long-term prognosis [3,4]. Thus, alternative therapeutic 
approaches for heart failure patients have been explored. Cardiac resynchronization therapy 
(CRT) has been introduced as a novel treatment option for patients with heart failure and 
conduction delay [5-9]. The initial results with this technique are promising, and improvement 
in clinical symptoms, exercise capacity, quality of life and systolic function, have been 
demonstrated in large controlled clinical trials [5-10]. In addition, a signiﬁcant reduction 
in hospitalisation-rate has been demonstrated with CRT and meta-analysis of 4 follow-up 
studies has shown an improved survival following CRT [11].  Still, not much information is 
available on the persistence of the beneﬁcial eﬀects of CRT over longer follow-up periods. 
In addition, individual responses vary signiﬁcantly [11], and it is estimated that 20-30% of 
patients do not respond to CRT in short-term follow-up studies [5,9]. 
In the present study, the eﬀects of CRT were evaluated over long-term follow-up (up to 3-
years) in a large cohort of patients with end-stage heart failure. 
Moreover, the outcome of responders and non-responders at long-term follow-up was 
evaluated.
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Patients
Patients were selected according to the traditional inclusion criteria for CRT [5-10]:
- end-stage heart failure, NYHA class III or IV
- LVEF (left ventricular ejection fraction) <35%
- QRS duration >120 ms, or >200 ms for paced QRS (in patients with a previous 
device)
- left bundle branch block morphology.
Patients with ischemic and idiopathic dilated cardiomyopathy were included; patients with 
atrial ﬁbrillation were not excluded. Patients who were referred for surgical positioning of 
the LV lead (n=4) were not included in the current study. 
Device implantation  
The left ventricular (LV) pacing lead was inserted transvenously via the subclavian route. A 
coronary sinus venogram was obtained during balloon occlusion, and the LV pacing lead was 
inserted through the coronary sinus with help of a dedicated 8F guiding catheter. The lead was 
positioned as far as possible in the venous system, preferably in the (postero-)lateral vein. The 
other leads were positioned conventionally, in the high right atrium and the right ventricle. 
When a conventional indication for an ICD existed, a combined device was implanted.
Total implant procedure duration, LV lead implantation time and ﬂuoroscopy time were 
registered.
Clinical evaluation        
Patients were evaluated at the outpatient clinic at baseline, 6 months follow-up and late 
follow-up. Heart failure symptoms were classiﬁed using the New York Heart Association 
(NYHA) classiﬁcation. Quality of life score was assessed using the Minnesota Living with 
Heart Failure questionnaire [12].  This questionnaire contains 21 questions concerning the 
patient’s perception of the eﬀects of heart failure on daily life activities. Questions are scored 
Patients & Methods
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from 0 to 5, resulting in a total score from 0 to 105, with the highest score reﬂecting the worst 
quality of life.
A surface ECG (12-lead at 50 mm/s) was obtained at all visits and the QRS morphology and 
duration were measured. 
Exercise capacity was evaluated using a 6-minute hall walk test [13].
Resting 2D echocardiography was performed at baseline and 6 months follow-up to assess 
LVEF. From the apical 2- and 4-chamber images, the LVEF was determined using the biplane 
Simpson’s rule [14].
Long-term follow-up   
The long-term follow-up was performed by chart review, telephone contact and outpatient 
clinical visits. At all evaluations (baseline, 6-months and latest follow-up) the NYHA class 
and quality of life score were assessed. Follow-up data were acquired up to 3-years. Events 
were classiﬁed as cardiac death (deﬁned by the hospital chart documenting arrhythmic death, 
sudden cardiac death or death attributable to congestive heart failure or myocardial infarction), 
nonfatal myocardial infarction and congestive heart failure requiring hospitalization. Moreover, 
the average length of hospital stay per patient (expressed in days/year) was compared before 
and after device implantation.
Statistical analysis 
Continuous data were expressed as mean ± SD and compared using the Student t test for 
paired and unpaired data when appropriate. Univariate analysis for categorical variables was 
performed using the chi-square test with Yates’correction. Simultaneous comparison of >2 
mean values was performed by using 1-way ANOVA. The (event-free) survival of patients was 
evaluated by the method of Kaplan-Meier. To assess which variables (age, gender, LVEF, LV 
lead position (postero-lateral vs other positions), NYHA class III vs IV, atrial ﬁbrillation vs 
sinus rhythm, QRS duration at baseline and shortening of QRS duration after implantation) 
were predictive of long-term outcome, uni- and multivariate analyses were performed.
Finally, at 6 months follow-up, the patients were classiﬁed as responders or non-responders, 
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based on the presence/absence of improvement in NYHA class [15]. The long-term outcome 
is then compared between responders and non-responders. For all tests a P-value <0.05 was 
considered signiﬁcant.
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Patient population
One hundred and twenty-ﬁve patients were included (93 men, mean age 64±10 years). The 
patient characteristics are summarized in Table 1. The mean NYHA class was 3.1±0.3. In 
detail, 14 patients were in NYHA class IV and 71% of these patients were implanted while 
hospitalized for heart failure. According to the inclusion criteria, all patients had severe LV 
dysfunction, and the mean LVEF was 23±8% (range 12% to 35%). Underlying etiology was 
ischemic cardiomyopathy in 67 (54%) patients and idiopathic dilated cardiomyopathy in 58 
(46%). Mean QRS duration on the surface ECG (before implantation) ranged from 120 ms 
to 240 ms. Amiodarone (34% of patients) was administered for either atrial ﬁbrillation or 
ventricular arrhythmias.
Device implantation 
Sixteen patients had previously undergone device implantation for conventional indications 
for permanent pacing (2VVI and 14 dual-chamber devices); in these patients a LV lead 
(Easytrack 4512-80, Guidant, MN, USA or Attain-SD 4189, Medtronic Inc., MN, USA) 
was implanted, while the right atrial and ventricular leads were left unchanged. All patients 
received a biventricular DDD-R device (118 Contak TR or CD, Guidant, MN, USA and 7 
InSync III or CD, Medtronic Inc., MN, USA), programmed in DDD-R mode when sinus 
rhythm was present (n=113) and for each patient the atrioventricular interval was adjusted 
to maximize the mitral inﬂow duration using pulsed Doppler echocardiography. In patients 
with atrial ﬁbrillation (n=12), the device was programmed in the VVI-R mode. In 83 (66%) 
patients, a combined CRT and ICD device was implanted. Indications for ICD implantation 
were ventricular tachy-arrhythmias (60%), primary prevention after infarction with reduced 
LV function (25%) or secondary prevention after aborted sudden death (15%). Mean 
implantation procedure time was 128±52 min, with a LV lead positioning time of 45±32 min 
and a ﬂuoroscopic time of 32±27 min. A success rate of 100% was achieved for the ventricular 
lead implantation. Early dislodgement of the LV lead occurred in 10 (8%) patients within 6 
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days after implantation and lead repositioning was necessary. No other complications were 
observed. The lead position of the individual patients is shown in Figure 1. The majority of 
LV leads (78%) were positioned in the postero-lateral region.
Short-term (6-month) beneﬁt
Six patients died and 2 underwent heart 
transplantation before the 6 months 
clinical evaluation, and accordingly 117 
patients were evaluated at 6 months follow-
up (Table 2).
NYHA class. The mean NYHA class 
improved from 3.1±0.3 at baseline to 2.1±0.7 
at 6-months (P<0.05 vs. baseline). At 6 
months follow-up, 20 (17%) patients were 
in NYHA class I, 66 (56%) in NYHA class 
II, 28 (24%) in NYHA class III and 3 (3%) 
in NYHA class IV.  
Quality of life, Minnesota score. Quality of life score at baseline was 42±14 and decreased by a 
mean of 33% at 6 months follow-up (P<0.05). Of note, 63 patients improved more than 25% 
in quality of life score.
QRS duration. At baseline (before CRT implantation) mean QRS duration was 176±25 ms, and 
decreased signiﬁcantly to 149±27 ms (biventricular paced ECG, P<0.05) at 6 months follow-
up. Thirty-three (28%) patients had a >25% reduction in QRS duration at 6 months follow-
up.
Six-minute walking distance. The mean walking distance was 270±128 m at baseline, which had 
improved on average 42% (P<0.05) at 6 months follow-up. Seventy-ﬁve (64%) patients had 
improved >25% in walking distance at 6 months follow-up. 
Left ventricular ejection fraction. LVEF was 23±8% at baseline and improved signiﬁcantly at 
Figure 1. Schematic presentation of possible lead locations 
in the patients; the actual numbers of patients according to 
the diﬀerent locations are indicated.
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Figure 2. Hospitalization rate 
(days/year) at baseline versus 
the ﬁrst, second and third 
year after CRT. A signiﬁcant 
reduction in hospitalisation 
rate was maintained over the 
years after CRT.
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6 months follow-up to 32±9% 
(P<0.05). A relative improvement 
of 25% or more was observed in 84 
(71%) patients. 
Medication. Ninety percent (n=113) 
of the patients were taking 
diuretics at the time of the device 
implantation. No change in 
percentage of the patients taking 
diuretics, ACE inhibitors and 
beta-blockers was observed after 6 
months of therapy (Table 2).
Long-term outcome: Hospitalization, survival and clinical status
Hospitalization before vs. after CRT. Before device implantation, patients were hospitalized 
on average 3.8±4.9 days/year for decompensated heart failure, as compared to 0.7±1.6 days/
year after implantation (P<0.05). This reduction is observed in the ﬁrst year after CRT and 
sustained at the following years thereafter (Figure 2). The number of annual hospitalizations 
per patient decreased from 0.9±1.2 before to 0.2±0.4 over the years following after implantation 
(P<0.05).
Long-term prognosis. The mean follow-up was 23±10 months (range 1-50 months). During follow-
up, 20 (16%) patients died: 4 sudden cardiac deaths, 13 due to end-stage heart failure and 3 of 
non-cardiac origin (1 septic shock, 1 prostate cancer and 1 cerebral ischemic infarction).  The 
actual survival curve is shown in Figure 3. The actual survival at 1-, 2- and 3-year follow-up was 
93%, 88% and 85% respectively.
Latest clinical follow-up. During long-term follow-up, 3 patients underwent heart transplantation 
and were subsequently censored from follow-up. The remaining 102 patients evaluated at 
long-term follow-up showed a maintained reduction in NYHA class (2.2±0.8, P<0.05 vs. 
Figure 3. Survival curve of the 125 patients. The actual survival at 
1-, 2- and 3-year follow-up was 93%, 88% and 85% respectively.
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baseline and NS vs. 6-months follow-up) and quality of life score (30±17, P<0.05 vs. baseline 
and NS vs. 6 months follow-up). 
Long-term outcome of subgroups. The event rate (death or cardiac transplantation) for diﬀerent 
subgroups was evaluated at long-term follow-up. Patients with atrial ﬁbrillation (n=12) had an 
event rate of 17% compared to 19% in the patients without atrial ﬁbrillation (NS). In patients 
treated with a CRT-ICD, the event rate was 15% compared to 26% in patients with CRT only 
(NS). In patients who had  RV pacing before CRT upgrade, the event rate was 25% versus 
17% in patients without previous pacing (NS). The 14 NYHA class IV patients had higher 
event rate compared to class III patients (43% vs 15%, P<0.05). Event rates were not diﬀerent 
between patients with LV leads positioned in the postero-lateral region as compared to other 
regions (18% vs 21%, NS). Finally, the event rate was not diﬀerent between patients with 
baseline QRS duration between 120 and 150ms and patients with QRS duration >150 ms (14% 
vs 19%, NS).  
Responders and non-responders to CRT
Responders were deﬁned as patients who improved at least 1 score in NYHA class after 6-
months of CRT. At 6-months follow-up, 117 patients were evaluated, and 91 (78%) patients 
were accordingly classiﬁed as responders and 26 (22%) as non-responders. No diﬀerences in 
baseline values for any of the clinical parameters were present between responders and non-
responders (Table 3).
In the responders, the mean NYHA class decreased from 3.1±0.3 to 1.9±0.5 (by deﬁnition). The 
responders also showed on average an improvement of 54% in 6-minute walking distance, and 
a signiﬁcant reduction of 45% in quality of life score, accompanied by a signiﬁcant increase in 
LVEF (Table 3). The number of patients on diuretics was reduced (from 88% to 82%) in the 
responders, although this diﬀerence was not signiﬁcant (P=0.07). The non-responders failed 
to show improvement in any of the aforementioned parameters (Table 3). 
Before implantation of the CRT device, the responders were hospitalized for decompensated 
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heart failure on average 3.7±5.1 days/year, as compared to 0.3±1.3 days/year after implantation 
(P<0.05). The non-responders did not show a reduction in hospitalization-rate after CRT 
(4.0±6.1 vs. 4.1±6.8 days/year, NS).
Long-term follow-up was 24±9 months (range 9-51 months) for the responders and 23±10 
months (range 7-49 months) for the non-responders. Six patients (7%) died in the group of 
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responders, 5 due to heart failure and 1 due to sudden cardiac death. In the non-responders, a 
31% (n=8) mortality rate was noted with 5 deaths due to heart failure, 1 due to sudden cardiac 
death and 2 of non-cardiac origin (1 sepsis and 1 cerebral ischemic infarction). In the non-
responders, one patient underwent cardiac transplantation. Survival curves of the 2 groups 
are shown in Figure 4. Long-term survival of responders to CRT was signiﬁcantly better than 
survival of non-responders; actual survival was 96% and 93% at 2 and 3 years follow-up for 
responders, as compared to 81% and 73% for non-responders (P<0.001).
At long-term follow-up, the NYHA class and quality of life score remained signiﬁcantly 
improved in responders as compared to non-responders (Figure 5)
The only parameter predictive for long-term outcome was NYHA class IV; patients with 
NYHA class IV at baseline had a signiﬁcantly worse long-term outcome as compared to 
patients in NYHA class III (Hazard ration 2.7, P=0.04, CI 1.04-6.99).  
Figure 4. Survival curve of the clinical responders (n=91) and non-responders (n=26). Survival at 2- and 3-year 
follow-up was signiﬁcantly better for responders as compared to non-responders (96% and 93% for responders 
versus 81% and 73% for non-responders, P=0.001).
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Figure 5. NYHA class and QOL score in the responders (Resp) and non-responders (Non-resp) at baseline, 6-months 
follow-up (6-months) and long-term follow-up (Long F-up).
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The results of the current study demonstrated a maintained improvement in NYHA class 
and quality of life score in 125 patients undergoing CRT with a mean follow-up of 23-months 
(range 1 to 51). In addition, a signiﬁcant reduction in hospitalizations/year for decompensated 
heart failure was noted, which was also maintained during long-term follow-up. Finally, the 1-, 
2- and 3-year survival-rates were 93%, 88% and 85% respectively. 
Beneﬁt from CRT: Comparison to previous studies
Many larger studies have evaluated clinical beneﬁt at 6-months follow-up after CRT, including 
the MIRACLE, MUSTIC, PATH-CHF, InSync, COMPANION and MIRACLE ICD trials 
[5-10]. These trials have demonstrated signiﬁcant improvements in NYHA class, quality of 
life score, exercise tolerance, and systolic LV function [5-10]. In the current study, comparable 
improvements in clinical parameters were noted at 6-months follow-up. Some studies have 
assessed improvement in clinical parameters at 1-year follow-up [6]. In the MUSTIC trial, 
quality of life score was assessed sequentially over 12-months after CRT in 76 patients [9,16]. 
The authors concluded that clinical beneﬁt was sustained at 12-months follow-up. Auricchio 
and coworkers [7] demonstrated in 29 patients (12 biventricular pacing, 17 LV pacing) from 
the PATH-CHF trial that improvements in NYHA class, 6-minute walking distance, quality 
of life score and oxygen uptake were maintained at 12-months follow-up. Similarly, Gras and 
colleagues [8] showed an improvement in NYHA class, quality of life score and 6-minute 
walking distance at 12-months follow-up in 67 patients of the InSync trial. Information on 
clinical improvement at longer follow-up is scarce. Leclercq et al [17] showed a sustained 
improvement in functional status and exercise capacity in 30 patients at a mean follow-up 
of 15.4±10.2 months.  The results of the current study extend these earlier observations and 
demonstrate a persistence of improvement in NYHA class and quality of life score at a mean 
follow-up of 22.7±10.2 months. Besides an improvement in functional status and symptoms, 
the eﬀect of CRT on hospitalization for heart failure was also evaluated. In the  MIRACLE 
trial, a signiﬁcantly lower hospitalization-rate for heart failure during 6 months of follow-up 
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was observed after CRT as compared to optimal medical therapy [5]. Pooled data from 4 trials 
(CONTAK CD, InSync ICD, MIRACLE and MUSTIC) with a total of 1634 patients showed 
a reduction of 29% in hospitalization for heart failure over 6 months of follow-up [11].  The 
data from the current study are unique in demonstrating a reduced hospitalization-rate over 
3 years of follow-up. In particular, the reduction in hospitalization-rate from 3.8±4.9 days/year 
to 0.7±1.6 days/year in the ﬁrst year after CRT was maintained over the following years (Figure 
2), indicating the continued response to CRT over longer time. Also, the number of annual 
hospitalizations per patient decreased signiﬁcantly over the entire follow-up.
The available studies on long-term survival after CRT are limited. In the pooled analysis 
by Bradley et al [11] a relative reduction of 51% (as compared to controls) in deaths from 
heart failure was shown. However, the follow-up was limited to 6 months after CRT. In the 
MIRACLE-ICD trial, the actual survival at 6 months was 92.4% [9]. Leclercq and colleagues 
evaluated 50 patients for a mean follow-up of 15.4±10.2 months and demonstrated a survival of 
47.5% in NYHA class IV patients as compared to 87.5% in NYHA class III patients [17].
The longest follow-up is obtained in the COMPANION trial and the 1-year survival was 85% 
after CRT [10]. In the current study, 125 consecutive patients were included and the 1-, 2- and 
3-year survival were 93%, 88% and 85% respectively.
Responders and non-responders
The issue of responders and non-responders to CRT remains intruiging. In the current study, 
non-responders were deﬁned as patients who did not improve in NYHA class after 6 months 
of CRT. Accordingly, 23% of patients were classiﬁed as non-responders, in line with previous 
studies. For example, Reuter et al evaluated 102 patients after 6- and 12-months of CRT 
and 18% were classiﬁed as non-responders [18]. Similarly, in the MIRACLE trial 20-30% of 
patients were classiﬁed as non-responders [5]. Besides the classiﬁcation as non-responder, 
not much attention has been paid to the prognosis of these patients. In the current study, we 
have demonstrated that non-responders at 6 months of CRT, did not exhibit improvement 
of functional status and quality of life score at long-term follow-up. Moreover, they did not 
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show a reduction in hospitalization-rate at 6 months nor at long-term follow-up. Moreover, 
as demonstrated in Figure 4, the long-term survival was signiﬁcantly less as compared to the 
survival of responders.
Hence, recent research has focused on the identiﬁcation of potential responders before 
device implantation. Reuter et al demonstrated that all traditional baseline characteristics 
were comparable between responders and non-responders [18].  Similarly, in the current study 
all baseline characteristics were comparable between the 2 groups (Table 3). Thus, additional 
criteria are needed to identify responders to CRT (before device implantation) and several 
studies have recently demonstrated that the presence of LV dyssynchrony may be the best 
predictor of response to CRT [19,20]. Prospective studies focusing on the prediction of 
response to CRT including the assessment of LV dyssynchrony are needed to conﬁrm the 
value of this parameter. However, if accurate pre-implantation prediction of responders is 
possible (and implantation in non-responders can be avoided), the data from the current 
study suggest a very good long-term survival after CRT.
Another interesting observation was made in the current study. Six patients who at 6-month 
follow-up were classiﬁed as responders, died during long-term follow-up. Five of these 
patients eventually died of worsening heart failure. Thus, it is possible that patients who 
initially respond to CRT, may become less responsive during follow-up. This issue needs 
further study.
Limitations
The current study is an observational one, and large controlled randomized trials should 
be performed to conﬁrm the ﬁndings. Also physicians were not blinded to the treatment 
(CRT)  which may have inﬂuenced to some extent, the results (in terms of re-admission 
for hospitalization). Finally, the group of patients is heterogenous (e.g. AF, sinus rhythm, 
upgrades of previous pacemakers, combined devices with ICD) but this reﬂects the use of 
CRT in the clinical setting.  
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The improvement in functional status and symptoms after CRT is maintained at long-term 
follow-up (up to 3-years). The clinical improvement was associated with a signiﬁcant reduction 
in hospitalization-rate which was also maintained over the years. Long-term survival was 
good with 1-, 2- and 3-year survival-rates of 93%, 88% and 85% respectively. Pre-implantation 
selection of responders may result in even better long-term survival. 
Conclusions
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Despite current selection criteria (NYHA class III-IV,LVEF<35%,QRS>120ms with LBBB), 
30% of patients does not beneﬁt from cardiac resynchronization therapy (CRT). The use 
of QRS duration as selection criterium for CRT has not been evaluated systematically yet. 
Accordingly, the value of QRS duration at baseline (and reduction in QRS duration after 
CRT) to predict responders was studied.
Patients were evaluated at baseline and after 6 months of CRT for NYHA class, quality of life 
score and 6-minute walk test. QRS duration was evaluated before, directly after implantation 
and after 6 months of CRT. 
61 patients were included;45(74%) patients were classiﬁed as responders (improvement of 
NYHA class, 6-min walking distance and quality of life score) and 16(26%) as non-responders. 
QRS duration at baseline was similar between the 2 groups: 179±30ms versus 171±32ms,NS. 
Directly after implantation, QRS duration was reduced from 179±30ms to 150±26ms (P<0.01) 
in responders; non-responders did not exhibit this reduction (171±32ms versus 160±26ms,NS). 
After 6 months of CRT, QRS shortening was only observed in responders (from 179±30ms to 
159±25ms, P<0.01). ROC analysis showed that a reduction in QRS duration >10ms had a high 
sensitivity (73%) with low speciﬁcity (44%); conversely, a >50ms reduction in QRS duration 
was highly speciﬁc (88%) but not sensitive (18%) to predict response to CRT. No optimal 
cutoﬀ value could be deﬁned. 
QRS duration at baseline is not predictive for response to CRT; responders exhibit a 
signiﬁcant reduction in QRS duration after CRT, but individual response varies highly, not 
allowing adequate selection of responders.
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The number of patients with end-stage heart failure, is increasing rapidly and becomes a 
major clinical problem, in terms of costs and management.1,2 Cardiac resynchronization 
therapy (CRT) has been proposed as an alternative treatment for patients with end-stage 
heart failure.3-12 Following this therapy, the majority of patients showed an improvement in 
heart failure symptoms, quality of life and exercise capacity.4-8
Current selection criteria for patients eligible for CRT include: end-stage heart failure, 
depressed left ventricular ejection fraction (<35%), QRS duration >120 ms and left bundle 
branch block conﬁguration.4-8 Despite these selection criteria, approximately 30% of patients 
does not beneﬁt from biventricular pacing.5 Several studies have provided some data on the 
use of the ECG (QRS duration) as a selection criterium, and the results are conﬂicting.13-
15 However, no study thusfar has systematically evaluated the QRS duration as potential 
selection criterium for CRT. In the current study, we have evaluated the value of the duration 
of the QRS complex for identiﬁcation of patients who may beneﬁt from CRT. Furthermore, 
it was evaluated whether the reduction in QRS duration after 6 months biventricular pacing 
could be used to discriminate responders from non-responders.
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Patients, study protocol
61 consecutive patients received a biventricular pacing device for congestive heart failure 
based on the following selection criteria: 
-NYHA class III or IV, 
-left ventricular ejection fraction (LVEF) <35%, 
-QRS duration >120 ms and,
-left bundle branch block morphology.
Before implantation and after 6 months of CRT, the patients were evaluated for NYHA class, 
quality of life score (Minnesota questionnaire), 6-minute walk test and LVEF (measured by 
2D echocardiography).
Electrocardiograms (ECGs) were obtained before, immediately after implantation and after 
6 months of CRT. All ECGs were evaluated for QRS duration and morphology.
Pacemaker implantation
The left ventricular pacing lead was inserted transvenously via the subclavian route. After a 
coronary sinus venogram was obtained, the LV pacing lead was inserted through the coronary 
sinus with the help of a 8F guiding catheter, and positioned in the venous system, preferably 
in the (postero-)lateral vein. Thereafter, the right atrial and ventricular leads were positioned. 
Thirty-three patients received a biventricular pacemaker (Contak TR, Guidant, MN, USA or 
InSync III, Medtronic Inc., MN, USA) and 28 received a biventricular pacemaker combined 
with an ICD (Contak CD, Guidant, MN, USA or InSync CD, Medtronic Inc., MN, USA).
Clinical evaluation
Clinical evaluation was performed at hospital admission before implantation of the
pacemaker and after 6 months of CRT at the outpatient clinic. NYHA score was used to 
classify heart failure symptoms. NYHA class evaluation was performed by the referring 
physician. The QRS duration was scored at hospital admission by two independent observers 
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without knowledge of the clinical status of the patient. Quality of life score was assessed 
using the Minnesota Living with Heart Failure questionnaire.16 This questionnaire contains 
21 questions concerning the patient’s perception of the eﬀects of heart failure on daily life 
activities. Questions are scored from 0 to 5, resulting in a total score from 0 to 105, with the 
highest score reﬂecting the worst quality of life.
Exercise capacity was evaluated by assessing the 6-minute walking distance and expressed in 
meters. 
Electrocardiographic evaluation
QRS duration and morphology were measured from the surface ECG before, immediately 
after pacemaker implantation and after 6 months of CRT. The 12-lead surface ECGs were 
obtained at the speed of 50 millimeters per second. The QRS duration was measured as 
the maximum value in leads II, V
1
, and/or V
6
. Each ECG was evaluated by two independent 
cardiologists for QRS duration and morphology.
Statistical analysis
Data were expressed as mean ± SD. Comparison of data was performed using the Student 
t test for paired and unpaired data when appropriate, in case of non-normal distribution 
the Mann-Whitney U test was used. The value of the reduction in QRS duration directly 
after CRT to predict late response (6 months follow-up) was determined by receiver operator 
characteristic (ROC) curve analysis. For all tests a P-value <0.05 was considered signiﬁcant.
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Patient population, baseline and 6 months follow-up
The baseline characteristics of the 61 patients receiving a biventricular pacemaker are 
summarized in Table 1. By deﬁnition, all patients had a severe heart failure and 51 were in 
NYHA class III and 10 in class IV. Etiology underlying the cardiomyopathy was ischemic 
in 46% and idiopathic in 54%. LVEF was severely depressed (mean 28±14%, range 12-
35%), whereas the LV was severely dilated (end-diastolic diameter 68±19 mm). In the entire 
population the mean QRS duration was 177±30 ms (range 120-240 ms) before implantation. 
Directly after implantation, the mean QRS duration decreased to 153±26 ms (range 100-210 
ms, P<0.01 versus baseline).
After 6 months of CRT, the mean NYHA class decreased from 3.2±0.4 to 2.2±0.7 (P<0.05) 
in the group as a whole. In particular, 32 (52%) patients improved in 1 class and 13 (21%) 
improved >1 class. In addition, the 6-minute walking distance improved from 295±144 m 
to 409±132 m (P<0.05). In 30 (54%) patients, the walking distance improved >25%. Also, 
Results
Figure 1. Distribution of reduction in QRS duration after 6 months of cardiac 
resynchronization therapy. 
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symptoms improved as evidenced 
by the signiﬁ cant decrease in quality 
of life score (from 39±16 at baseline 
to 29±15 at 6 months follow-up, 
P<0.05).
At 6 months of CRT, QRS duration 
remained unchanged as compared 
to directly after implantation 
(161±24 ms, range 120-200 ms, NS 
versus directly post-implantation 
and P<0.01 versus baseline). The 
distribution of QRS shortening 
after 6 months CRT as compared to 
baseline (“delta QRS”) is depicted 
in Figure 1. After 6 months of CRT, 
the QRS duration shortened ≥ 30 
ms in 22 (36%) patients. Of note, 22 
(36%) patients had a reduction in 
QRS duration <10%.
Responders versus non-responders 
Responders were deﬁ ned as those patients who improved at least 1 class in NYHA classiﬁ cation 
score after 6 months of CRT. At 6 months follow-up, 45 (74%) patients were accordingly 
classiﬁ ed as responders and 16 (26%) as non-responders. No signiﬁ cant diﬀ erences in baseline 
characteristics were present between responders and non-responders (Table 2). 
In the responders the mean NYHA class decreased from 3.2±0.4 to 2.0±0.6 (by deﬁ nition). The 
responders also showed a signiﬁ cant improvement in 6-minute walking distance (from 279±104 
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m to 414±112 m, P<0.05) and a 
signiﬁcant reduction in the 
quality of life score (from 39±15 
m to 27±13, P<0.05). In the non-
responders, the mean NYHA 
class remained unchanged 
after 6 months of CRT (2.9±0.7 
versus 3.1±0.3, by deﬁnition). 
Also, the 6-minute walking 
distance did not improve in 
the non-responders (293±219 
m versus 288±233 m, NS), and 
the quality of life score remained unchanged (35±17 versus 40±18, NS).
Value of QRS duration and/or change in QRS duration to predict response to CRT
There was no signiﬁcant diﬀerence in QRS duration at baseline between the responders and 
non-responders (179±30 ms versus 171±32 ms, NS, see Figure 2). Immediately after implantation 
of the pacemaker, the QRS duration was reduced from 179±30 ms to 150±26 ms (P<0.01) in 
the responders, with a mean reduction of 29±29 ms. In the non-responders however, QRS 
duration reduced from 171±32 ms to 160±26 ms, but this reduction was not signiﬁcant; the 
mean reduction was 11±39 ms. There was a trend towards a larger reduction in QRS duration 
in the responders, although not signiﬁcant (P=0.07).
Next, baseline QRS duration and 6-months QRS duration were compared. 
In the responders, a signiﬁcant decrease was observed (from 179±30 ms to 159±25 ms, P<0.01). 
In contrast, no reduction was observed in the non-responders (171±32 ms at baseline versus 
168±19 ms, NS, see Figure 3). 
Due to the large standard deviations, the mean reductions in QRS duration were not 
signiﬁcantly diﬀerent (20±29 ms in responders versus 3±38 ms in non-responders, P=0.08).
Figure 2. Baseline QRS duration of the responders versus the non-responders.
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ROC analysis was performed on the reduction in QRS duration (baseline versus directly after 
implantation) to deﬁne an optimal cutoﬀ value for prediction of responders. A reduction in 
QRS duration >10 ms had a high sensitivity (73%) but a lower speciﬁcity (44%). Conversely, a 
reduction in QRS duration >50 ms was highly speciﬁc (88%) but not sensitive (18%) to predict 
response to CRT. The optimal cutoﬀ value was identiﬁed at 30 ms, yielding a sensitivity of 
58% and a speciﬁcity of 56% (Figure 4).
Figure 3. Baseline QRS duration and 6-months QRS duration of the responders versus the non-responders.
Figure 4. ROC analysis on the 
reduction in QRS duration directly 
following cardiac resynchronization 
therapy.
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Cardiac resynchronization therapy is emerging as a valuable tool in the treatment of patients 
with drug-refractory end-stage heart failure.4-11 Recent studies have shown an improvement 
in NYHA class, symptoms and exercise capacity following CRT.4-6 
In the current study, the patients also exhibited a signiﬁcant improvement in these parameters, 
in line with previous studies.4-6 However, anecdotal data already suggested that a substantial 
percentage of patients did not respond to CRT.17-19 These suggestions were conﬁrmed in the 
MIRACLE Trial5 demonstrating a clear beneﬁt in the entire population of patients treated 
with CRT, but, on an individual basis, 20-35% did not respond, depending on the deﬁnition 
of a non-responder. When a responder was deﬁned by an improvement in NYHA class, 
32% of the patients did not respond. Similar ﬁndings were noted in the present study; 16 of 
61 (26%) patients did not respond to CRT. Of interest, all baseline characteristics between 
responders and non-responders were comparable in the present study. Reuter et al 18 suggested 
that patients with ischemic cardiomyopathy had a higher likelihood of non-response; in the 
current study 50% of non-responders had an ischemic etiology.
In view of costs, identiﬁcation of non-responders is of utmost importance. As a consequence, 
current research is focused on prediction of response.4 The currently most used selection 
criteria for CRT include end-stage heart failure, severely depressed LVEF (<35%), wide QRS 
complex (duration >120 ms) and left bundle branch block conﬁguration.4-11,20 It has been 
suggested that QRS duration in itself may predict response to CRT, but a systematic study 
is lacking. In a small study (n=18 patients), Leclercq and colleagues21 demonstrated that CRT 
acutely improved hemodynamics in patients with end-stage heart failure; 6 of 18 patients did 
not improve and QRS duration was not signiﬁcantly diﬀerent between the 2 groups.
Alonso et al15 evaluated 26 patients and 7 did not respond to CRT. Baseline QRS was comparable 
between responders and non-responders (179±2 ms versus 176±30 ms), but the QRS duration 
after CRT diﬀered between the 2 groups: responders demonstrated a signiﬁcant reduction in 
QRS duration, whereas the non-responders did not exhibit a reduction. In contrast, Kass et 
al.15 showed that CRT improved dP/dtmax in 18 patients with end-stage heart failure, and the 
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baseline QRS duration correlated with improvement in dP/dtmax, but reduction in QRS after 
CRT was not related to response. Auricchio and coworkers13 also indicated that baseline QRS 
duration was predictive of response to CRT. The current study was speciﬁcally set out to deﬁne 
the value of QRS duration (and reduction after CRT) to predict response to CRT. Baseline 
QRS was not predictive for response, since baseline QRS duration was comparable between 
responders and non-responders. However, responders showed a signiﬁcant reduction in QRS 
duration directly after initiation of CRT, and this reduction in QRS duration was maintained 
at 6 months follow-up. In contrast, the non-responders did not exhibit a signiﬁcant reduction 
to CRT, neither directly after implantation, nor at 6 months follow-up.
The main problem is however that individual reduction in QRS duration after CRT varied 
substantially among patients, and therefore accurate prediction based on direct reduction 
in QRS duration after CRT is not possible, as indicated by the ROC analysis. When a short 
reduction in QRS duration (>10 ms) is used as a cutoﬀ value, a high sensitivity is obtained 
with a lower speciﬁcity. When a larger reduction (>50 ms) is used, speciﬁcity increased 
substantially, but at the cost of a low sensitivity. 
Moreover, if one wants to use the reduction in QRS duration, the pacemaker leads have to be 
placed (temporarily), and the ultimate goal is to identify the patient with a high likelihood of 
response beforehand.
Recently, other markers have been suggested to identify responders.12,22-24 These markers 
focus on the dyssynchrony in the left ventricle, as can be determined by tissue Doppler 
echocardiography and strain-rate imaging.12,22-24  Prospective studies evaluating the precise 
value of intra-ventricular dyssynchrony are needed. In addition, the issue of (adequate) lead 
positioning is also extremely relevant, as recently pointed out by Ansalone.25 
Limitations
First, only patients with wide QRS complex and LBBB conﬁguration were included; however, 
patients with RBBB and interventricular conduction disturbances may also beneﬁt from 
CRT.5
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Responders were deﬁned as those patients who improved at least 1 grade in NYHA  score 
after 6 months of CRT. This clinical improvement was associated with an improvement in 
QOL score and an increase in 6 minute walking distance. It should be emphasized that the 
results in the present study are dependent on this deﬁnition of a responder to CRT. The use 
of other deﬁnitions for responders may alter the results. 
Preferably, the deﬁnition of a responder should comprehend various issues, including clinical 
status, reduction in re-hospitalizations and survival. 
Still, the 26% of non-responders observed in the current study is in line with previous 
studies.5
 The present study included 61 patients; additional studies with larger cohorts of patients are 
needed to conﬁrm the ﬁndings.
In conclusion, QRS duration at baseline is not predictive for response to CRT; responders do 
exhibit a signiﬁcant reduction in QRS duration after pacemaker implantation, but individual 
response varies highly, and does not allow adequate selection of responders.
Conclusions
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Patients with drug-refractory heart failure have been demonstrated to beneﬁt from 
biventricular pacing. Besides optimization of AV-delay and resynchronization of 
dyssynchrony between the left and right ventricle, resynchronization of the dyssynchrony 
within the left ventricle appears important. Myocardial tissue Doppler imaging (TDI) 
is an echocardiographic technique that allows noninvasive quantiﬁcation of the peak 
systolic myocardial velocity (PSV) and the timing of this peak velocity in relation to 
electrical activity (QRS on ECG). Patients (n=22) with idiopathic dilated cardiomyopathy, 
LVEF <35%, NYHA class III or IV, QRS duration >120 ms and left bundle branch 
block underwent implantation of a biventricular pacemaker. Before and after pacemaker 
implantation routine echo and TDI were performed, and the following parameters were 
derived: LVEF, peak systolic velocities in the septum and lateral wall, dyssynchrony 
between the septum and lateral wall (expressed as the delay in peak systolic velocity in the 
septum vs lateral wall); in addition, clinical parameters (NYHA class, quality of life score 
and  6-minute walking distance) were evaluated at 3 months follow-up. After pacing, LVEF 
increased from 21±7% to 31±9% (P<0.05), the PSV increased signiﬁcantly in the septum 
(from 2.1±1.3 cm/s to 3.9±1.8 cm/s, P<0.05)  and lateral wall (from 2.4±1.7 cm/s to 4.5±1.5 cm/s, 
P<0.05). Resynchronization was established indicated by the reduction in the delay between 
peak systolic velocity of the septum vs lateral wall (from 97±35 ms at baseline to 28±21 ms 
after pacing, P<0.05).
At 3 months, the NYHA class, quality of life score and 6-minute walking distance all had 
improved signiﬁcantly. In conclusion, TDI allows noninvasive assessment of improvement 
in contractile function and resynchronization after biventricular pacing. 
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Patients presenting with end-stage heart failure become a major clinical problem, in terms 
of number and management [1]. Over the past 10 years the number of patients suﬀering 
from heart failure has increased rapidly. Therapeutic management is diﬃcult; the options 
include heart transplantation, surgical revascularization (if the underlying cause is coronary 
artery disease) and medical treatment. Heart transplantation has an excellent prognosis, but 
the number of donor hearts is limited. Surgical revascularization is associated with a high 
mortality and peri-operative morbidity which makes surgeons reluctant to operate on these 
patients [2].
Although substantial progress has been obtained in the ﬁeld of medical therapy (with the 
introduction of ACE inhibitors, beta-blockers and spironolactone), long-term prognosis 
remains poor [3]. Recently, simultaneous biventricular pacing has been proposed as an 
alternative treatment in patients with drug-refractory heart failure [4]. The clinical 
beneﬁt of biventricular pacing has been demonstrated in various studies; improvement in 
heart failure symptoms, quality-of-life, exercise capacity and left ventricular (LV) systolic 
performance have been shown [5]. It has been suggested that the success of biventricular 
pacing is mainly related to resynchronization of the interventricular septum to the lateral 
free wall of the LV [5]. Myocardial tissue Doppler imaging (TDI) is an echocardiographic 
technique that allows noninvasive quantiﬁcation of the peak systolic myocardial velocity 
and the timing of this peak velocity in relation to electrical activity (QRS on ECG) [6]. 
Theoretically, this technique could be very useful to evaluate the dyssynchrony in patients 
with dilated cardiomyopathy and the resynchronization after biventricular pacing, and 
initial data are promising [7,8]. Accordingly, consecutive patients with drug-refractory heart 
failure (secondary to idiopathic dilated cardiomyopathy) who underwent implantation of a 
biventricular pacemaker were evaluated with TDI before and after implantation.
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Patients
Consecutive patients with end-stage heart failure secondary to idiopathic cardiomyopathy, 
scheduled for implantation of a permanent biventricular pacemaker, were included in the 
present study. 
The following selection criteria for biventricular pacing were used:
-severe heart failure (NYHA class III or IV), 
-severely depressed left ventricular ejection fraction (LVEF ≤35%),
-QRS exhibiting left bundle branch block conﬁguration with a duration >120 ms.
These criteria have been used in small clinical studies [4,5,9] and in ongoing multicenter 
trials [10]. 
Study Protocol 
Before implantation (baseline), both clinical parameters and echocardiographic parameters 
were derived. The echocardiographic parameters included:
-LVEF determined by 2D echocardiography [11],
-Peak systolic velocities (in basal septal and lateral segments) assessed by TDI,
-Septal to lateral dyssynchrony derived from TDI.
The day after implantation, these parameters were re-assessed. In 10 patients, the 
pacemaker was turned oﬀ on the day after implantation and the echocardiographic 
parameters were re-assessed.
The clinical parameters were collected at baselineand after 3 months of pacing.
These parameters included:
-QRS duration on surface ECG,
-New York Heart Association (NYHA) score,
-Exercise tolerance using the 6-minute walk test [12].
Methods
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Echocardiography
Patients were imaged in the left lateral decubitus position using a commercially available 
system (Vingmed system FiVe, General Electric – Vingmed, Milwaukee, WI, USA). Images 
were obtained using a 3.5 MHz transducer, at a depth of 16 cm in the parasternal and apical 
views (standard long-axis, 2-chamber and 4-chamber images). Standard 2-dimensional and 
color Doppler data, triggered to the QRS complex, were saved in cineloop format. The 
LVEF was calculated from the conventional apical 2- and 4-chamber images, using the 
biplane Simpson’s rule [11]. 
For TDI, color Doppler frame rates varied between 80 and 115 frames/sec depending on 
the sector width of the range of interest, and pulse repetition frequencies between 500 
Hz to 1 KHz, resulting in aliasing velocities between 16 and 32 cm/sec. Tissue Doppler 
parameters were measured from color images by oﬀ-line analysis. The digital cineloops were 
analyzed using commercial software (Echopac 6.1, General Electric – Vingmed, Milwaukee, 
WI, USA). The sample volume was placed in the basal portions of the septal and lateral 
walls (using the 4-chamber images), to derive velocity proﬁles. Timing of peak systolic 
velocity was measured from the onset of the QRS-complex to the peak systolic velocity 
and expressed in ms. The diﬀerence between the timing of the peak systolic velocities 
of the septum versus the lateral wall was considered an indicator of LV dyssynchrony. All 
parameters were assessed before and on the day after implantation.
Pacemaker Implantation
The left ventricular pacing lead was inserted transvenously via the subclavian route. First, 
a coronary sinus venogram was obtained using the balloon catheter. Next, the LV pacing 
lead was inserted through the coronary sinus with the help of a 8F guiding catheter, and 
positioned as far as possible in the venous system, preferably in the (postero-)lateral vein 
[12]. The right atrial and ventricular leads were positioned conventionally. A biventricular 
DDD-R system was used in all patients, programmed in DDD-R mode. When a 
conventional indication for an ICD existed, a combined device was implanted.
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Statistical Analysis
Results are presented as mean ± SD. Data were compared using paired or unpaired Student’s 
t-test when appropriate. Proportions were compared using Chi-square analysis with Yates’ 
correction. A P-value <0.05 was considered statistically signiﬁ cant.
Figure 1. LVEF before and after biventricular 
pacing; the LVEF increased signiﬁ cantly. 
LVEF: left ventricular ejection fraction.
. 
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Study Population
Twenty-two patients were included. The patient characteristics are summarized in Table 
1. Patients had severe LV dysfunction, with a mean LVEF of 21±7% (range 10-31%).  The 
QRS duration was prolonged, ranging from 120 to 225 ms, with a mean duration of 172±33 
ms. A biventricular pacemaker was implanted in 15 patients, whereas 7 patients received 
a biventricular ICD (Contak TR or CD, Guidant, MN, USA and InSync III or CD, 
Medtronic Inc., MN, USA). Two types of left ventricular leads were used (Easytrack 4512-
80, Guidant, MN, USA or Attain-SD 4189, Medtronic Inc., MN, USA). The procedure was 
uncomplicated in all patients. For each patient the atrioventricular interval was adjusted to 
maximize the mitral inﬂow duration using pulsed Doppler echocardiography. 
Echocardiographic parameters
At baseline, the mean LVEF was 21±7% and improved to 31±9% after pacing (P<0.05, Figure 
1). The peak systolic velocity in the septum increased from 2.1±1.3 cm/s to 3.9±1.8 cm/s 
after pacing (P<0.05, Figure 2). The peak systolic velocity in the lateral wall increased from 
2.4±1.7 cm/s to 4.5±1.5 cm/s (P<0.05, Figure 3). The delay between peak systolic velocity in 
the septum and the lateral wall was was 97±35 ms at baseline, and decreased to 28±21ms after 
pacing (P<0.05, Figure 4).
The data of the 10 patients in whom 3 measurements were obtained (baseline, day after 
implantation pacemaker on and pacemaker oﬀ) are shown in Table 2.
Clinical parameters
The QRS duration assessed from the surface ECG declined from 172±33 ms to 158±26 ms 
(P<0.05) at 3 months after implantation. The mean NYHA class decreased from 3.3±0.5 at 
baseline to 2.1±0.9 (P<0.05) at 3 months post-implantation. The 6-minute walking distance 
was 253±105 m at baseline and improved signiﬁcantly to 392±145 m (P<0.05) at 3 months 
follow-up.
Results
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Figure 2. Peak systolic velocity (PSV) of the septum 
before and after biventricular pacing; the PSV 
increased signiﬁcantly after pacing.
Figure 3. Peak systolic velocity (PSV) of the lateral wall 
before and after biventricular pacing; the PSV increased 
signiﬁcantly after pacing.
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Over the past decade, the number of patients with heart failure has increased rapidly [1]. 
Although pharmacological treatment has improved substantially, the long-term survival of 
these patients remains poor [3]. In patients with drug-refractory heart failure, biventricular 
pacing has been proposed as an alternative treatment modality [4]. 
Earlier studies have demonstrated an acute improvement in hemodynamics following 
biventricular pacing. Kass and colleagues [13] evaluated 18 patients with end-stage heart 
failure and demonstrated a direct improvement in dP/dtmax and pulse pressure following 
biventricular pacing. These immediate beneﬁts were associated with an improvement 
in well-being, heart failure symptoms and systolic performance at 3 months follow-up, 
as demonstrated in small clinical 
studies. Preliminary data from the 
large multicenter Miracle Trial tend to 
conﬁrm these ﬁndings [10]. In this trial, 
300 patients underwent implantation 
of a biventricular pacemaker and are 
randomly assigned to resynchronization 
therapy “on” or “oﬀ” for 6 months. 
In the patients with the pacemaker 
activated, the 6-minute walking distance 
improved signiﬁcantly (from 318±77 m 
to 356±11 m, P<0.05), associated with 
an improvement in quality of life score 
(from 59±20 to 40±24, P<0.05), and a 
reduction in NYHA classiﬁcation (from 
3.1±0.3 to 2.3±0.7, P<0.05). In the patients 
with the pacemaker “oﬀ”, none of these 
parameters improved [10].
Discussion
Figure 4. Timing of the peak systolic velocity of the septum 
as compared to the lateral wall (septal to lateral delay). The 
delay decreased signiﬁcantly after pacing.
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The precise mechanism of action underlying the beneﬁt of pacing is yet unclear, but 
resynchronization of the left ventricle appears mandatory [5]. TDI has been recently 
proposed to assess left ventricular dyssynchrony [7,8]. In the current study, the feasibility 
of TDI to assess left ventricular resynchronization was shown. Before pacing, a signiﬁcant 
delay in electromechanical activity existed within the left ventricle, as indicated by the 
diﬀerence in timing of peak systolic velocities of the septum and the lateral wall; on average, 
a delay of  89±21 ms existed between the peak systolic velocities of the interventricular 
septum and the lateral free wall. Immediately after biventricular pacing, this delay 
decreased signiﬁcantly to 24±14 ms. Moreover, when the pacemaker was turned oﬀ, the 
resynchronization was lost again.
The peak systolic velocities of the septum and the lateral wall also improved signiﬁcantly 
after pacing. The improvements in these peak systolic velocities were associated with an 
improvement in LVEF; this is not surprising, since a close relation exists between the LV 
systolic function and the peak systolic velocities [14].  
These direct eﬀects were followed by improvements in clinical parameters assessed at 
3 months. The mean NYHA class decreased from 3.3±0.4 to 2.1±0.3 (P<0.05), and the 6-
minute walking distance imcreased from 234±87 m to 384±68 m (P<0.05); these ﬁndings are 
in line with previous results [5]. 
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In conclusion, in the present series of 22 patients with idiopathic dilated cardiomyopathy, 
TDI allowed evaluation of left ventricular dyssynchrony and subsequent resynchronization 
following biventricular pacemaker implantation. Moreover, a direct improvement in 
peak systolic velocities of the septum and lateral wall were observed; TDI permitted 
quantiﬁcation of these velocities. These increments were associated with an improvement 
in LVEF. The eﬀects were reversed immediately when the pacemaker was turned oﬀ. 
Finally, the immediate eﬀects were followed by an improvement in clinical status (NYHA 
class, exercise capacity).
It should be stated that in the current study only patients with idiopathic dilated 
cardiomyopathy were included; further studies in patients with ischemic cardiomyopathy 
need to be performed.
Conclusions
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10
LEFT VENTRICULAR DYSSYNCHRONY PREDICTS BENEFIT 
OF CARDIAC RESYNCHRONIZATION THERAPY IN 
PATIENTS WITH END-STAGE HEART FAILURE BEFORE 
PACEMAKER IMPLANTATION. 
Jeroen J. Bax, Thomas H. Marwick, Sander G. Molhoek, Gabe B. Bleeker, Lieselot van 
Erven, Eric Boersma, Paul Steendijk, Ernst E. van der Wall, Martin J. Schalij.
Am J Cardiol 2003;92:1238–1240
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Better identiﬁcation of patients likely to beneﬁt from CRT is needed before 
implantation. Left ventricular dyssynchrony was the only predictor of beneﬁt 
from CRT; 13 of 17 (76%) responders had a septal to lateral delay ≥60 ms, whereas 
7 of 8 (87.5%) non-responders had a septal to lateral delay <60 ms, indicating that 
tissue Doppler imaging can be used to identify patients who beneﬁt from CRT. 
 The number of patients presenting with heart failure is increasing rapidly. Recently, cardiac 
resynchronization therapy (CRT) has been proposed as treatment in patients with drug-
refractory heart failure [1]. The clinical beneﬁt of CRT, evidenced by improvement in 
heart failure symptoms, quality-of-life, exercise capacity and left ventricular (LV) systolic 
performance, has been demonstrated [1-5]. However, 20-30% of patients do not respond 
to CRT, despite application of established selection criteria [1]. Therefore, additional 
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Figure 1. Individual changes in left ventricular ejection fraction before (LVEF pre) and after CRT (LVEF post). DCM: 
idiopathic dilated cardiomyopathy; ISCH: ischemic cardiomyopathy.
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selection criteria are needed.  Myocardial tissue Doppler imaging (TDI) is a noninvasive, 
echocardiographic, approach that allows measurement of both the amplitude (peak systolic 
myocardial velocity) and timing (time from electrical activation to peak velocity) of myocardial 
function [6], and is useful in evaluation of LV dyssynchrony and resynchronization following 
CRT [7-12]. The degree of LV dyssynchrony could be used to predict the beneﬁt of pacing 
before implantation of the pulse generator. Accordingly, the aim of the present study was to 
evaluate whether dyssynchrony assessed from TDI, could predict improvement in systolic LV 
function directly following CRT.
* * *
Consecutive patients (n=25) with end-stage heart 
failure, scheduled for implantation of a permanent 
biventricular pacemaker, were included (vv 1), using 
established selection criteria for CRT [1]: New 
York Heart Association (NYHA) class III or IV, 
LV ejection fraction (LVEF) ≤35%, QRS with left 
bundle branch block conﬁguration and duration 
>120 ms. Before pacemaker implantation resting 
two-dimensional (2D) echo was performed to 
measure LVEF and LV volumes. Next, myocardial 
TDI was performed to quantify maximum systolic 
velocity of the diﬀerent walls and assess timing 
of maximum velocity following the beginning of 
the QRS-complex. The day after implantation, 
LVEF and TDI parameters were re-assessed. A 
commercially available system (Vingmed system 
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FiVe, GE – Vingmed, Milwaukee, WI, USA) was used and standard images were obtained 
(long-axis, 2-chamber, 4-chamber), and saved in cineloop format. LV volumes and LVEF 
were calculated using the biplane Simpson’s rule. Improvement was deﬁned as an increase in 
LVEF ≥5% after CRT. TDI was performed as previously described [11], and parameters were 
measured from color images by oﬀ-line analysis by an independent observer (THM), blinded 
to the other echocardiographic results and unaware whether images were acquired pre- or 
post-CRT. The sample volume was placed in the basal portions of the septal and lateral walls; 
peak systolic velocities and time to peak systolic velocities were obtained and the septal to 
lateral delay in peak velocity was calculated as an indicator of LV dyssynchrony [11].
Results are presented as mean ± SD, and compared using (un-)paired Student’s t-test when 
appropriate; proportions were compared using Chi-square analysis with Yates’ correction. 
Linear regression analysis was performed to evaluate relations between echocardiographic 
parameters and the change in LVEF. Multivariate analysis was performed to identify predictors 
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Figure 2. Relation between the change in peak systolic velocity after pacing (δPSV) and the change in left 
ventricular ejection fraction (δLVEF) after CRT.
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of improvement in LVEF after CRT. A P-value <0.05 was considered statistically signiﬁcant.
In the entire group of patients, LVEF improved from 22±5% to 31±10% (P<0.05) following 
pacing; the individual data are shown in Figure 1. Of note, signiﬁcant improvement in 
LVEF was observed more frequently in patients with idiopathic dilated cardiomyopathy as 
compared to patients with ischemic cardiomyopathy (11 of 14, 79% versus 6 of 11, 66%). 
Moreover, the change in LVEF post-implantation was larger in patients with idiopathic 
dilated cardiomyopathy as compared to patients with ischemic cardiomyopathy (Figure 1). 
Seventeen patients did improve ≥5% in LVEF post-pacing (from 22±5% to 36±9%) and 8 
patients did not improve their LVEF (21±6% versus 21±7%). In the septum and lateral wall, 
peak systolic velocities improved from 2.2±1.1 cm/s to 2.9±1.2 cm/s (P<0.05) and from 2.0±1.0 
cm/s to 2.9±2.1 cm/s (P<0.05).
The septal to lateral delay in peak velocity improved from 71±38 ms to 36±34 ms (P<0.01) after 
CRT. There was a signiﬁcant relation between the change in peak systolic velocity of the 
septum (y = 4.7*x + 5.1, P<0.001, r = 0.71, n = 25) and the change in LVEF (Figure 2); a similar 
relation was observed for the lateral wall (y = 1.8*x + 7.2, P=0.02, r = 0.45). The septal to lateral 
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Figure 3. Relation between the septal to lateral delay in peak systolic velocity at baseline and the change in LVEF 
after CRT. 
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delay in peak systolic velocity before implantation was also related to the change in LVEF after 
CRT (Figure 3). 
Baseline variables (including age, sex, etiology of cardiomyopathy, use of medication, NYHA 
class, QRS-duration at baseline, LVEF, LV volumes,  peak systolic velocities in the diﬀerent 
walls) were not diﬀerent between patients with improvement or without improvement in 
LVEF; the only variable that diﬀered between responders/non-responders was the septal to 
lateral delay (86±36 ms vs 39±17 ms, P<0.01). Multivariate analysis conﬁrmed that this parameter 
was the only predictor of improvement in LVEF. Importantly, 13 of 17 (76%) patients with 
an improvement of LVEF after CRT had a septal to lateral delay in peak systolic velocity 
at baseline of 60 ms or more, whereas only 1 of 8 (12.5%) patients without improvement of 
LVEF had a delay of 60 ms or more (P<0.05). At 6 months follow-up, patients with improved 
LVEF (responders), exhibited a signiﬁcant improvement in NYHA class (from 3.4±0.5 to 
1.8±0.5, P<0.001). In addition, the Minnesota score decreased from 44.1±10.6 to 25.6±10.2 
(P<0.001), and the 6-minute walking distance increased from 246±73 m to 401±112 m (P<0.001). 
Conversely, in the patients without improved LVEF (non-responders), no improvement in 
NYHA class was observed, the Minnesota score did not improve (50.2±6.9 vs 52.3±10.9, ns) 
and the 6-minute walking distance remained unchanged (250±68 m vs 254±75 m, ns). 
* * *
The ﬁndings in the current study can be summarized as follows:
1.two-third of patients exhibit an improvement in LVEF following CRT; 2.improvement in 
LVEF is related to LV dyssynchrony at baseline; a cutoﬀ value of 60 ms in septal to lateral 
delay appears to diﬀerentiate between responders and non-responders; 3.the immediate 
improvement in LVEF is followed by an improvement at 6 months in NYHA class, exercise 
capacity and quality of life score.
The precise mechanisms of beneﬁt from CRT are not entirely clear, but appear related to 
resynchronization of the LV, resulting in improvement in systolic LV function [1]. In the 
current study, TDI showed LV resynchronization after CRT, as evidenced by a signiﬁcant 
reduction in septal to lateral delay in peak systolic velocities. Besides the resynchronization, 
an acute improvement in LVEF was observed, in agreement with previous reports [1,7,9,13]. 
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Sogaard and coworkers [9] showed an improvement in LVEF from 29±7% to 35±8%, whereas 
the LVEF improved from 28±10% to 40±15% in the study by Yu et al [7]. The improvement 
in LVEF was accompanied by an improvement in peak systolic velocities of the basal walls. 
However, not all patients exhibited improvement in LVEF; 32% of patients failed to improve 
in LVEF despite the use of generally accepted selection criteria for CRT. Comparable numbers 
of non-responders are observed in various other studies; in the MIRACLE Trial for example, 
30% of the patients did not respond to CRT despite the use of traditional selection criteria 
[4]. These ﬁndings suggest that additional criteria are needed to identify potential responders 
to CRT. In particular, when one considers the substantial costs of the device and the large 
number of patients with end-stage heart failure [1]. The only predictor of improvement in 
LVEF after CRT was the presence of substantial  LV dyssynchrony. Using a cutoﬀ value of 
≥60 ms in septal to lateral delay, separation between responders and non-responders was 
possible. Patients with a delay ≥60 ms had a high likelihood of improvement in LVEF after 
CRT, followed by an improvement in NYHA class, quality of life score and 6-minute walking 
distance.
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Objectives To predict the response and prognosis after cardiac resynchronization therapy 
(CRT) in patients with end-stage heart failure.
Background CRT improves heart failure symptoms, exercise capacity and left ventricular 
(LV) function. Since not all patients respond, pre-implantation identiﬁcation of responders 
is needed. In the present study, response to CRT was predicted by the presence of LV 
dyssynchrony assessed by tissue Doppler imaging (TDI). Moreover, the prognostic value of 
LV dyssynchrony in patients undergoing CRT was assessed.
Methods Eighty-ﬁve patients with end-stage heart failure, QRS duration >120 ms and LBBB 
were evaluated by TDI before CRT. At baseline and 6 months follow-up, NYHA class, 
quality of life and 6-minute walking distance, LV volumes and LV ejection fraction (EF) were 
determined. Events (death, hospitalization for decompensated heart failure) were obtained 
during 1-year follow-up.
 Results Responders (74%) and non-responders (26%) had comparable baseline characteristics, 
except for a larger dyssynchrony in responders (87±49 ms versus 35±20 ms, P<0.01). ROC curve 
analysis demonstrated that an optimal cutoﬀ value of 65 ms for LV dyssynchrony yielded a 
sensitivity and speciﬁcity of 80% to predict clinical improvement and of 92% to predict 
LV reverse remodeling. Patients with dyssynchrony ≥65 ms had an excellent prognosis (6% 
event-rate) after CRT, as compared to a 50% event-rate in patients with dyssynchrony <65 ms 
(P<0.001).
Conclusion Patients with LV dyssynchrony ≥65 ms respond to CRT and have an excellent 
prognosis after CRT.
Structured Abstract
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Cardiac resynchronization therapy (CRT) has been proposed as an alternative treatment 
in patients with drug-refractory heart failure [1-3]. Initial studies demonstrated acute 
improvement in hemodynamics immediately after CRT [4]. Other studies have demonstrated 
the sustained clinical beneﬁt of CRT at longer follow-up, evidenced by improvement in 
heart failure symptoms, quality-of-life, exercise capacity and left ventricular (LV) systolic 
performance [1-3,5-7]. However, it has also become clear that 20-30% of patients do not 
respond to CRT [1-3]. Therefore, interest has shifted towards identiﬁcation of potential 
responders to CRT before implantation of the pacemaker [8,9]. It is hypothesized that LV 
dyssynchrony is the most important determinant of response to CRT and various techniques 
to detect and quantify LV dyssynchrony are currently under investigation [8,9]. However, 
no large studies have focused on the prediction of beneﬁt from CRT based on the degree of 
LV dyssynchrony. More important, it is unclear whether patients with LV dyssynchrony who 
respond to CRT have a better prognosis as compared to patients without dyssynchrony.
Accordingly, we have related the extent of LV dyssynchrony prior to implantation of the 
CRT device (assessed by tissue Doppler imaging, TDI) to clinical outcome and LV reverse 
remodeling after CRT, in 85 consecutive patients. The accuracy of this approach (and the 
cutoﬀ value for LV dysynchrony) to predict outcome was determined using receiver operator 
characteristic (ROC) curve analysis. Finally, the most important issue was addressed: would 
identiﬁcation of responders prior to pacemaker implantation translate in a favourable 
prognosis during follow-up?
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Patients, Study Protocol
Eighty-ﬁve consecutive patients with end-stage heart failure, scheduled for implantation of 
a biventricular pacemaker, were included in the current study. The patients were selected 
according to the established selection criteria for CRT: 1. severe heart failure (New York 
Heart Association (NYHA) class III or IV), 2. severely depressed LV ejection fraction (LVEF 
≤35%), QRS exhibiting left bundle branch block conﬁguration with a duration ≥120 ms [1-3].
Patients with atrial ﬁbrillation or with a previously implanted pacemaker were excluded. 
The study protocol was as follows: before pacemaker implantation, resting two-dimensional 
(2D) and color Doppler transthoracic echocardiography were performed to measure LVEF 
and LV volumes, and analyze the severity of mitral regurgitation. Next, myocardial TDI was 
performed to assess inter- and intraventricular dyssynchrony.
Clinical status was assessed at baseline and 6 months follow-up, including assessment of 
NYHA class, quality of life (using the Minnesota Living with Heart Failure questionnaire) 
[10], and evaluation of exercise capacity using the 6-minute walking test [11]. At 6 months 
follow-up, LVEF and LV volumes and severity of mitral regurgitation were re-assessed by 
echocardiography; LV dyssynchrony was also re-assessed.
Hospitalization for heart failure and survival were assessed during 1 year follow-up after 
pacemaker implantation.
Echocardiography, Data Acquisition/Analysis
Patients were imaged in the left lateral decubitus position using a commercially available 
system (Vivid Seven, General Electric – Vingmed, Milwaukee, WI, USA). Images were 
obtained using a 3.5 MHz transducer, at a depth of 16 cm in the parasternal and apical views 
(standard long-axis, 2-chamber and 4-chamber images). Standard 2-dimensional and color 
Doppler data (3 consecutive beats), triggered to the QRS complex, were saved in cineloop 
format. For TDI, color Doppler frame rates varied between 100 and 120 frames/sec depending 
on the sector width of the range of interest, and pulse repetition frequencies between 500 Hz 
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to 1 KHz, resulting in aliasing velocities between 16 and 32 cm/sec. Tissue Doppler parameters 
were measured from color images by oﬀ-line analysis. 
The LV volumes and the LVEF were calculated from the apical 2- and 4-chamber images, 
using the biplane Simpson’s rule [12]. The severity of mitral regurgitation was graded semi-
quantitatively from color-ﬂow Doppler in the conventional parasternal long-axis and apical 
4-chamber images. Mitral regurgitation was characterized as: mild=1+ (jet area/left atrial 
area<10%), moderate=2+ (jet area/left atrial area 10-20%), moderately severe =3+ (jet area/left 
atrial area 20-45%), and severe=4+ (jet area/left atrial area >45%) [13]. 
For TDI analysis, the digital cineloops were analyzed using commercial software (Echopac 6.1, 
General Electric – Vingmed, Milwaukee, WI, USA) by 2 independent observers, blinded to 
the clinical outcome. The sample volume was placed in the LV basal portions of the anterior, 
inferior, septal and lateral walls (using the 2- and 4-chamber images), and per region, the time 
interval between the onset of the QRS complex and the peak systolic velocity was derived. 
LV dyssynchrony was deﬁned as the maximum delay between peak systolic velocities among 
the 4 walls within the LV (most frequently observed between the interventricular septum 
and the lateral wall) [14]. Interventricular dyssynchrony was assessed by comparing the delay 
between peak systolic velocity of the right ventricular free wall and the LV lateral wall [15]. 
The time required to analyze the tissue Doppler data was 10-15 min.
Pacemaker Implantation
The LV pacing lead was inserted transvenously via the subclavian route. First, a coronary sinus 
venogram was obtained using the balloon catheter. Next, the LV pacing lead was inserted 
via the coronary sinus using an 8F guiding catheter and positioned preferably in a (postero-
)lateral vein. 
The right atrial and ventricular leads (with separate connectors) were positioned conventionally. 
The atrioventricular delay was optimized by 2D echocardiography so that it provided the 
longest ﬁlling time for completion of the end-diastolic ﬁlling ﬂow before LV contraction 
[16]. A dedicated resynchronization device was used in all patients. When a conventional 
indication for an ICD existed, a combined device was implanted.
Chapter 11
 158 
Statistical Analysis
Results are presented as mean ± SD. Data were compared using paired or unpaired Student’s 
t-test when appropriate. Proportions were compared using Chi-square analysis with Yates’ 
correction. Optimal cutoﬀ values of parameters to predict response to CRT were determined 
by ROC curve analysis. The optimal cutoﬀ value was deﬁned as that providing the maximal 
accuracy to distinguish between responders/non-responders. 
Diﬀerences in cardiac event-rates (death and hospitalization for heart failure) over time were 
analyzed by the method of Kaplan-Meier, and log-rank test. For all tests, a P-value <0.05 was 
considered signiﬁcant.
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Study Population
Eighty-ﬁve patients were included. The patient characteristics are summarized in Table 
1. Patients had severe LV dysfunction (mean LVEF 23±7%, range 9-34%), with extensive 
dilatation (LV end-diastolic volume 258±56 ml). Approximately equal numbers of patients 
had heart failure of ischemic and non-ischemic etiology. The QRS duration was prolonged, 
ranging from 120 to 240 ms. 
The mean LV dyssynchrony was 73±49 ms (range 0 - 221 ms) before CRT. The site of latest 
activation was the lateral wall in 89% of patients; in the remaining 11%, the site of latest 
activation was the septum (n=4), anterior wall (n=2) or the inferior wall (n=3). The mean RV-
LV dyssynchrony was 47±38 ms.
Thirty-seven patients received a resynchronization pacemaker (Contak TR (n=27), Guidant, 
MN, USA or InSync III (n=10), Medtronic Inc., MN, USA) and 48 a combined CRT-ICD 
device (Contak CD (n=15) or Contak Renewal (n=30), Guidant, MN, USA and InSync III CD 
(n=3), Medtronic Inc., MN, USA). Two types of LV leads were used (Easytrack 4512-80 (n=73), 
Guidant, MN, USA or Attain-SD 4189 (n=12), Medtronic Inc., MN, USA). The procedure was 
successful in all patients and no procedure related complications were observed. 
Following CRT, the QRS-duration was reduced from 178±36 ms to 155±22 ms (P<0.01).
The optimized atrioventricular delay was 115±32 ms. 
Within 6 months after CRT, 5 patients died of worsening heart failure. Since these patients 
did not have the 6 month follow-up assessment, they were could not be included in the 
prediction of response to CRT, but they were included in the prognostic evaluation.
Clinical Improvement Following CRT
At baseline and 6 months follow-up, the clinical status of the patients was assessed. 
NYHA class improved from 3.2±0.4 to 2.1±0.7 (P<0.01). In addition, the Minnesota score 
decreased from 42±16 to 29±16 (P<0.01), and the 6-minute walking distance increased from 
278±132 m to 399±149 m (P<0.01). The LVEF demonstrated a modest improvement (from 
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23±7% to 28±8%, P<0.05), with a reduction in LV end-diastolic volume (259±57 ml to 237±58 
ml, P<0.05) and end-systolic volume (201±54 ml to 173±53 ml, P<0.05). Mitral regurgitation 
improved by at least 1 grade in 12 of 19 (63%) patients with severe regurgitation (2 patients 
of the 21 patients with severe mitral regurgitation at baseline died before echocardiographic 
follow-up).
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Responders and 
Non-responders
The patients were subsequently 
divided into responders and 
non-responders, based on an 
improvement in NYHA class by ≥1 
score and an improvement by ≥25% 
in 6-minute walking distance (Tables 
2 and 3). In the responders, the mean 
NYHA class improved from 3.2±0.4 
to 1.7±0.5, whereas it remained 
unchanged in the non-responders (by 
deﬁnition). The 6-minute walking 
distance improved from 291±122 m to 
438±116 m and remained unchanged 
in the non-responders (279±155 m vs 
254±175 m) (by deﬁnition).
At baseline, no signiﬁcant diﬀerences were observed between responders and non-responders, 
except that the non-responders tended to have larger LV end-diastolic and end-systolic 
volumes, although these diﬀerences were not signiﬁcant (Table 2). The only variable that was 
signiﬁcantly diﬀerent between the 2 groups was the LV dyssynchrony, which was extensive in 
the responders and minimal in the non-responders (Table 2). Of note, RV-LV dyssynchrony 
was not diﬀerent between responders and non-responders.
The responders showed a signiﬁcant improvement in clinical parameters after CRT (Table 
3), whereas none of the clinical parameters improved in the non-responders after CRT. 
Furthermore, the LVEF improved in the responders, and reverse remodeling was observed 
after CRT. In the non-responders, the LVEF did not improve and the LV volumes did not 
decrease after CRT.
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In the responders, 12 patients had severe mitral regurgitation and 11 (92%) patients improved 
in mitral regurgitation by at least 1 grade after CRT. In the non-responders, 7 patients had 
severe mitral regurgitation, and only 1 (14%, P<0.05 vs responders) improved at least 1 grade 
after CRT.
In responders, the LV dyssynchrony had decreased from 87±49 ms to 21±28 ms (P<0.01), 
whereas in the non-responders, the LV dyssynchrony tended to increase, although the 
diﬀerence was not signiﬁcant (35±20 ms vs 42±23 ms, ns).
Prediction of Response
The only variable at baseline that was signiﬁcantly diﬀerent between responders and non-
responders was the LV dyssynchrony. To deﬁne the optimal cutoﬀ value to predict clinical 
response, ROC curve analysis was performed. When responders were deﬁned as patients 
exhibiting an improvement in NYHA class ≥1 score and an improvement ≥25% in 6-minute 
walking distance, an optimal sensitivity and speciﬁcity of 80% were obtained at a cutoﬀ level 
of 65 ms for LV dyssynchrony (Figure 1).
ROC curve analysis was also performed to deﬁne the optimal cutoﬀ value for LV dyssynchrony 
to predict reverse LV remodeling. At a cutoﬀ value of 65  ms for LV dyssynchrony a sensitivity 
Figure 1. ROC curve 
analysis demonstrated a 
sensitivity and speciﬁcity 
of 80% to predict response 
to CRT (deﬁned as an 
improvement in NYHA 
class ≥1 score and an 
improvement ≥25% in 6-
minute walking distance) 
at a cutoﬀ level of 65 ms 
for LV dyssynchrony.
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Figure 2. ROC curve analysis demonstrated a sensitivity and speciﬁcity of 92% to predict reverse LV remodeling after 
CRT (deﬁned as an improvement in LV end-systolic volume ≥15%) at a cutoﬀ level of 65 ms for LV dyssynchrony.
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Figure 3. A linear relation existed between the extent of LV dyssynchrony and the change in LV end-systolic volume 
after CRT. However, LV dyssynchrony over 100 ms did not result in further reduction in LV end-systolic volume.
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and speciﬁcity of 92% were obtained to predict a reduction of ≥15% LV end-systolic volume 
(Figure 2).
The continuous relation between the LV dyssynchrony and the reduction in LV end-systolic 
volume is displayed in Figure 3. A linear relation existed between the LV dyssynchrony and 
the reduction in LV end-systolic volume until the LV dyssynchrony reached 100 ms. After 
this point, even if LV dyssynchrony increased further, no further reduction in LV end-systolic 
volume occurred (as evidenced by the horizontal line, y=55, Figure 3).
Prediction of Prognosis
Follow-up was performed during 1 year after implantation. A total of 16 events occurred 
in the 80 patients, including 7 deaths (1 non-cardiac death, 6 worsening heart failure), 
and 9 hospitalizations for decompensated heart failure. The event-rate in responders was 
signiﬁcantly lower than in non-responders (8% vs 52%, <0.01).
Moreover, when patients were divided according to the presence/absence of LV dyssynchrony 
(using a 65 ms cutoﬀ value), only 3 (6%) events occurred in the 49 patients with dyssynchrony 
as compared to 13 (33%) in the 31 patients without dyssynchrony. None of the 5 patients who 
died before the 6 months follow-up assessment had LV dyssynchrony; inclusion of  these 
patients resulted in a 50% event-rate during the 1-year follow-up in the patients without 
dyssynchrony (Figure 4).
Moreover, 6 of 48 (13%) patients with a combined CRT-ICD device experienced adequate 
shocks (for ventricular arrhythmias) during the 1-year follow-up; all of these patients were 
non-responders.
Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy.
 165 
The ﬁndings in the current study can be summarized as follows:
1. all baseline characteristics are comparable in responders and non-responders to CRT, except 
for the LV dyssynchrony, which was larger in responders; 2. baseline LV dyssynchrony of 65 
ms or more has a sensitivity and speciﬁcity of 80% to predict clinical response and 92% to 
predict reverse LV remodeling; 4. patients with extensive dyssynchrony who undergo CRT 
have an excellent prognosis (6% event-rate) whereas patients who do not have dyssynchrony 
and undergo CRT have a  poor prognosis (event-rate 50%).
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Figure 4. Cardiac events (cardiac death, hospitalization for decompensated heart failure) during 1-year follow-up 
after cardiac resynchronization therapy. Patients with left ventricular dyssynchrony ≥65 ms had a signiﬁcantly lower 
event-rate after cardiac resynchronization therapy as compared to patients with dyssynchrony <65 ms (6% vs 50%, 
P<0.001).
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Beneﬁt of CRT
In the entire study population, an improvement in all clinical parameters was observed, in 
line with previous studies concerning CRT [5-7]. Comparable to recent randomized clinical 
trials (MIRACLE, MUSTIC, PATH-CHF), a reduction in NYHA class and quality of life 
score were noted and an increase in 6-minute walking distance was observed [5-7]. Moreover, 
in the present study, a modest improvement in LVEF was shown, comparable to results of 
the MIRACLE trial [6]. In addition, signiﬁcant reverse remodeling was demonstrated, also 
in line with data from the MIRACLE trial [17]. 
However, not all patients responded equally to CRT, and when patients were divided in 
responders and non-responders, based on improvement in NYHA class, it became evident 
that an improvement in clinical parameters was only observed in the responders. Moreover, 
improvement in LVEF and reverse remodeling were also observed only in the responders. 
When individual results were analyzed, it became clear that 21 (26%) patients did not respond 
to CRT. When the 5 patients who died before the 6-month follow-up were also included, 
the percentage of non-responders was 31%. This observation is in agreement with previous 
studies [8,9]. For example, in the MIRACLE trial, 20% of patients did not experience an 
improvement in symptoms and 32% did not improve in NYHA class [6]. Similarly, Reuter 
and coworkers [18] demonstrated that 18% of 102 consecutive patients undergoing CRT did 
not improve in NYHA class and quality of life score.
In the current study and in most of the large clinical trials, the selection criteria included 
severe heart failure (NYHA class III or IV) with severely depressed LVEF (≤35%), and wide 
QRS complex (≥120 ms). Thus, additional selection criteria are needed to reduce the high 
number of non-responders. 
Left Ventricular Dyssynchrony to Select Candidates for CRT
When baseline characteristics were compared between responders and non-responders 
(Table 2), the only variable that was diﬀerent among the 2 groups was the LV dyssynchrony 
(whereas the RV-LV dyssynchrony was also not diﬀerent). This ﬁnding was not unexpected, 
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since various studies have recently emphasized the importance of LV dyssynchrony for 
the response to CRT. Pitzalis et al [19] have used M-mode echocardiography to assess LV 
dyssynchrony by measuring the septal-to-posterior wall motion delay. Although this is an 
elegant and simple method to assess LV dyssynchrony, in patients with ischemic heart disease 
and previous anterior infarction, assessment of septal movement is frequently not possible. 
Recent studies have therefore focused on TDI applications to assess dyssynchrony. Sogaard 
and colleagues [20,21] have used tissue tracking in 25 patients to detect regions with delayed 
longitudinal contraction. The authors demonstrated that the extent of delayed longitudinal 
contraction predicted response to CRT. Breithardt and coworkers [22] used strain rate 
imaging in 18 patients to assess dysynchrony.  More recent studies have focused on timing 
of peak systolic velocities of diﬀerent myocardial regions to assess LV dyssynchrony. Yu and 
colleagues [23] have evaluated 30 patients before and after CRT with TDI and demonstrated 
that LV dyssynchrony allowed separation between patients with and without LV remodeling 
as expressed by a reduction in end-systolic volume by more than 15%. Assessment of 
dyssynchrony was comparable to the present analysis, with the exception that 12 segments 
were used, instead of 4 segments in the present study. 
ROC curve analysis demonstrated a sensitivity and speciﬁcity of 80% for prediction of 
clinical status and 92% for the prediction of reverse LV remodeling. ROC curve analysis 
identiﬁed the cutoﬀ value of 65 ms as optimal. Of interest, Gorcsan et al [24] have recently 
evaluated a small group of patients and also reported a similar value (65 ms) as optimal cutoﬀ 
value to predict response to CRT. This cutoﬀ level may now be used in further studies to 
prospectively select patients for CRT. 
Prognostic Value of CRT and Left Ventricular Dyssynchrony
The typical patients who are eligible for CRT (heart failure, depressed LVEF and wide QRS 
complex) have a poor prognosis when treated conservatively [1-3]. Moreover, Bader et al [14] 
have recently shown that in these patients the presence of LV dyssynchrony is an important 
predictor of poor outcome.
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Prognostic studies in patients undergoing CRT are still scarce. Various studies have evaluated 
patients after CRT; the initial studies have reported the acute beneﬁt [4], other studies have 
demonstrated response after 6 months to 1 year, and preliminary data have shown sustained 
beneﬁt over time [5-7]. A recent meta-analysis of the 11 published studies of 4 randomized 
trials (including 1634 patients) demonstrated a short-term (6-month) survival beneﬁt after 
CRT as compared to optimized medical therapy [25].
However, none of the studies have evaluated the relation between baseline dyssynchrony in 
patients undergoing CRT and prognosis. In the current study, 1-year follow-up was obtained 
and the results demonstrated a low event-rate (6%) after CRT in patients with LV dyssynchrony 
at baseline as compared to patients without dyssynchrony (50% event-rate). This observation 
further supports the hypothesis that the degree of LV dyssynchrony is not only predictive of 
response to CRT but is also related to favourable prognosis when treated by CRT. 
Patients with extensive LV dyssynchrony responded well to CRT. Using a cutoﬀ level of 65 
ms, a sensitivity and speciﬁcity of 80% were obtained to predict clinical response and of 92% 
to predict reverse LV remodeling. Moreover, patients with LV dyssynchrony ≥65 ms had an 
excellent prognosis after CRT, in contrast to patients with <65 ms who had a high event-rate 
(50%) during 1-year follow-up.
Conclusions
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Introduction
Cardiac resynchronization therapy (CRT) is a promising technique for patients with end-
stage, drug-refractory heart failure. Still 20-30% of the patients treated with CRT do not 
respond. Accordingly, the current selection criteria need to be reﬁned, and it appears that 
demonstration of left ventricular dyssynchrony may be mandatory for response to CRT. 
Novel echocardiographic methods are currently investigated to detect left ventricular 
dyssynchrony and thereby improve the selection of candidates for CRT. In this brief review, 
these techniques will be discussed.
Health care costs for patients with heart failure are rising rapidly due to the exponential rise in 
the number of patients.[1,2] Current therapeutic options for this speciﬁc patient population 
include heart transplantation, surgical revascularization or optimized medical therapy.[1,2] 
Since the number of donor hearts is limited and revascularization is associated with a high 
morbidity and mortality for heart failure patients, optimized medical therapy remains the 
only option in this patient population. However, medical treatment still remains suboptimal 
in terms of clinical beneﬁt and long-term prognosis.[3,4] Thus, alternative therapeutic 
approaches for heart failure patients have been explored. Cardiac resynchronization therapy 
(CRT) has been introduced as a novel 
therapeutic option for patients with  heart 
failure and a wide QRS complex.[5-9] The 
initial results with CRT are promising and 
improvement in clinical status has been 
demonstrated in large trials.[5-9]  
Clinical results of the large CRT trials
Currently, 5 major trials have been published 
including MIRACLE, MUSTIC, PATH-
Summary
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CHF, INSYNC and MIRACLE ICD [5-9]. In these trials diﬀerent parameters of response 
to CRT have been used (Table 1). The most frequently used clinical parameters include 
NYHA class, quality of life score, exercise tolerance (or 6-minute walking distance), and left 
ventricular (LV) function.[5-9] Moreover, major clinical end-points include hospitalization 
and survival. Besides these clinical parameters, echocardiographic parameters have been 
evaluated, including LV ejection fraction (EF), LV volumes (to assess reverse remodeling), 
mitral regurgitation and diastolic function [5-11].
The MIRACLE trial evaluated 453 patients with moderate-to-severe heart failure treated by 
CRT during 6 months of follow-up. The patients were divided into a CRT group (n=228) and 
a control group (optimal medical therapy, n=225). At 6 months follow-up the CRT patients did 
not only experience an improvement in functional class, 6-minute walking distance and quality 
of life score, but also a reduction in morbidity and mortality, when compared to the control 
group. Moreover, fewer patients in the CRT group required hospitalization or intravenous 
medication for the treatment of heart failure when compared to the control group.[5] 
A meta-analysis of 4 randomized controlled CRT trials with a follow-up ranging  from 3 to 6 
months, showed a reduction in heart failure mortality of 51% compared to controls (mortality 
rate 1.7% in CRT group vs 3.5% in no-CRT group). The number of patients requiring heart 
failure hospitalization was 13% in the CRT group compared to 17% in the control group 
(reduction of 29% with CRT).[12]      
Echocardiographic data from the MIRACLE trial demonstrated a progressive reverse 
remodeling over 6 months CRT.[10] Similarly, data from the PATH-CHF trial showed a 
reduction in LV end-systolic volume from 202±79 ml to 174±101 ml (P<0.01) with a reduction 
in LV end-diastolic volume from 253±83 ml to 227±112 ml (P<0.05) after 6 months of CRT.[11] 
Decrease of mitral regurgitation was also demonstrated in the MIRACLE trial, with an 
average reduction of 2.5 cm2 in jet area.[10]
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Non-responders
Currently, the patients for CRT are selected according to the following criteria: 
-end-stage heart failure with NYHA class III or IV, 
-severely depressed LVEF (<35%) and,
-QRS duration >120 ms with left bundle branch block morphology.[5-9]  
These criteria have been applied in all major clinical trials. However, despite the encouraging 
results and beneﬁcial response to CRT as compared to optimized medical therapy [2,5], 
individual responses to CRT vary signiﬁcantly, and a substantial percentage of patients does 
not respond to CRT.[5-9] When data from the MIRACLE trial are analyzed carefully, the 
number of non-responders (according to patient’s perception) ranged from 12% to 20%, 
depending on the deﬁnition of  response. In particular, 30% of patients did not improve 
in NYHA class and 2% of patients even deteriorated in NYHA class after CRT.[5] At the 
Leiden University Medical Center, 22% of the CRT patients did not improve in  NYHA 
functional class after 6 months of CRT.[13]
Thus, despite the traditional inclusion criteria, it is estimated that 20-30% of patients may 
not respond to CRT. These observations have shifted the attention to the identiﬁcation of 
patients, with a high likelihood of response to CRT, before implantation of the pacemaker, in 
order to reduce the number of non-responders. 
Initially, demographic parameters were evaluated to explain the varying response. Reuter and 
coworkers studied 102 patients over a period of 12 months of CRT and showed that 18% 
of the CRT patients did not respond clinically.[14] Multivariate analysis was performed to 
identify predictive parameters for non-response after CRT. However, neither age, presence 
of chronic atrial ﬁbrillation, electrical parameters, NYHA class, nor LVEF could predict 
clinical response to CRT.[14] 
Molhoek and colleagues [15]evaluated  whether the underlying etiology of heart failure 
(ischemic versus idiopathic cardiomyopathy) could explain non-response. The authors included 
34 patients with ischemic cardiomyopathy and 40 patients with idiopathic cardiomyopathy, 
and follow-up was obtained 2 year after CRT. All clinical parameters, QRS duration, LVEF 
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and mitral regurgitation improved signiﬁcantly at 6 months follow-up, while no diﬀerence in 
improvement was noted between the ischemic or non-ischemic patients. Long-term (2 year) 
survival rate was 87.5% for the the non-ischemic and 88.3% for the ischemic cardiomyopathy 
patients. The percentages of responders to CRT (deﬁned as an improvement in NYHA class 
≥1 grade) was comparable in the 2 groups (65% versus 71%, ns). Accordingly, it was concluded 
that underlying etiology was not related to the response to CRT.[15]
Next, the value of the duration of the QRS complex was evaluated. Kass et al [16] showed that 
CRT improved dP/dtmax in 18 patients with end-stage heart failure. The authors described 
a linear relation between the QRS duration and mechanical response (improvement in dP/
dtmax) to pacing. Molhoek and coworkers [17] performed a more in-depth analysis of the 
value of QRS duration at baseline to predict clinical response. A consecutive cohort of 61 
patients was evaluated and 74% of patients were classiﬁed as clinical responders. However, 
QRS duration at baseline was similar between the 2 groups: 179±30 ms versus 171±32 ms. 
Immediately following pacemaker implantation, the QRS duration was reduced from 179±30 
Figure 1: Reduction in QRS 
duration after 6 months of cardiac 
resynchronization therapy in 
clinical responders (20±29 ms) 
and non-responders (3±38 ms) 
to CRT. The reduction in QRS 
duration tended to be more 
outspoken in the responders.
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ms to 150±26 ms (P<0.01) in the responders while non-responders did not exhibit this 
reduction (171±32 ms versus 160±26 ms, ns). After 6 months follow-up, the shortening in QRS 
duration was sustained in responders (Figure 1). Although there was a signiﬁcant diﬀerence in 
reduction of QRS duration in responders, ROC curve analysis revealed suboptimal sensitivity 
and speciﬁcity to predict response.
Accordingly,  additional inclusion criteria are needed to predict clinical response and to 
reduce the percentage of  non-responders to CRT. During the last 2 years diﬀerent groups 
have explored the use of echocardiography to select potential responders to CRT. Before the 
role of echocardiography  in CRT will be discussed in detail, the diﬀerent mechanisms of 
beneﬁt following by CRT will be addressed brieﬂy. 
 
Mechanism of beneﬁt from CRT
The mechanism underlying the beneﬁt of CRT is related to 3 issues. First, CRT results in 
optimization of the AV-delay resulting in an atrial and ventricular activation sequence with 
an optimal LV ﬁlling time to improve systolic performance. Aurricchio et al [18] evaluated 27 
patients for optimal AV-delay by evaluating hemodynamic function (increase in dP/dtmax) 
with CRT. Five patient-speciﬁc optimal AV-delays were preset for each patient depending on 
the percentages of the patient`s intrinsic PR-interval. The authors concluded that patients 
with wide surface QRS complex had maximum acute beneﬁt when a patient-speciﬁc AV-
delay was programmed.
Second, CRT has been demonstrated to shorten the interventricular delay, resulting in a 
reduction of the RV-LV dyssynchrony. St John Sutton et al [10] demonstrated a signiﬁcant 
reduction in interventricular mechanical delay after CRT.
 And third, CRT has been demonstrated to restore LV synchrony, and is mainly caused by 
mechanical dispersion of motion between the septum and the lateral wall. 
Yu and coworkers [19] have shown an improvement in LV dyssynchrony (assessed by tissue 
Doppler imaging) after CRT, with a near normalization of the LV dyssynchrony.
The AV optimization and the restoration of inter- and intra-ventricular dyssynchrony all 
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contribute to the eﬀects observed after CRT (improvement of systolic function, reduction 
of mitral regurgitation, reverse remodeling). Importantly, the relative contribution of 
these 3 mechanisms to the success of CRT is currently unknown. From recent work 
however [19] it has become clear that resynchronization of dyssynchrony within the left 
ventricle may be a very important component contributing to the success of CRT. Yu and 
coworkers [20] have recently evaluated 200 individuals and demonstrated a high prevalence 
of LV dyssynchrony. As expected the majority (79%) of patients with a wide QRS complex 
(>120 ms) had substantial LV dyssynchrony, but 51% of the patients with a narrow QRS (<120 
ms) also exhibited LV dyssynchrony.
Since the traditional selection criteria are insuﬃcient for accurate identiﬁcation of 
responders and assessment of LV dyssynchrony may provide additional information, many 
studies are currently conducted focusing on this topic. Various techniques including MRI 
[21], scintigraphic phase imaging [22] and echocardiography are explored for their value in 
assessing LV dyssynchrony.
At present, echocardiography appears the most available technique for this purpose. In the 
next paragraph, the various echocardiographic approaches (in particular tissue Doppler 
imaging) will be discussed,  
Assessment of LV dyssynchrony and prediction of  response to CRT 
Various echocardiographic approaches to identify potential responders to CRT have 
been proposed. These studies were mainly focused on the detection of intra-ventricular 
dyssynchrony. These approaches will be discussed brieﬂy. 
Pitzalis and colleagues [23] evaluated intraventricular dyssynchrony using M-mode 
echocardiography. From a left ventricular M-mode image, the septal-to-posterior wall motion 
delay was calculated as a parameter reﬂecting the intraventricular dyssynchrony. Twenty-ﬁve 
patients were evaluated before and 1 month after implantation of a biventricular pacemaker. 
Patients were considered as responders when a reduction in LV end-systolic volume index of 
at least 15% was observed after 1 month of CRT. The authors concluded that intraventricular 
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dyssynchrony and QRS duration correlated with reverse remodeling after 1 month of CRT. 
However, the accuracy to predict reverse remodeling after CRT was superior when the 
intraventricular dyssynchrony was used as compared to the QRS duration. Using ROC curve 
analysis, a cut-oﬀ value of ≥130ms for the intraventricular delay  was determined to predict a 
positive response to CRT (with an accuracy of 85%).[23]
Breithardt and coworkers [24] used echocardiographic phase analysis to identify intraventricular 
dyssynchrony in 34 patients from the PATH-CHF trial. The intraventricular dyssynchrony 
was determined by the diﬀerence between the phase angles of the lateral and septal wall 
motions of the LV before and after 4 weeks of CRT. A large positive phase angle diﬀerence 
between septal and lateral wall motion (before pacemaker implantation) correlated with an 
improved systolic function after 1 month of therapy. The improvement in LV function was 
directly related to the reduction in intraventricular dyssynchrony. 
Figure 2: Tracing derived from color tissue Doppler image with the sample placed in the basal part of the septum, 
demonstrating peak systolic velocity (PSV), and diastolic parameters (E’ and A’).
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Tissue Doppler imaging to assess LV dyssynchrony. 
The majority of the echocardiographic studies aiming to assess intraventricular dyssynchrony, 
have used tissue Doppler imaging (TDI). Myocardial TDI is an echocardiographic technique 
that allows noninvasive quantiﬁcation of the peak systolic velocities of the diﬀerent myocardial 
segments.[25] The timing of this peak systolic velocity can be evaluated in relation to electrical 
activity (QRS on ECG), allowing assessment of  electromechanical (un-)coupling.[26] With 
the recent technological advances, color TDI images can be obtained, making post-processing 
possible. An example of color TDI is presented in Figure 2, which shows the typical TDI 
tracing obtained from color TDI images in a normal individual. The sample volume is placed 
on the septum and peak systolic velocity and diastolic velocities (E’ and A’) can be obtained. 
Also, the timing of events can be derived, based on the time-intervals between the beginning 
of the QRS complex and TDI tracings. When sample volumes are placed simultaneously 
Figure 3: Color tissue Doppler image of a normal individual.
The TDI tracings are obtained from samples placed in the basal part of the septum (yellow line) and the lateral wall 
(green line), illustrating perfect mechanical synchrony of these 2 walls.
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on the septum and the lateral wall (see Figure 3), the mechanical delay between these two 
walls can be derived, which may serve as a parameter of left ventricular dyssynchrony.[27,19] 
Various studies have subsequently used TDI to assess LV dyssynchrony. Yu and coworkers 
[19] evaluated 25 patients with NYHA class III to IV heart failure, LVEF 28±10%, with 
wide QRS complex who underwent CRT. Echocardiography was performed serially up to 3 
months of CRT; in addition echocardiography was also performed when pacing was withheld 
for an episode of 4 weeks. The authors demonstrated a signiﬁcant improvement in clinical 
parameters after 3 months of CRT. In addition, LVEF improved to 40±15% and LV volumes 
decreased signiﬁcantly indicating reverse LV remodeling. The extent of LV dyssynchrony 
was assessed by TDI tracings obtained from diﬀerent myocardial regions. In particular, 
the authors obtained tracings from 6 basal  and 6 mid-ventricular segments; for each of the 
segments, the time from onset of QRS to peak systolic velocity was calculated. The standard 
deviation from the mean peak systolic velocities was used as marker of dyssynchrony. 
A more simple approach was used by Bax and coworkers.[27,28] These authors evaluated 
intraventricular dyssynchrony by measuring the diﬀerences between the timing of the peak 
systolic velocities of the septum and the lateral wall. Oﬀ-line analysis of the color 4-chamber 
tissue Doppler images was performed by placing 2 sample volumes in the basal portions of 
the septal and lateral walls. Velocity proﬁles were derived from the samples by measuring 
the time diﬀerence from the onset of the QRS complex to the peak systolic velocities (in 
milliseconds). The delay between peak systolic velocity of the septum versus peak systolic 
velocity of the lateral wall (2-segment model) was referred to as “septal-to-lateral delay”, an 
indicator for intraventricular dyssynchrony. An example of a patient with severe heart failure, 
depressed LV function and wide QRS complex is demonstrated in Figure 4. The simultaneous 
tracings demonstrate a septal-to-lateral delay of 200ms. After CRT, a signiﬁcant reduction in 
septal-to-lateral delay (to 20ms) was observed (Figure 5).
Both of the above described TDI approaches have been evaluated to detect resynchronization. 
Yu and coworkers [19] have demonstrated that CRT abolished the intersegmental diﬀerence 
in timing to peak systolic velocities (using the 12-segment model). It became clear that the 
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maximum delay was virtually always observed between the septum and the lateral wall, with 
the latest activation in the lateral wall.
In a subsequent study, these authors demonstrated that the dyssynchrony, as detected by TDI, 
can actually be used to predict response to CRT.[29] Thirty patients were studied before CRT 
to assess LV dyssynchrony. At baseline and after 3 months of CRT, clinical parameters were 
evaluated, including 6-minute walking distance, peak oxygen uptake, quality of life score and 
NYHA class. In addition, speciﬁc echocardiographic parameters were obtained including 
LVEF, LV volumes and a sphericity index. The responders (evidence by an improvement 
in both clinical and echocardiographic parameters) had a signiﬁcantly larger extent of LV 
dyssynchrony before CRT. Using a dyssynchrony index of 32.6 ms, it was possible to identify 
all patients with a signiﬁcant reverse remodeling.
The septal-to-lateral delay (using the 2-segment model) was also evaluated in additional 
studies. Immediate resynchronization after initiation of CRT using this approach was 
demonstrated by Schuster et al [30] in 18 patients. Bax et al [27] evaluated 22 patients with 
idiopathic cardiomyopathy, severe heart failure, depressed LVEF (21±7%) and widened QRS 
complex (172±33 ms). Immediately after CRT, the septal-to-lateral delay was reduced from 
110±33 ms to 29±22 ms (P<0.05). Of interest, when the pacemaker was switched oﬀ again, the 
septal-to-lateral delay returned to 105±47 ms, indicating the immediate loss of eﬀect after 
termination of CRT. In addition, the LVEF improved immediately from 19±8% to 32±10% 
(P<0.05) after CRT, followed by a direct worsening to 20±6% when the pacemaker was 
switched oﬀ. The immediate eﬀect translated into long-term clinical beneﬁt, as evidenced 
by the signiﬁcant improvement in 6-minute walking distance and the reduction in NYHA 
class. In a subsequent study, the same group evaluated 25 patients with TDI before CRT. 
Left ventricular dyssynchrony was the only predictor of beneﬁt from CRT; 13 of 17 (76%) 
responders had a septal-to-lateral delay ≥60 ms, whereas 7 of 8 (87.5%) non-responders had a 
septal to lateral delay <60 ms, indicating that tissue Doppler imaging can be used to identify 
patients who beneﬁt from CRT.[28] The precise cutoﬀ value (for the extent of dyssynchrony) 
to predict response to CRT remains to be identiﬁed, followed by prospective validation. 
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Instead of tracings derived from color tissue Doppler images, pulsed-wave TDI can also 
be used [31-34]; the shortcoming of pulsed-wave TDI is that simultaneous interrogation of 
diﬀerent myocardial walls or regions is not possible during one cardiac cycle. The use of 
pulsed-wave TDI for assessment of LV dyssynchrony and resynchronization was demonstrated 
extensively by Ansalone and colleagues.[31,32] In addition, Garrigue et al [33,34] also used 
pulsed-wave TDI and showed extensive LV dyssnchrony even in patients with right bundle 
branch block.
Two TDI measurements can be derived with further extended oﬀ-line analysis from pre-
recorded color TDI cine-loops. First, tissue tracking which visualizes the degree of systolic 
shortening by tracking each myocardial point throughout the cardiac cycle [35], and  second, 
strain rate analysis which can evaluate systolic performance of the myocardium and diﬀerentiate 
whether this performance represents contraction or is merely passive motion.[35-37] 
Figure 4: Color tissue Doppler image a patient with severe heart failure and dilated cardiomyopathy. The sample 
volumes are placed in the basal part of the septum and lateral wall, and tracings are derived (yellow trace = septum; 
green trace = lateral wall). The septal-to-lateral delay is 200 ms, indicating severe left ventricular dyssynchrony.
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This approach has been explored by Sogaard et al [35] in 25 patients undergoing CRT. 
Application of tissue tracking and strain rate analysis allowed precise identiﬁcation of the 
myocardium with the latest activation. Patients with a substantial amount of myocardium 
exhibiting delayed longitudinal contraction had a high likelihood of response to CRT. In 
particular, the extent of delayed longitudinal contraction was linearly related to the change 
in LVEF after CRT. The same group has applied the same TDI technique to optimize 
interventricular delay of CRT [36]. Optimized interventricular delays, guided by the TDI 
approach, resulted in a direct improvement in LVEF with an additional improvement at 
long-term follow-up.
Breithardt and colleagues [37] also recently explored the use of strain rate analysis in patients 
undergoing CRT. Before CRT, septal peak strain rate was lower as compared to the lateral 
wall, whereas the opposite was observed during CRT. The authors suggested that these 
Figure 5: Color tissue Doppler image (same patient as in Figure 3) illustrating resynchronization after CRT; the 
septal-to-lateral delay is reduced to 20 ms.
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abnormal strain rate patterns in the septum versus the lateral wall may allow identiﬁcation of 
potential responders to CRT.
Based on the observations with these diﬀerent TDI approaches, the issue of lead positioning 
has been addressed. The diﬀerent TDI studies have indicated that the site of latest activation 
(maximal dyssynchrony) is most frequently located in the lateral wall. However, Ansalone et 
al [31] have demonstrated with the use of pulsed-wave TDI that the site of latest activation 
may sometimes even be the anterior wall or the interventricular septum. The authors 
demonstrated that inadequate lead positioning resulted in suboptimal response. 
Supported by the published results, it can be anticipated that TDI will be implemented 
in the work-up (and selection-process) of patients eligible for CRT, in order to assess LV 
dyssynchrony, to guide lead positioning, and to document resynchronization after pacemaker 
implantation. 
Despite the excellent clinical results observed after CRT, 20-30% of patients do not respond 
to this therapeutic option for heart failure. The current inclusion criteria should therefore be 
expanded with novel methods to detect LV dyssynchrony. In particular TDI may become the 
method of choice to select the best candidates for CRT.
Conclusions
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The eﬀectiveness of cardiac resynchronization therapy (CRT) in heart failure patients has been 
descried in the diﬀerent chapters of this thesis. Characterization of the clinical responders 
and non-responders from the CRT registry at the Leiden University Medical Center was 
performed to evaluate if diﬀerent parameters could predict clinical outcome of CRT and 
potentially lead to an increase of the percentage of clinical responders to CRT.
In Chapter 2, the percentage of patients with an implantable cardioverter deﬁbrillator 
(ICD) who could potentially beneﬁt from a CRT device were evaluated. All patients who 
received an ICD were analyzed for eligibility of CRT using the following criteria: NYHA 
class III or IV, QRS duration >120 ms and depressed LVEF. An ICD was implanted in 390 
consecutive patients from June 1996 till March 2001. Of the included patients, 20% were 
in NYHA class  III-IV and 16% were in NYHA class II with an LVEF <30%.  Of these 
140 patients, 79 had a QRS duration >120 ms. Thus, 79 (20%) patients were eligible for 
CRT in addition to ICD-therapy. The included patients who received a CRT pacemaker in 
addition to ICD-therapy had a superior survival, improved NYHA class and a signiﬁcantly 
lower hospitalization rate as compared to patients who received an ICD only. In conclusion, 
screening for eligibility of CRT should be considered in patients with congestive heart failure 
scheduled for ICD implantation.
In Chapter 3 the ﬁrst 40 CRT implantations at the Leiden University Medical Center 
were monitored for clinical response and long term follow-up. All included patients had end-
stage heart failure, NYHA class III or IV, left ventricular (LV) ejection fraction (EF) <35%, 
QRS duration >120 ms and left bundle branch block morphology. At baseline, at 3, and 6 months 
after implantation the following parameters were evaluated: New York Heart Association 
(NYHA) class, Minnesota Quality of life score, QRS duration on surface electrocardiogram, 
6-minute walking distance and LVEF. Long-term follow-up was obtained up to 2 years. All 
clinical parameters improved signiﬁcantly at 3 months and remained unchanged at 6 months 
follow-up. Also LVEF increased from 24 ± 9 % to 34 ± 11%. Before implantation, patients 
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were hospitalized (for congestive heart failure) on average 3.9 ± 5.3 days/year, as compared to 
0.5 ± 1.5 days/year after implantation. The survival at 2 years was 87.5%. The  results show that 
CRT improves of clinical symptoms and quality of life, accompanied by improvement in 6-
minute walking distance and LVEF. Long-term survival (up to 2 years) was excellent for these 
congestive heart failure patients treated with CRT.
Chapter 4, evaluates potential diﬀerences in clinical outcome between sinus rhythm 
and atrial ﬁbrillation (AF) patients treated with CRT. Two issues were unresolved in patients 
with AF. First, various studies have shown that 20-30% of patients (with sinus rhythm) do not 
respond to CRT, despite adequate selection criteria; it is unknown what this percentage is 
in patients with AF. Second, the long-term beneﬁt of CRT in patients with AF has not been 
demonstrated. Large experience has been obtained in patients with sinus rhythm, whereas 
the use of CRT in patients with chronic atrial ﬁbrillation has not been studied extensively. 
Accordingly the clinical response and long-term survival of CRT in heart failure patients with 
chronic AF (n=30) was evaluated and the results were compared to patients with sinus rhythm 
(n=30). NYHA class, Minnesota Quality of Life score, and 6-minute walking distance were 
evaluated at baseline and after 6 months of CRT. NYHA class, Quality of life score and the 
6-minute walking distance improved signiﬁcantly in both groups after 6 months of CRT. On 
an individual basis, the number of non-responders was higher in the group of patients with 
AF. Still, long-term survival was comparable between patients with sinus rhythm and AF. 
Patients with AF demonstrated comparable beneﬁt from CRT as compared to patients with 
sinus rhythm. So patients with AF can also beneﬁt from CRT and should not be excluded.
In Chapter 5, the response to CRT in patients with ischemic cardiomyopathy (IC) 
versus idiopathic cardiomyopathy (IDC) is studied. Of the 74 included patients, 46% had 
ischemic and 54% idiopathic cardiomyopathy. At 6 months follow-up all clinical paramaters 
(NYHA class, Minnesota Quality of life score, 6-minute walking distance), QRS duration, LV 
ejection fraction and mitral regurgitation improved signiﬁcantly in both groups. Long-term 
follow-up showed a survival rate of 87.5% for patients with IDC and 88.3% for patients with 
IC. The percentages of responders to CRT were also comparable in both groups. Thus, the 
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underlying etiology of heart failure (IC vs IDC) was not related to the response to CRT and 
both groups are eligible for CRT.
In Chapter 6, the value of the plasmamarkers of congestive heart failure (atrial- 
(ANP) and brain natriuretic peptide (BNP)) to objectively assess response to CRT, was 
evaluated. Clinical evaluation included assessment of NYHA class, QRS-duration, quality of 
life, and 6-minute walking distance. Blood samples were obtained for analysis of natriuretic 
peptides (ANP, BNP). The evaluation was repeated 7 months after CRT. In patients who 
responded clinically to CRT, a decrease in natriuretic peptides was observed at 7 months after 
implantation, whereas this eﬀect was not observed in non-responders. Natriuretic peptides 
may provide an objective measure to evaluate response to CRT. However, no prediction of 
response could be made before implantation of the biventricular device.
In Chapter 7 all diﬀerent clinical parameters were assessed at long term follow-up in 
a large group of CRT treated patients. This study shows that the improvement in functional 
status and symptoms after CRT is maintained at long-term follow-up (up to 3-years). This 
clinical improvement was associated with a signiﬁcant reduction in hospitalization-rate which 
was also maintained over the years. Of the 125 included patients, still 22% did not respond 
to CRT at follow-up. The only predictor found for no response to CRT and poor long-term 
outcome was NYHA class IV in this study. So, pre-implantation selection of responders may 
result in even better long-term survival. 
The QRS duration is evaluated to predict clinical outcome before CRT device 
implantation in chapter 8. Despite current selection criteria 20 - 30% of patients does not 
beneﬁt from CRT. In this study, the value of QRS duration at baseline (and reduction in 
QRS duration after CRT) to predict respons to CRT was studied. Patients were evaluated 
at baseline and after 6 months of CRT for clinical paramaters. QRS duration was evaluated 
before, directly after implantation and after 6 months of CRT. 61 patients were included;45 
(74%) patients were classiﬁed as responders and 16 (26%) as non-responders. QRS duration 
at baseline was similar between the 2 groups. Directly after implantation, QRS duration 
was signiﬁcantly reduced (P<0.01) in responders and non-responders did not exhibit this 
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reduction. After 6 months of CRT, QRS shortening was only observed in clinical responders. 
ROC analysis showed that a reduction in QRS duration >10ms had a high sensitivity but 
a low speciﬁcity; conversely, a >50ms reduction in QRS duration was highly speciﬁc but 
not sensitive to predict response to CRT. No optimal cutoﬀ value could be deﬁned so QRS 
duration at baseline is not predictive for response to CRT. Clinical responders exhibit a 
signiﬁcant reduction in QRS duration after CRT, but individual response varies highly, not 
allowing adequate selection of responders with the use of the QRS complex.
In chapter 9, 10 and 11 tissue Doppler imaging (TDI) is used to assess and predict left 
ventricular dyssynchrony before and after CRT.  Besides optimization of AV-delay and 
resynchronization of dyssynchrony between the left and right ventricle, resynchronization 
of the dyssynchrony within the left ventricle appears important in patients treated with 
CRT. Myocardial tissue Doppler imaging is an echocardiographic technique that allows 
noninvasive quantiﬁcation of the peak systolic myocardial velocity (PSV) and the timing of 
this peak velocity in relation to electrical activity (QRS on ECG). In Chapter 9, 22 patients 
with idiopathic dilated cardiomyopathy who received a CRT device are described. Before and 
after pacemaker implantation echo and TDI were performed, and the following parameters 
were derived: LVEF, peak systolic velocities in the septum and lateral wall, dyssynchrony 
between the septum and lateral wall (expressed as the delay in peak systolic velocity in the 
septum vs lateral wall). In addition, clinical parameters were evaluated at 3 months follow-up. 
After pacing, LVEF increased from 21±7% to 31±9% (P<0.05), the PSV increased signiﬁcantly 
in the septum (from 2.1±1.3 cm/s to 3.9±1.8 cm/s, P<0.05)  and lateral wall (from 2.4±1.7 
cm/s to 4.5±1.5 cm/s, P<0.05). The reduction in the delay between peak systolic velocity 
of the septum vs lateral wall indicated that resynchronization was obtained. At 3 months, 
the clinical parameters had improved signiﬁcantly and can be concluded that TDI allows 
noninvasive assessment of improvement in contractile function and resynchronization after 
CRT. Since better identiﬁcation of patients likely to beneﬁt from CRT is needed before 
implantation, TDI can be a useful tool. The study decribed in Chapter 10 was to evaluate 
whether dyssynchrony assessed from TDI, could predict improvement in systolic LV function 
directly following CRT. Left ventricular dyssynchrony was the only predictor of beneﬁt from 
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CRT. Of the clinical responders 76% had a septal to lateral delay ≥60 ms, whereas 87.5% 
of the non-responders had a septal to lateral delay <60 ms, indicating that tissue Doppler 
imaging can be used to identify patients who beneﬁt from CRT. In Chapter 11 we tried to 
predict the response and prognosis after CRT in a large group of patients with the use of LV 
dyssynchrony assessed by TDI. Of the 58 included patients, 74% were responders and 26% 
non-responders at long term follow-up. The only baseline characteristics that was diﬀerent 
between the two groups was a larger dyssynchrony in responders assesed by TDI (87±49 ms 
versus 35±20 ms, P<0.01). ROC curve analysis demonstrated that an optimal cutoﬀ value of 
65 ms for LV dyssynchrony yielded a sensitivity and speciﬁcity of 80% to predict clinical 
improvement and of 92% to predict LV reverse remodeling. Patients with dyssynchrony ≥65 
ms had an excellent prognosis (6% event-rate) after CRT, as compared to a 50% event-rate in 
patients with dyssynchrony <65 ms (P<0.001). In conclusion, patients with LV dyssynchrony 
≥65 ms (assesed by TDI) respond well to CRT and have an excellent prognosis after CRT. 
Chapter 12, provides a review of the diﬀerent echocardiographic methods to assess 
and predict clinical respons for CRT treated patients. Despite the excellent clinical results 
observed after CRT, 20-30% of patients do not respond to this therapeutic option for heart 
failure and the current selection criteria need to be reﬁned. Diﬀerent studies have shown 
that presentation of left ventricular dyssynchrony is mandatory for a positive response to 
CRT. Novel echocardiographic methods are currently investigated to detect left ventricular 
dyssynchrony and thereby improve the selection of candidates for CRT. In particular TDI 
may become the method of choice to select the best candidates for CRT.
Conclusions
Since 20% of the ICD treated patients are eligible for CRT, screening for CRT
should be considered in patients with congestive heart failure scheduled for ICD
implantation. 
Patients with end-stage heart failure, NYHA class III or IV, left ventricular (LV)
ejection fraction (EF) <35%, QRS duration >120 ms and left bundle branch block
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morphology should receive a CRT device. 
Follow-up shows that CRT gives an improvement of clinical symptoms, quality of
life, 6-minute walking distance and LVEF, also long-term survival is excellent for
these congestive heart failure patients.
Patients with AF have comparable beneﬁt from CRT as patients with sinus rhythm.
Patients with ischemic cardiomyopathy have comparable beneﬁt from CRT as
patients with idiopathic cardiomyopathy.
Natriuretic peptides may provide an objective measure to evaluate response to CRT.
However, no prediction of response can be made before implantation of the
biventricular device. 
At long-term follow-up, still 22% ot the patients does not respond to CRT at follow
up. So, the pre-implantation selection of responders may result in even better long
term outcome.
No adequate selection of clinical responders with the use of the QRS complex is
possible.
Tissue Doppler Imaging (TDI) allows noninvasive assessment of improvement in
contractile function and resynchronization after CRT.
TDI can be used to identify patients who beneﬁt from CRT.
With TDI response to CRT can be predicted before implantation of the CRT
device.
Since still 20-30% of the patients do not respond to CRT, the current inclusion
criteria should be expanded with novel echocardiographic methods to detect LV
dyssynchrony.
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In dit proefschrift wordt de eﬀectiviteit van cardiale resynchronizatie therapie (CRT) in 
patiënten met hartfalen geëvalueerd. De voorspellende waarde van verschillende parameters 
is in kaart gebracht door patiënten, die klinisch wel en patiënten die klinisch niet verbeteren 
te karakteriseren. Mogelijk leidt toepassing van deze parameters tot een toename van het 
percentage klinische verbeteraars van deze therapie. 
 Hoofdstuk 1 is de inleiding van dit proefschrift. Cardiale resynchronizatie therapie 
(CRT), oftewel biventriculair pacen, is een relatief nieuwe behandelmethode voor de patiënt 
met hartfalen. Deze behandeling gebeurt door middel van implantatie van een resynchronizatie 
pacemaker in patiënten met hartfalen die aan bepaalde inclusie criteria voldoen.
 In Hoofdstuk 2 wordt in een met een ICD (implanteerbare cardiale deﬁbrillator) 
behandelde patiëntengroep het percentage patiënten bepaald dat mogelijk baat heeft bij een 
resynchronizatie pacemaker naast de deﬁbrillator. 
Om te bepalen of het implanteren van een dergelijke pacemaker mogelijk toegevoegde waarde 
had werden alle patiënten die een ICD hebben gekregen, gescreend door middel van de 
volgende inclusie criteria: NYHA hartfalen klasse III of IV, duur QRS complex >120 ms en 
een verminderde ejectiefractie van de linker hartkamer. Bij 390 opeenvolgende patiënten werd 
tussen juni 1996 en maart 2001 een ICD geïmplanteerd. Negenenzeventig patiënten (20%) 
voldeden aan de inclusie criteria voor CRT naast hun deﬁbrillator therapie. De patiënten die 
reeds een resynchronizatie pacemaker in combinatie met een ICD hadden gekregen, hadden 
een betere overleving, verminderde hartfalen symptomen en een lager aantal heropnamen in 
het ziekenhuis in vergelijking met de patiënten die alleen een ICD hadden gekregen. Uit deze 
studie kan men concluderen dat patiënten die met ICD therapie behandeld zijn mogelijk 
baat hebben bij CRT in combinatie met een ICD. Het verdient dus aanbeveling om patiënten 
met een ICD te screenen voor CRT ter behandeling van hun hartfalen.   
In Hoofdstuk 3 worden de eerste 40 patiënten die behandeld zijn met CRT in het 
LUMC in de loop van de tijd geëvalueerd op hun klinische verbetering en lange termijn 
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overleving. Alle 40 patiënten voldeden aan de inclusie criteria voor CRT: eindstadium 
hartfalen klasse III of IV, ejectiefractie van de linker hartkamer <35%, duur QRS complex 
>120ms en een morfaolgie op het ECG dat wijst op een linker bundeltak blok.
Voor implantatie en op 3 en 6 maanden na implantatie van de resynchronizatie pacemaker 
werden de volgende parameters geëvalueerd; NYHA hartfalen klasse, Minnesota`s kwaliteit 
van leven score, duur van het QRS complex op het ECG, 6 minuten inspanningstest en ejectie 
fractie van de linker hartkamer. De patiënten werden gevolgd tot 2 jaar na de implantatie. 
Alle klinische parameters verbeterden na 3 maanden therapie en bleven onveranderd na 6 
maanden. Ook de ejectie fractie van de linker hartkamer verbeterde bij deze therapie. Voor 
implantatie van de resynchronizatie pacemaker werden de patiënten gemiddeld 3.9 ± 5.3 dagen 
per jaar opgenomen voor hartfalen en na implantatie slechts 0.5 ± 1.5 dagen per jaar. De 2-
jaars overleving was 87.5%. De resultaten tonen aan dat CRT niet alleen een verbetering van 
de klinische symptomen van hartfalen geeft, maar ook een goede 2-jaars overleving voor de 
patiënt met hartfalen laat zien. 
Hoofdstuk 4 evalueert de uitkomsten van CRT bij patiënten met hartfalen  en 
atrium ﬁbrilleren (AF) en bij patiënten met hartfalen en sinus ritme (SR). In patiënten met 
AF zijn 2 belangrijke vragen nog niet beantwoord. Allereerst, is het aantal klinische niet 
verbeteraars van CRT gelijk aan het aantal bij patiënten met SR, namelijk rond de 20-30%? 
Ten tweede, is de lange termijn overleving van AF patiënten hetzelfde als bij patiënten met 
SR behandeld met CRT? Grote studies hebben met name patiënten met hartfalen en SR 
geïncludeerd en niet patiënten met AF. Klinische verbetering en lange termijn overleving van 
de met CRT behandelde patiënten met AF (n=30) werd geëvalueerd en vergeleken met de met 
CRT behandelde patienten met SR (n=30). NYHA hartfalen klasse, Minnesota kwaliteit van 
leven score en 6 minuten inspanningstest werden voor implantatie van de resynchronizatie 
pacemaker en 6 maanden na implantatie gemeten. Deze parameters verbeterden signiﬁcant in 
beide groepen na 6 maanden therapie. Op een individuele basis was het percentage klinische 
niet verbeteraars met CRT hoger in de AF groep, echter niet signiﬁcant. Ook de lange termijn 
overleving was vergelijkbaar tussen de patiënten met SR en patiënten met AF. Concluderend 
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hebben zowel patiënten met hartfalen en AF als patiënten met hartfalen en SR baat bij CRT. 
Atrium ﬁbrilleren is daarom geen contra-indicatie voor een resynchronizatie pacemaker.    
In Hoofdstuk 5 zijn de verschillende uitkomsten bestudeerd tussen  patiënten met 
ischemisch hartfalen en patiënten met idiopathisch hartfalen beide behandeld met CRT. 
Van de 74 geïncludeerde patiënten had 46% ischemisch en 54% idiopathisch hartfalen. Na 6 
maanden follow-up verbeterden alle klinische parameters (NYHA hartfalen klasse, kwaliteit 
van leven score, 6 minuten inspanningstest), duur QRS complex, ejectiefractie van de linker 
hartkamer en mitralisklep insuﬃciëntie in beide groepen. Lange termijn overleving was 87.5% 
voor de idiopathische en 88.3% voor de ischemische cardiomyopathiën. Het percentage 
klinische verbeteraars was vergelijkbaar in beide groepen. De onderliggende etiologie van 
het hartfalen (ischemisch vs idiopathisch) is niet gerelateerd aan de klinische verbetering bij 
CRT. Beide categorieen patiënten kunnen in aanmerking komen voor de behandeling met 
een resynchronizatie pacemaker. 
In Hoofdstuk 6 wordt de waarde geëvalueerd van de plasmamarkers van congestief 
hartfalen (atrial- (ANP) en brain natriuretic peptides (BNP)) om de uitkomsten van CRT 
te objectiveren. De klinische follow-up van patiënten na CRT bestond uit evaluatie van de 
NYHA hartfalen klasse, de duur van het QRS complex, de kwaliteit van leven en de gelopen 
afstand bij de 6 minuten inspanningstest. Bloed monsters werden afgenomen voor de analyse 
van natriuretische peptiden (ANP, BNP). Na 7 maanden werd dit herhaald. Bij de patiënten 
die klinisch verbeterden na CRT werd na 7 maanden een daling van de peptiden geobserveerd. 
Deze daling werd niet gezien bij patiënten die klinisch niet verbeterden. Het was echter 
niet mogelijk te voorspellen of patiënten klinisch zouden verbeteren na deze therapie voor 
hartfalen. De plasmamakers kunnen  gebruikt worden als objectieve maat voor de klinische 
verbetering na  CRT.
In Hoofdstuk 7 worden alle klinische parameters geëvalueerd in een grote groep 
patiënten met hartfalen (n=125) die behandeld zijn met een resynchronizatie pacemaker. Deze 
studie toont aan dat de klinische verbetering van de NYHA hartfalen klasse en de symptomen, 
na 3 jaar behandeling nog steeds aanwezig is. Deze klinische verbetering is geassocieerd met 
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een signiﬁcante reductie van het aantal ziekenhuis opnamen per patiënt. Van de 125 met 
CRT behandelde patiënten verbeterd 22% klinisch niet. Selectie voor implantatie van de 
resynchronizatie pacemaker resulteert mogelijk in een toename van het percentage klinische 
verbeteringen en een betere lange termijn overleving. 
In Hoofdstuk 8 wordt de duur van het QRS complex geëvalueerd om de klinische 
uitkomsten van CRT te voorspellen. Ondanks de huidige inclusie criteria bestaat er nog steeds 
een percentage van 20 tot 30% klinische niet-verbeteraars onder de patiënten met hartfalen 
na behandeling met CRT. In deze studie wordt gekeken of de duur van het QRS complex 
voor implantatie van de resynchronizatie pacemaker en de reductie van de duur van het QRS 
complex na implantatie gebruikt kan worden om te voorspellen of een patiënt klinisch zal 
verbeteren met CRT. De patiënten werden voor en 6 maanden na implantatie geëvalueerd 
op klinische parameters. De duur van het QRS complex werd voor implantatie, direct na 
implantatie en na 6 maanden follow-up gemeten. Er werden 61 patiënten geïncludeerd; 74% 
werden geclassiﬁceerd als klinische verbeteraars en 26% als klinische niet-verbeteraars. De 
duur van het QRS complex voor implantatie was gelijk in beide groepen. Direct na implantatie 
was de duur van het QRS complex signiﬁcant afgenomen bij de klinische verbeteraars terwijl 
bij de klinische niet-verbeteraars deze afname niet werd gezien. Na 6 maanden werd de 
verkorting van de duur van het QRS complex alleen geobserveerd bij de klinische verbeteraars. 
Het was niet mogelijk met behulp van ROC analyse een optimale waarde voor de verkorting 
van de duur van het QRS complex te verkrijgen om zo de klinische verbetering na CRT te 
voorspellen. Klinische verbeteraars na CRT hebben een signiﬁcante reductie van de duur 
van het QRS complex na CRT, maar individuele verbetering variëert sterk. Adequate selectie 
van de klinische verbeteraars voor implantatie van de resynchronizatie pacemaker  is niet 
mogelijk met behulp van de duur van het QRS complex.
In Hoofdstuk 9, 10 en 11 wordt de Tissue Doppler Imaging (TDI) gebruikt ter 
evaluatie en voorspelling van dyssynchronie van de linker hartkamer voor en na CRT. In 
patiënten met hartfalen wordt getracht met CRT de geleidingstijd  te optimaliseren en de 
dyssynchronie tussen de hartkamers te verminderen. Tevens lijkt de verminderde dyssynchronie 
Chapter 13
 204 
in de linker hartkamer een belangrijke rol te spelen bij de klinische verbetering na CRT. De 
TDI is een niet-invasieve echocardiograﬁsche techniek, waarmee de dyssynchronie van de 
linker hartkamer wordt gemeten. In Hoofdstuk 9 zijn 22 patiënten met hartfalen met een 
resynchronizatie pacemaker behandeld. Voor en na het implanteren van de pacemaker werd 
een routine echocardiograﬁe met behulp van TDI verricht. De volgende parameters werden 
bepaald; de ejectiefractie van de linker hartkamer, de pieksnelheden in het septum en de 
laterale wand, en de dyssynchronie tussen het septum en de laterale wand (uitgedrukt als 
het verschil in pieksnelheden tussen het septum en de laterale wand). Aanvullend werden de 
klinische parameters na 3 maanden follow-up geëvalueerd. Met CRT nam de ejectiefractie 
van de linker kamer toe van 21 ±7% naar 31 ±9% (P<0.05), de pieksnelheid van het septum 
steeg van 2.1 ±1.3 cm per seconde naar 3.9 ±1.8 cm per seconde (P<0.05) en de pieksnelheid van 
de laterale wand steeg van 2.4 ±1.7 cm per seconde naar 4.5 ±1.5 cm per seconde (P<0.05).
Na 3 maanden CRT verbeterden alle klinische parameters. Concluderend geeft TDI de 
verbeterde contractie en resynchronizatie weer van met CRT behandelde patiënten met 
hartfalen. De studie beschreven in Hoofdstuk 10 is verricht om aan te tonen dat dyssynchronie 
van de linker hartkamergebruikt kan worden om de directe verbetering van de pompfunctie van 
de linker hartkamer na CRT te voorspellen. Van de verschillende echograﬁsche parameters had 
alleen de dyssynchronie van de linker hartkamer een voorspellende waarde voor verbetering 
na CRT. Van de klinische verbeteraars had 76% een septale tot laterale wandvertraging van 
≥60 ms, terwijl 87.5% van de klinische niet-verbeteraars een septale tot laterale wandvertraging 
had van <60 ms. TDI kan gebruikt worden om de klinische verbetering van een patiënt 
na CRT te evalueren. In Hoofdstuk 11 wordt in een grote groep patiënten met hartfalen 
getracht de klinische verbetering en prognose na CRT te voorspellen door de dyssynchronie 
van de linker hartkamer met TDI te meten. Van de 58 geïncludeerde patiënten vertoonde 
74% een klinische verbetering en 26% geen klinische verbetering na CRT. De enige baseline 
karakteristiek verschillend tussen de 2 groepen, was de grotere dyssynchronie van de linker 
hartkamer in de klinische verbeteraars (87 ±49 ms versus 35 ±20 ms, P<0.01). ROC analyse 
gaf een optimale waarde van 65 ms voor de dyssynchronie van de linker hartkamer, met een 
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sensitiviteit en speciﬁciteit van 80% ter voorspelling van de klinische verbetering en 92% ter 
voorspelling van de verbetering van de functie van de linker hartkamer na CRT. Patiënten 
met een dyssynchronie van de linker hartkamer ≥65 ms hadden een uitstekende prognose 
na CRT (6% heropnamen in het ziekenhuis of sterfgevallen), in vergelijking met patiënten 
met een dyssynchronie van de linker hartkamer <65 ms (P<0.001) (50% heropnamen in het 
ziekenhuis of sterfgevallen). Concluderend laten patiënten met een dyssynchronie van de 
linker hartkamer van ≥65 ms gemeten met TDI voor implantatie van de resynchronizatie 
pacemaker een klinische verbetering zien. Tevens hebben zij  een uitstekende prognose na 
CRT behandeling.
 Hoofdstuk 12 is een review betreﬀende de verschillende echocardiograﬁsche 
methoden ter evaluatie en voorspelling van de klinische verbetering van de met CRT 
behandelde patiënten met hartfalen. Ondanks de uitstekende klinische resultaten van CRT, 
laat 20 tot 30% van de behandelde patiënten met hartfalen geen klinische verbetering zien. 
De huidige selectie criteria voor CRT dienen dan ook te worden uitgebreid om het percentage 
klinische verbeteraars te verhogen. Verschillende studies hebben reeds aangetoond dat 
evaluatie van de dyssynchronie van de linker hartkamer noodzakelijk is om de verbetering 
na CRT te evalueren. Nieuwe echocardiograﬁsche methoden worden momenteel gebruikt 
en geëvalueerd om de dyssynchronie van de linker hartkamer te meten. De huidige inclusie 
criteria voor CRT dienen dan ook te worden uitgebreid met een nieuwe methode die de 
dyssynchronie van de linker hartkamer kan bepalen. In de toekomst kan TDI een bruikbare 
methode zijn om de meest geschikte patiënten voor een resynchronizatie pacemaker te 
selecteren.
Conclusies
Aangezien 20% van de met een ICD behandelde patiënten in aanmerking komen
voor een resynchronizatie pacemaker, dient men deze patiënten  te screenen op de
mogelijkheid van CRT voor de behandeling van hartfalen.   
Patiënten met eind stadium hartfalen, NYHA hartfalen klasse III of IV,
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ejectiefractie van de linker hartkamer <35%, duur van het QRS complex >120ms
en een morfologie wijzend op een linker bundeltakblok komen in aanmerking voor
een resynchronizatie pacemaker. 
Follow-up laat zien dat CRT een verbetering geeft van de klinische symptomen van
hartfalen, kwaliteit van leven, 6 minuten inspanningstest en functie van de linker
hartkamer. Tevens is de lange termijn overleving uitstekend.
Patiënten met atrium ﬁbrilleren hebben een vergelijkbare klinische verbetering na
CRT in vergelijking met patiënten met sinus ritme. 
De klinische verbetering na CRT bij patiënten met ischemisch hartfalen is
vergelijkbaar met die van patiënten met idiopathisch hartfalen.
Natriuretische peptiden geven een objectieve weergave van de verbetering na CRT.
Er kan echter geen voorspelling gedaan worden over de klinische verbetering voor
aanvang van implantatie van de resynchronizatie pacemaker.
Bij follow-up op lange termijn is 22% van de patiënten klinisch niet verbeterd na
CRT. Een betere selectie van de patiënten met hartfalen voor aanvang van de
implantatie kan leiden tot een hoger percentage klinische verbeteraars.
Met behulp van de duur van het QRS complex is voor implantatie van de
resynchronizatie pacemaker geen adequate selectie van de klinische verbeteraars
mogelijk.
Tissue Doppler Imaging (TDI) maakt niet-invasieve meting van de verbetering van
de hartfunctie en resynchronizatie van de met CRT behandelde patiënten met
hartfalen mogelijk. 
TDI kan worden gebruikt ter evaluatie van de klinische verbetering na CRT.
Tevens kan met TDI voor implantatie van de resynchronizatie pacemaker de
klinische verbetering worden voorspeld bij patiënten met hartfalen.
Aangezien nog steeds 20-30% van de met CRT behandelde patiënten met hartfalen
klinisch niet verbeteren, wordt aanbevolen de inclusie criteria uit te breiden met
nieuwe echocardiograﬁsche technieken die de linkerkamer dyssynchronie
detecteren.
